WO2006081259A2 - Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis - Google Patents

Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis Download PDF

Info

Publication number
WO2006081259A2
WO2006081259A2 PCT/US2006/002523 US2006002523W WO2006081259A2 WO 2006081259 A2 WO2006081259 A2 WO 2006081259A2 US 2006002523 W US2006002523 W US 2006002523W WO 2006081259 A2 WO2006081259 A2 WO 2006081259A2
Authority
WO
WIPO (PCT)
Prior art keywords
gnal
polypeptide
neisseria species
species bacterium
bacterium
Prior art date
Application number
PCT/US2006/002523
Other languages
French (fr)
Other versions
WO2006081259A3 (en
Inventor
Dan M. Granoff
Victor Hou
Original Assignee
Children's Hospital & Research Center At Oakland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ555937A priority Critical patent/NZ555937A/en
Application filed by Children's Hospital & Research Center At Oakland filed Critical Children's Hospital & Research Center At Oakland
Priority to BRPI0607374A priority patent/BRPI0607374B8/en
Priority to AU2006208208A priority patent/AU2006208208B2/en
Priority to CN2006800029319A priority patent/CN101107007B/en
Priority to CA2590974A priority patent/CA2590974C/en
Priority to US11/795,739 priority patent/US9034345B2/en
Priority to JP2007553181A priority patent/JP4993750B2/en
Priority to EP06733859A priority patent/EP1855715B1/en
Priority to MX2007008785A priority patent/MX2007008785A/en
Publication of WO2006081259A2 publication Critical patent/WO2006081259A2/en
Publication of WO2006081259A3 publication Critical patent/WO2006081259A3/en
Priority to HK08100214.2A priority patent/HK1107526A1/en
Priority to US13/279,006 priority patent/US8968748B2/en
Priority to US14/688,594 priority patent/US9452208B2/en
Priority to US15/237,495 priority patent/US10046043B2/en
Priority to US16/024,145 priority patent/US10478484B2/en
Priority to US16/596,556 priority patent/US10857221B2/en
Priority to US17/085,924 priority patent/US11801293B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Definitions

  • This invention relates to broad-spectrum vaccines for the prevention of diseases caused by Neisseria meningitidis.
  • Neisseria meningitidis is a Gram-negative bacterium which colonizes the human upper respiratory tract and is responsible for worldwide sporadic and cyclical epidemic outbreaks of, most notably, meningitis and sepsis. The attack and morbidity rates are highest in children under 2 years of age. Like other Gram negative bacteria, Neisseria meningitidis typically possess a cytoplasmic membrane, a peptidoglycan layer, an outer membrane which together with the capsular polysaccharide constitute the bacterial wall, and pili which project into the outside environment. Encapsulated strains of Neisseria meningitidis are a major cause of bacterial meningitis and septicemia in children and young adults (Rosenstein et al. J Infect Dis 1999;180:1894-901).
  • Neisseria! species have evolved a wide variety of highly effective strategies to evade the human immune system. These include expression of a polysaccharide capsule that is structurally identical with host polysialic acid (i.e. serogroup B) and high antigenic mutability for the immunodominant noncapsular epitopes, i.e. epitopes of antigens that are present at the surface in relatively large quantities, are accessible to antibodies, and elicit a strong antibody response.
  • host polysialic acid i.e. serogroup B
  • high antigenic mutability for the immunodominant noncapsular epitopes i.e. epitopes of antigens that are present at the surface in relatively large quantities, are accessible to antibodies, and elicit a strong antibody response.
  • OMV meningococcal outer membrane vesicle
  • the efficacy of OMV vaccines for prevention of meningococcal B disease also has been demonstrated directly in older children and adults in randomized, prospective clinical trials, and in retrospective case-control studies.
  • Such vaccines are licensed for use in children in New Zealand, and close to licensure in Norway for use in older children and adults, and are in late-stage clinical development for licensure in other European countries.
  • An OMV vaccine prepared by the Finley Institute in Cuba also is available commercially and has been given to millions of children in South America.
  • the serum bactericidal antibody response to OMV vaccines tends to be strain specific (Tappero et al., 1999, JAMA 281:1520; and Rouupe van der Voort ER, 2000, Vaccine, 18:1334-1343).
  • currently available OMV vaccines are also limited in that the bactericidal antibody responses are largely directed against surface-exposed loops of a major porin protein, PorA (Tappero et al. JAMA 1999;281 : 1520-7), which is antigenically variable (Sacchi et al. J Infect Dis 2000; 182:1169-76).
  • GNAl 870 Genome derived Neisserial Antigen 1870
  • NMB 1870 WO 2004/048404
  • LP2086 is an approximately 27 IcDa lipoprotein expressed in all K meningitidis strains tested (Masignani et al. J Exp Med 2003;197:789 ⁇ 99; Giuliani et al. Infect. Immun 2005; 73:1151-60; Welsch et al. J Immunol 2004; 172:5606-15).
  • N. meningitidis strains can be sub-divided into three GNAl 870 variant groups
  • Variant 1 strains account for about 60% of disease-producing group B isolates (Masignani et al. 2003, supra). Within each variant group, there is on the order of about 92% or greater conservation of amino acid sequence.
  • mice immunized with recombinant GNAl 870 developed high serum bactericidal antibody responses against strains expressing GNAl 870 proteins of the homologous variant group (Masignani et al. 2003, supra; Welsch et al. 2004, supra).
  • a number of strains that expressed sub-variants of the respective GNAl 870 protein were resistant to anti-GNA1870 complement-mediated bacteriolysis.
  • the cause of this phenomenon is not known, conceivably this may be due to minor GNAl 870 polymorphisms, or due to strain differences in the accessibility of critical GNAl 870 epitopes on the surface of the bacteria that result in decreased binding and/or complement activation by the anti-GNA1870 antibodies.
  • the recombinant GNAl 870 protein vaccine used in the above immunogenicity studies was expressed in E. coli as a His-Tag protein devoid of the leader peptide.
  • the recombinant protein also lacked the motif necessary for post- translational lipidation, which may decrease immunogenicity (Fletcher et al. Infect Immun 2004;72:2088-100).
  • O'Dwyer et al. (Infect Immun 2004;72:6511-80) describes preparation of an outer membrane vesicle (OMV) vaccine from a commensal N. flavescens strain that was genetically engineered to express Neisserial surface protein A (NspA), a highly conserved meningococcal membrane protein vaccine candidate that is not naturally-expressed by N. flavescens.
  • NspA Neisserial surface protein A
  • the immunized mice developed NspA-specific serum opsonophagocytic activity.
  • the residual anti-NspA antibodies conferred passive protection to mice given a lethal challenge of an encapsulated N. meningitidis strain.
  • the antibodies elicited by the modified JV. flavescens OMV vaccine in this study were not shown to give superior protection to those elicited by the OMV from N. flavescens that did not express the heterologous antigen.
  • the modified iV. flavescens OMV did not elicit serum bactericidal antibody responses whereas in previous studies, mice immunized with recombinant NspA expressed in E. coli vesicles (Moe et al.
  • US 20040126389 also describes OMV prepared from strains engineered to over-express aNeisserial antigen, with NspA, Omp85, pili (PiIQ, PiIC), PorA, PorB, Opa, Tb ⁇ 2, TbpA, TbpB, Hsf, PIdA, HasR, FrpA/C, FrpB, Hap, LbpA/LbpB, FhaB, Iipo02, MItA, and ctrAi listed as specific examples of such antigens.
  • the present invention overcomes the disadvantages of prior art approaches to vaccination and elicits protective immunity against a broad spectrum of Neisseria meningitidis strains, notably (but not exclusively) including strains belonging to serogroup B.
  • the present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.
  • the invention features compositions comprising antigenic vesicles prepared from a first Neisseria species bacterium, wherein the Neisseria species bacterium produces a level of a GNAl 870 polypeptide sufficient to provide for production of a vesicle that, when administered to a subject, elicits anti-GNA1870 antibodies; and a pharmaceutically acceptable carrier.
  • the vesicle can be outer membrane vesicles (OMVs), microvesicles (MV), or a mixture of OMVs and MVs.
  • the Neisseria species bacterium can be a naturally occurring bacterium, or genetically modified in GNAl 870 polypeptide production (e.g., to provide for expression of a GNAl 870 polypeptide from a heterologous promoter, to express an exogenous GNAl 870 polypeptide, and the like).
  • the GNAl 870 polypeptide can be endogenous to the host cell.
  • the Neisseria species bacterium is genetically modified to disrupt production of an endogenous GNAl 870 polypeptide, and is genetically modified to produce a GNAl 870 polypeptide from a nucleic acid exogenous to the host cell.
  • the Neisseria species bacterium is genetically modified to produce at least two different GNAl 870 polypeptides (e.g., GNAl 870 polypeptides of different variant groups (v.l, v.2, and v.3).
  • the Neisseria species bacterium is deficient in production of capsular polysaccharide.
  • the composition further comprises an antigenic vesicle prepared from a second Neisseria species bacterium, wherein the second Neisseria species bacterium produces a level of a GNAl 870 polypeptide sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNA1870 antibodies, and wherein the second Neisseria species bacterium is genetically diverse to the first Neisseria species bacterium (e.g., the first and second bacteria differ in at least one of serogroup, serotype, or serosubtype).
  • the GNAl 870 polypeptide of the second Neisseria species bacterium is different from the GNAl 870 polypeptide of the first Neisseria species bacterium.
  • the composition further comprises an antigenic vesicle prepared from a third Neisseria species bacterium, wherein the second Neisseria species bacterium produces a level of a GNAl 870 polypeptide sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNA1870 antibodies, and wherein the third Neisseria species bacterium is genetically diverse to the first Neisseria species bacterium (e.g., differ in at least one of serogroup, serotype, or serosubtype).
  • the GNAl 870 polypeptides of the first, second and third Neisseria species bacterium are different.
  • the composition comprises a first antigenic vesicle prepared from a first Neisseria meningitidis bacterium genetically modified to overexpress a GNAl 870 polypeptide; a second antigenic vesicle prepared from a second Neisseria meningitidis bacterium genetically modified to overexpress a GNAl 870 polypeptide; and a pharmaceutically acceptable carrier; wherein the GNAl 870 polypeptide of the first and second bacterium are different GNAl 870 polypeptide variant groups, and the first and second bacteria produce different PorA polypeptides.
  • the composition further comprises a third antigenic vesicle prepared from a third Neisseria meningitidis bacterium genetically modified to overexpress a GNAl 870 polypeptide, wherein the GNAl 870 polypeptide of the third bacterium is of a different GNAl 870 polypeptide variant group than that of the first and second bacteria, and wherein the third bacterium produces a PorA polypeptide different from the PorA polypeptide of the first and second bacteria.
  • the vesicles are prepared without use of a detergent.
  • the invention features a method of producing an antigenic composition by culturing a Neisseria species bacterium producing a GNAl 870 polypeptide, wherein the GNAl 870 polypeptide is produced at a level sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNA1870 antibodies; preparing vesicles from the cultured bacterium; and combining the vesicles with a pharmaceutically acceptable carrier to produce an antigenic composition suitable for administration to a subject.
  • the first and second vesicles can be, independently, an outer membrane vesicle (OMV) or a microvesicle (MV).
  • the Neisseria species bacterium can be a naturally occurring bacterium and thus express an endogenous GNAl 870, or genetically modified in GNAl 870 polypeptide production (e.g., to provide for expression of a GNAl 870 polypeptide from a heterologous promoter, to express an exogenous GNAl 870 polypeptide, and the like).
  • the GNAl 870 polypeptide can be endogenous to the host cell.
  • the Neisseria species bacterium is genetically modified to disrupt production of an endogenous GNAl 870 polypeptide.
  • the Neisseria species bacterium is genetically modified to produce at least two different GNAl 870 polypeptides .
  • the Neisseria species bacterium is genetically modified to disrupt production of an endogenous full-length GNAl 870 polypeptide, and produces a GNAl 870 polypeptide from a nucleic acid exogenous to the host cell.
  • the Neisseria species bacterium is deficient in production of capsular polysaccharide.
  • the invention features a method of eliciting an immune response against Neisseria by administering to a mammal an immunologically effective amount of a composition comprising a first antigenic preparation comprising vesicles prepared from a first Neisseria species bacterium, wherein the Neisseria species bacterium produces a level of a GNAl 870 polypeptide sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNAl 870 antibodies; wherein said administering is sufficient to elicit an immune response to a GNAl 870 polypeptide present in the vesicles.
  • the vesicles can be outer membrane vesicles (OMVs), microvesicles (MVs), or a mixture of OMVs and MVs.
  • the Neisseria species bacterium can be a naturally occurring bacterium and thus express an endogenous GNAl 870, or genetically modified in GNAl 870 polypeptide production (e.g., to provide for expression of a GNAl 870 polypeptide from a heterologous promoter, to express an exogenous GNAl 870 polypeptide, and the like).
  • the GNAl 870 polypeptide can be endogenous to the host cell.
  • the Neisseria species bacterium is genetically modified to disrupt production of an endogenous GNAl 870 polypeptide.
  • the Neisseria species bacterium has been engineered to over-express GNAl 870.
  • the GNAl 870 polypeptide is a chimeric protein (a fusion protein), wherein the chimeric protein contains at least an antigenic portion of GNAl 870 for presentation on vesicles (e.g., OMVs, MVs).
  • the Neisseria species bacterium is deficient in production of capsular polysaccharide.
  • the Neisseria species bacterium is genetically modified to produce at least two different GNAl 870 polypeptides (e.g., GNAl 870 polypeptides of different variant groups (v.l, v.2, and v.3).
  • the Neisseria species bacterium is genetically modified to disrupt production of an endogenous full-length GNAl 870 polypeptide, and produces a GNAl 870 polypeptide from a nucleic acid exogenous to the host cell.
  • the composition administered in the method comprises an immunologically effective amount of a second antigenic preparation comprising vesicles prepared from a second Neisseria species bacterium, wherein the second Neisseria species bacterium produces a level of a GNA 1870 polypeptide sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNA1870 antibodies, and wherein the second Nesseria species bacterium is genetically diverse to the first Neisseria species bacterium (e.g., the first and second bacteria are of a different serogroup, serotype, or serosubtype).
  • the GNA1870 polypeptide of the second Neisseria species bacterium can be different from the GNAl 870 polypeptide of the first Neisseria species bacterium.
  • the composition further comprises a third isolated antigenic preparation comprising vesicles prepared from a third Neisseria species bacterium, wherein the second Neisseria species bacterium produces a level of a GNAl 870 polypeptide sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNAl 870 antibodies, and wherein the third Neisseria species bacterium is genetically diverse to the first or second Neisseria species bacterium (e.g.,. the first, second and third Neisseria species bacteria are genetically diverse in that they differ in at least one of serogroup, serotype, or serosubtype).
  • the GNAl 870 polypeptides of the first, second and third Neisseria species bacteria can be different.
  • the method can provide for eliciting a protective immune response in the subject against more than one strain of Neisseria, particularly N. meningitidis, more particularly serogroup B Neisseria meningitidis.
  • the antigenic compositions described herein can elicit a combination of optimal anti-GNAl 870, anti-PorA, and/or anti-OpC bactericidal antibody responses and, thereby, confer broad protection against meningococcal disease.
  • Vaccines prepared from GNAl 870 over-expressing strains as described herein can elicit an antibody response that is bactericidal for Neisserial strains that share the GNAl 870 variant and/or PorA of the strain from which the vesicles were prepared, as well as an antibody response that is bactericidal for Neisserial strains that have a GNAl 870 subvariant and have a heterologous PorA relative to the vesicle production strain.
  • Vaccines prepared from GNAl 870 over-expressing strains can also decrease the likelihood of selection and emergence of disease-causing JV. meningitidis strains in the population with decreased expression of PorA. These mutants are of particular concern if conventional OMV vaccines are widely used in the population. Because expression of PorA is phase-variable (van der Ende et al, J. Bacteriology 1995:177:2475-2480), and mutants deficient in PorA expression are relatively common and can be readily selected by killing JV. meningitidis with anti-PorA antibody and complement. PorA-deficient strains also are virulent and capable of causing disease.
  • the present disclosure also provides methods that can be advantageous with respect to the ease of preparation of an effective vaccine composition relative to preparation of a vaccine involving a recombinant polypeptide, or a combination vaccine formulation that incorporates multiple individual antigens, or a recombinant protein such as PorA that require renaturation of conformational epitopes to elicit bactericidal antibody.
  • a recombinant polypeptide or a combination vaccine formulation that incorporates multiple individual antigens, or a recombinant protein such as PorA that require renaturation of conformational epitopes to elicit bactericidal antibody.
  • Figure IA shows the results of a flow cytometry experiment measuring binding of anti-GNA1870 antibodies on the surface of live encapsulated JV. meningitidis cells of strain RM1090 and RM1090 mutants as determined by indirect fluorescence.
  • Row A RM1090 ⁇ GNA1870 strain.
  • Row B RM1090 wild-type strain.
  • Row C RM1090 strain transformed with shuttle vector pFP12 containing the GNAl 870 gene.
  • Positive control anti-PorA mAb (anti-Pl.2, 1:500 dilution).
  • Anti-GNA1870 (v. 1) mAb (2 ⁇ g/ml).
  • Polyclonal anti-GNA1870 antisera prepared against v. 1, 2 and 3 recombinant proteins (1:10 dilution).
  • Column 6. Same as column 5 but a 1:250 dilution of serum.
  • Figure IB shows the binding of antibodies to the surface of live Group B JV. meningitidis cells as determined by indirect fluorescence cytometry.
  • Row 1 wildtype H44/76 strain (grey area); H44/76 mutant over-expressing GNAl 870 (black area).
  • Panel A anti-adjuvant negative control antiserum 1:10 dilution
  • Panel B anti-PorA niAb (Pl.16) 1:500 dilution
  • Panel C anticapsular mAb 10 ⁇ g/ml
  • Panel D anti-rGNA1870 mAb JAR3 10 ⁇ g/ml
  • Panel E anti-rGNA1870 polyclonal antiserum 1:10 dilution
  • Panel F same as Panel E with a 1 :250 dilution.
  • Figure 2A provides results of SDS PAGE and Western blot analysis of
  • Panel A is a photograph of a Commassie-stained SDS PAGE. Lanes 1 to 5, OMV preparations (about 5 ⁇ g of protein in each lane except in lane 5 where 10 ⁇ g was loaded). Lane 1, wild-type (WT) strain RMl 090; lane 2, WT strain transformed with shuttle vector pFP12 without the GNA1870 gene; lane 3.
  • WT wild-type
  • RM1090 ⁇ GNA1870 knockout (KO); lane 4, RM1090 ⁇ GNA1870 KO transformed with pFP12 without the GNAl 870 gene; lane 5, RM1090 ⁇ GNA1870 KO transformed with shuttle vector ⁇ FP12-GNA1870 containing the GNAl 870 gene; lane 6, rGNA1870 (about 1 ⁇ g).
  • Panels B and C are photographs of Western blots using polyclonal anti-GNA1870 antisera from mice immunized with variant 1, 2 and 3 rGNA1870 proteins.
  • Panel B The sensitivity of detection of this antiserum was slightly higher for the variant 2 (v.2) recombinant GNAl 870 protein as compared with the variant 1 recombinant GNAl 870 protein (v.l).
  • Panel C Lane 1, recombinant GNAl 870 v.l; Lane 2, OMV from WT RM1090; Lane 3, OMV from RM1090 ⁇ GNA1870; Lane 4, OMV from RM1090 transformed with the pFP12 shuttle vector containing the GNA1870 gene.
  • the over-expression of GNAl 870 v.l in the RM1090 ⁇ GNA 1870 strain transformed with the shuttle vector is greater than the native expression level of GNAl 870 in the wild-type strain (lane 2).
  • Figure 2B provides results of Western-Blot analysis of OMV vaccines probed with anti-rGNA1870 polyclonal antibody.
  • Wildtype OMV prepared from wildtype H44/76 strain
  • ⁇ GNA1870 OMV prepared from a mutant of H44/76 in which the gene encoding GNAl 870 had been inactivated
  • OE GNAl 870 OMV from a mutant of H44/76 engineered to over-express GNAl 870
  • rGNA1870 purified His-Tag GNAl 870 expressed in E. coli.
  • Figure 3 A shows graphs of the serum bactericidal titers of mice as measured against four representative encapsulated N.
  • meningitidis strains Cu385, M6190, Z1092 and NZ98/254.
  • the vaccine groups were: bar 1, aluminum phosphate adjuvant alone; bar 2, OMV vaccine from RMl 090 wild-type; bar 3, OMV vaccine from RM1090 ⁇ GNA1870; bar
  • Figure 3B shows graphs of the serum bactericidal activity (1/GMT ⁇ SD) of sera from mice immunized with H44/76 OMV vaccines. Serum pools were prepared as described in legend to Fig. 3 A. Groups of mice immunized with (1) Adjuvant, (2) rGNA1870, (3) H44/76 wildtype (4) H44/76 ⁇ GNA1870 (5) H44/76 OE GNAl 870. Although not shown on panels, all strains were killed by complement plus positive control anticapsular and/or anti-PorA monoclonal antibodies.
  • Figure 4A is a series of graphs showing activation of human C3b and iC3b complement deposition on the surface of live encapsulated JV. meningitidis cells as determined by indirect fluorescence flow cytometry.
  • Row A Strain NZ98/254.
  • Row B Strain M1390.
  • Column 1 complement plus a positive control group B anticapsular MAb, 25 ⁇ g/ml (open area) or a 1 :40 dilution of a serum pool from negative control mice immunized with aluminum phosphate alone (closed area).
  • FIG. 6 is a series of graphs showing activation of human C3b and iC3b complement deposition on the surface of live encapsulated TV. meningitidis cells as determined by indirect fluorescence flow cytometry.
  • Panel A open area: complement plus anticapsular mAb (25 ⁇ g/ml for Group B strains NZ98/254, BZ198, and M61903, and 1 ⁇ g/ml for Group A strain Z1092); filled area: complement plus 1:100 dilution of anti-adjuvant antisera.
  • Panel B open area: complement plus anti-rGNA1870 mAb JAR3 25 ⁇ g/ml; filled area: complement plusl: 100 dilution of polyclonal anti-rGNA1870 antisera.
  • Panel C complement plus 1:100 dilution of antisera against OMV from wildtype H44/76
  • Panel D open area: complement plus 1 : 100 dilution of antisera prepared against OMV with over-expressed GNAl 870 that had been absorbed with a negative control column (Ni-NTA only); filled area: complement plus 1 :25 dilution of antisera prepared against OMV with over-expressed GNAl 870 after absorption with a solid phase GNAl 870 column.
  • Figure 5 is a bar graph showing serum anti-GNA1870 antibody responses as measured by ELISA (GMT ⁇ SD).
  • the antigen on the plate was rGNA1870 variant 1.
  • the secondary antibody was alkaline phosphatase-conjugated goat anti-mouse IgG+ A+M.
  • the bars represent the respective geometric mean titers of 2 antiserum pools (4-5 mice per pool) from groups of mice immunized with (1) Adjuvant; (2) rGNA1870; (3) H44/76 wildtype OMV; (4) H44/76 ⁇ GNA1870 OMV; (5) H44/76 OE GNAl 870 OMV.
  • Figure 6 provides graphs showing results of analysis of passive protection in the infant rat meningococcal bacteremia model.
  • Quantitative blood cultures were obtained 4 to 6 hours after the bacterial challenge.
  • Panel A 1 :15 serum dilutions.
  • Panel B 1:60 serum dilutions.
  • Bar 1 Serum from mice immunized with aluminum phosphate only; bar 2: Anticapsular mAb (10 ⁇ g/rat); bar 3: Anti-GNA1870 mAb (10 ⁇ g/rat); bar 4: Serum from mice immunized with OMV vaccine from RM1090 ⁇ GNA1870; bar 5: Serum from mice immunized with mixture of OMV vaccine from RM1090 ⁇ GNA plus recombinant GNAl 870 protein vaccine; bar 6: Serum from mice immunized with OMV vaccine from RM1090 over- expressing GNAl 870; bar 7: Serum from mice immunized with recombinant GNAl 870 protein vaccine.
  • Figure 7 is an alignment of exemplary amino acid sequences of GNAl 870 variants 1, 2 and 3 fromiV. meningitidis strains MC58, 951-5945, and M1239, respectively. "1" indicates that first amino acid of the mature protein, with amino acids indicated by negative numbers part of the leader sequence. Grey and black backgrounds indicate conserved and identical amino acid residues, respectively.
  • Figures. 8A-8H provide amino acid sequences of exemplary GNAl 870 polypeptides useful in the invention, including an amino acid sequence alignments of selected exemplary GNAl 870 polypeptides (Fig. 8H).
  • Figure 9 provides alignments of the amino acid sequences of exemplary PorA
  • the present invention is based on the discovery that an OMV vaccine prepared from a mutant JV. / ⁇ eningitidis strain engineered to over-express GNAl 870 elicits broader bactericidal antibody responses in mice than a recombinant GNAl 870 (rGNA1870) protein vaccine or an OMV prepared from a naturally-occurring strain, or a combination of a recombinant protein vaccine and an OMV vaccine.
  • rGNA1870 recombinant GNAl 870
  • OMV vaccines have been administered safely to millions of humans, and are proven to be efficacious against developing meningococcal disease. As noted in the introduction section, their principal limitation is that they elicit strain-specific bactericidal antibody responses. Also there is concern that if OMV vaccines are used widely in the population that the immune response may select for emergence of "escape mutants" of JV. meningitidis strains (i.e., strains with mutations in PorA amino acid sequence of surface- accessible loops or with decreased expression of PorA).
  • the invention provides that, by selection of a prevalent PorA serosubtype and preparing a mutant that over-expresses GNAl 870, it is possible to prepare a vesicle-based vaccine (e.g., OMV, MV) that elicits a combination of optimal anti-GNA1870 and anti-PorA bactericidal antibody responses and, thereby, confers broad protection against meningococcal disease.
  • a vesicle-based vaccine e.g., OMV, MV
  • Use of such a vaccine also has a lower risk than a convention OMV vaccine for selection of disease-producing PorA- deficient mutant strains in the population.
  • vesicles prepared from a strain over-expressing GNAl 870 have an altered protein profile compared with vesicles prepared from a strain that expresses a relatively lower level of GNAl 870.
  • OMV prepared from GNAl 870 over-expressing strains showed decreased expression of a number of other cell envelope proteins as compared with OMV prepared from the wild-type vaccine RM1090 strain, or the RM1090 ⁇ GNA1870 knockout strain.
  • meningitidis strain that over- expresses e.g., is genetically engineered to over-express GNAl 870.
  • Functional activities of the anti-GNA1870 antibodies elicited by the OMV vaccine that over-expressed GNAl 870 were greater than that of the antibodies elicited by the recombinant GNAl 870 vaccine, or a combination of recombinant GNAl 870 and OMV prepared from the wildtype strain.
  • mice immunized with the OMV vaccine prepared from the strain engineered to over-express GNAl 870 showed higher bactericidal activity against strain Zl 092 than that of sera from mice immunized with the recombinant protein GNAl 870 vaccine, or with OMV vaccines prepared from the wild-type or GNAl 870 knock-out RMl 090 strains, or with OMV vaccine mixed with the recombinant GNAl 870 protein vaccine (Fig. 3).
  • the modified OMV vaccine conferred broader protective activity than the GNAl 870 recombinant protein or the OMV vaccine from the wild-type vaccine strain as a result of the ability of the modified OMV vaccine to elicit both serosubtype-specific bactericidal activity against strains expressing a homologous PorA molecule to that of the vaccine strain, and anti-GNA1870 antibodies with greater functional activity against strains expressing sub-variants of the GNAl 870 variant 1 protein than elicited by recombinant GNAl 870 vaccine.
  • the modified OMV vaccine prepared from a GNAl 870 over-expressing strain was advantageous over recombinant GNAl 870 against strains expressing sub-variants of the variant 1 GNAl 870 protein and/or expressing a homologous PorA serosubtype.
  • mice immunized with a vesicle vaccine prepared from a N. meningitidis strain (RMl 090) engineered to over-express NspA had more 10-fold higher ELISA anti-NspA antibody titers but lower serum bactericidal titers against some N.
  • mice immunized with OMV from wildtype strain RMl 090 mice immunized with OMV prepared from wildtype H44/76 developed anti-GNA1870 antibody responses as measured by ELISA ( Figure 5).
  • the group of mice given OMV from the strain with over- expressed GNAl 870 had ⁇ 10-fold higher titers. The titers measured by ELISA did not correlate well with antibody functional activity.
  • the highest serum anti- GNAl 870 titers were in mice immunized with the recombinant GNAl 870 vaccine but the bactericidal and C3b deposition activity of serum from mice immunized with the recombinant protein were limited to strain H44/76. Susceptibility of this strain was expected because virtually all N. meningitides strains with genetic lineage of ET 5 are high expressers of the canonical GNAl 870 v. 1 protein (identical amino acid sequence to that of MC58) and these strains are highly susceptible to complement-mediated bactericidal activity of anti- GNAl 870 antibodies (Masignani et al. 2003,su ⁇ ra; Welsch et al. 2004, supra).
  • the remaining five N. meningitidis test strains in our study express lower amounts of GNAl 870 than strain H44/76, and the respective proteins are subvariants of GNAl 870 v.l.
  • the five strains also have heterologous PorA molecules to that of the H44/76 vaccine strain. These five strains were resistant to bactericidal activity and complement activation by antibodies elicited by the recombinant GNAl 870 vaccine, or by the anti-PorA antibodies elicited by the OMV vaccines. In contrast, four of the five strains were susceptible to bactericidal activity and/or complement deposition activity of sera from mice immunized with H44/76 OMV vaccine with over-expressed GNAl 870.
  • an OMV vaccine prepared from a mutant strain with only a modest increase in GNAl 870 level elicited higher and broader GNA1870-specific bactericidal antibody responses and/or greater C3 deposition than an OMV vaccine prepared from a wildtype strain selected to have relatively high expression of GNAl 870.
  • GNAl 870 a slight change in the ratio of GNAl 870 to total protein in the OMV vaccine preparation appears to determine whether or not there is an antibody response to GNAl 870.
  • the quality of the antibodies elicited by the OMV vaccine with over-expressed GNAl 870 is superior to that of antibodies elicited by the recombinant GNAl 870 vaccine.
  • the recombinant vaccine elicited higher ELISA antibody binding titers than those elicited by the OMV vaccine with over-expressed GNAl 870, but the antibodies to the recombinant protein had lower bactericidal and complement activation activity. Defining the mechanisms by which the modified GNA1870-OMV vaccine elicits serum antibodies with broader functional activity than the recombinant protein or control OMV vaccine will require further study.
  • the present invention thus provides methods and compositions for eliciting an immune response that is broadly reactive with diverse disease-producing JV. meningitidis strains.
  • the invention circumvents the problem of immunodominance of antigenically variable domains of PorA in vesicle-or PorA-based vaccines by enhancing the antibody response to GNAl 870 and, possibly, to other common antigens in the vaccine strains.
  • the methods of the invention elicit serum bactericidal antibody, the only proven serologic correlate of protection in humans (Goldschneider et al. 1969, supra), against strains of Neisseria expressing serosubtype epitopes that were not used in the vaccine preparations.
  • the method elicits serum bactericidal antibody against strains that are not killed by antibody to a conserved protein such as Neisserial surface protein A, a candidate meningococcal vaccine (Martin et al., 2000. J. Biotechnol. 83:27-31; Moe et al. (1999 Infect. Immun. 67: 5664; Moe et al. Infect Immun. 2001 69:3762).
  • a conserved protein such as Neisserial surface protein A
  • Moe et al. (1999 Infect. Immun. 67: 5664; Moe et al. Infect Immun. 2001 69:3762 elicits serum bactericidal antibody against strains that are not killed by antibody to a conserved protein such as Neisserial surface protein A, a candidate meningococcal vaccine (Martin et al., 2000. J. Biotechnol. 83:27-31; Moe et al. (1999 Infect. Immun. 67: 5664;
  • the term "protective immunity” means that a vaccine or immunization schedule that is administered to a mammal induces an immune response that prevents, retards the development of, or reduces the severity of a disease that is caused by Neisseria meningitidis, or diminishes or altogether eliminates the symptoms of the disease.
  • the phrase "a disease caused by a strain of serogroup B of Neisseria meningitidis” encompasses any clinical symptom or combination of clinical symptoms that are present in an infection with a member of serogroup B of Neisseria meningitidis. These symptoms include but are not limited to: colonization of the upper respiratory tract (e.g.
  • mucosa of the nasopharynx and tonsils by a pathogenic strain of serogroup B of Neisseria meningitidis, penetration of the bacteria into the mucosa and the submucosal vascular bed, septicemia, septic shock, inflammation, haemmorrhagic skin lesions, activation of fibrinolysis and of blood coagulation, organ dysfunction such as kidney, lung, and cardiac failure, adrenal hemorrhaging and muscular infarction, capillary leakage, edema, peripheral limb ischaemia, respiratory distress syndrome, pericarditis and meningitis.
  • the phrase "broad spectrum protective immunity” means that a vaccine or immunization schedule elicits "protective immunity” against at least one or more (or against at least two, at least three, at least four, at least five, against at least eight, or at least against more than eight) strains of Neisseria meningitidis, wherein each of the strains belongs to a different serosubtype as the strains used to prepare the vaccine.
  • the invention specifically contemplates and encompasses a vaccine or vaccination regimen that confers protection against a disease caused by a member of serogroup B of Neisseria meningitidis and also against other serogroups, particularly serogroups A, C, Y and W-135.
  • an antigen such as a polysaccharide, phospholipid, protein or peptide
  • the specified antibody or antibodies bind(s) to a particular antigen or antigens in a sample and do not bind in a significant amount to other molecules present in the sample.
  • Specific binding to an antibody under such conditions may require an antibody or antiserum that is selected for its specificity for a particular antigen or antigens.
  • Immune response indicators include but are not limited to: antibody titer or specificity, as detected by an assay such as enzyme-linked immunoassay (ELISA), bactericidal assay, flow cytometry, immunoprecipitation, Ouchter-Lowny immunodiffusion; binding detection assays of, for example, spot, Western blot or antigen arrays; cytotoxicity assays, etc.
  • ELISA enzyme-linked immunoassay
  • a "surface antigen” is an antigen that is present in a surface structure of
  • Neisseria meningitidis e.g. the outer membrane, inner membrane, periplasmic space, capsule, pili, etc.
  • Neisseria meningitidis e.g. the outer membrane, inner membrane, periplasmic space, capsule, pili, etc.
  • Genetic diversity of strains can be accomplished by selecting strains that differ in at least one or more, preferably at least two or more, of serogroup, serotype, or serosubtype (e.g., two strains that differ in at least one of the proteins selected from outer membrane, PorA and PorB proteins, are said to genetically diverse with respect to one another).
  • Genetic diversity can also be defined by, for example, multi-locus sequence typing and/or multi-locus enzyme typing (see, e.g., Maiden et al.,
  • Serogroup refers to classification of Neisseria meningitides by virtue of immunologically detectable variations in the capsular polysaccharide. About 12 serogroups are known: A, B, C, X, Y, Z, 29-E, W- 135, H, I, K and L. Any one serogroup can encompass multiple serotypes and multiple serosubtypes.
  • Serotype refers to classification of Neisseria meningitides strains based on monoclonal antibody defined antigenic differences in the outer membrane protein Porin B. A single serotype can be found in multiple serogroups and multiple serosubtypes.
  • Spherosubtype refers classification of Neisseria meningitides strains based on antibody defined antigenic variations on an outer membrane protein called
  • a single serosubtype can be found in multiple serogroups and multiple serotypes.
  • Enriched means that an antigen in an antigen composition is manipulated by an experimentalist or a clinician so that it is present in at least a three-fold greater concentration by total weight, usually at least 5-fold greater concentration, more preferably at least 10-fold greater concentration , more usually at least 100-fold greater concentration than the concentration of that antigen in the strain from which the antigen composition was obtained.
  • concentration of a particular antigen is 1 microgram per gram of total bacterial preparation (or of total bacterial protein)
  • an enriched preparation would contain at least 3 micrograms per gram of total bacterial preparation (or of total bacterial protein).
  • heterologous refers to two biological components that are not found together in nature.
  • the components may be host cells, genes, or regulatory regions, such as promoters. Although the heterologous components are not found together in nature, they can function together, as when a promoter heterologous to a gene is operably linked to the gene.
  • a Neisserial sequence is heterologous to a Neisserial host of a different strain.
  • "Heterologous” as used herein in the context of proteins expressed in two different bacterial strains, e.g., "heterologous PorA" or “heterologous GNAl 870” indicates that the proteins in question differ in amino acid sequence. For example, a first Neisserial strain expressing PorA 1.5-2,10 and a second Neisserial strain expressing PorA 7- 2,4 are said to have “heterologous PorA proteins" or are "heterologous with respect to PorA".
  • the term "immunologically naive with respect to Neisseria meningitidis” denotes an individual (e.g., a mammal such as a human patient) that has never been exposed (through infection or administration) to Neisseria meningitidis or to an antigen composition derived from Neisseria meningitidis in sufficient amounts to elicit protective immunity, or if exposed, failed to mount a protective immune response. (An example of the latter would be an individual exposed at a too young age when protective immune responses may not occur. Molages et al., 1994, Infect. Immun. 62: 4419-4424).
  • the "immunologically na ⁇ ve" individual has also not been exposed to a Neisserial species other than Neisseria meningitidis (or an antigen composition prepared from a Neisserial species), particularly not to a cross-reacting strain of Neisserial species (or antigen composition).
  • Individuals that have been exposed (through infection or administration) to a Neisserial species or to an antigen composition derived from that Neisserial species in sufficient amounts to elicit an immune response to the epitopes exhibited by that species are "primed” to immunologically respond to the epitopes exhibited by that species.
  • the invention involves production of vesicles (microvesicles or outer membrane vesicles) from a naturally-occurring or genetically modified Neisserial strain that produces a level of GNAl 870 protein sufficient to provide for vesicles that, when administered to a subject, evoke serum anti-GNA1870 antibodies.
  • vesicles microvesicles or outer membrane vesicles
  • the anti-GNA1870 antibodies produced facilitate immunoprotection against 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more Neisserial strains, which strains can be genetically diverse (or “heterologous") with respect to, for example, serogroup, serotype, serosubtype (e.g., as determined by PorA protein), Sequence type, electrophoretic type, GNAl 870 variant, and/or GNAl 870 subvariant.
  • Any of a variety of Neisseria spp. strains that produce or can be modified to produce GNAl 870, and, optionally, which produce or can be modified to produce other antigens of interest, such as PorA, can be used in the methods of the invention. Characteristics of suitable strains with respect to GNAl 870 production are discussed in more detail below.
  • Nessserial spp. include N. meningitidis, N. flavescens N. gonorrhoeae, N. lactamica, N. polysaccharea, N. cinerea, N. mucosa, N. subflava, N. sicca, N. elongata, and the like.
  • “Derived from” in the context of bacterial strains is meant to indicate that a strain was obtained through passage in vivo, or in in vitro culture, of a parental strain and/or is a recombinant cell obtained by modification of a parental strain.
  • N. meningitidis strains are of particular interest in the present invention.
  • N. meningitidis strains can be divided into serologic groups, serotypes and subtypes on the basis of reactions with polyclonal (Frasch, C. E. and Chapman, 1973, J. Infect. Dis. 127: 149-154) or monoclonal antibodies that interact with different surface antigens.
  • Serogrouping is based on immunologically detectable variations in the capsular polysaccharide. About 12 serogroups (A, B, C, X, Y, Z, 29-E, and W-135) are known. Strains of the serogroups A, B, C, Y and W-135 account for nearly all meningococcal disease.
  • Serotyping is based on monoclonal antibody defined antigenic differences in an outer membrane protein called Porin B (PorB). Antibodies defining about 21 serotypes are currently known (Sacchi et al, 1998, CUn. Diag. Lab. Immunol. 5:348). Serosubtyping is based on antibody defined antigenic variations on an outer membrane protein called Porin A (PorA). Antibodies defining about 18 serosubtypes are currently known. Serosubtyping is especially important in Neisseria meningitidis strains where immunity may be serosubtype specific. Most variability between PorA proteins occurs in two (loops I and IV) of eight putative, surface exposed loops.
  • variable loops I and IV have been designated VRl and VR2, respectively. Since more PorA VRl and VR2 sequence variants exist that have not been defined by specific antibodies, an alternative nomenclature based on VR typing of amino acid sequence deduced from DNA sequencing has been proposed (Sacchi et al., 2000, J Infect. Dis. 182:1169; see also the Multi Locus Sequence Typing web site). Lipopolysaccharides can also be used as typing antigens, giving rise to so-called immunotypes: Ll, L2, etc.
  • N. meningitidis also may be divided into clonal groups or subgroups, using various techniques that directly or indirectly characterize the bacterial genome. These techniques include multilocus enzyme electrophoresis (MLEE), based on electrophoretic mobility variation of an enzyme, which reflects the underlying polymorphisms at a particular genetic locus. By characterizing the variants of a number of such proteins, genetic "distance" between two strains can be inferred from the proportion of mismatches. Similarly, clonality between two isolates can be inferred if the two have identical patterns of electrophoretic variants at number of loci.
  • MLEE multilocus enzyme electrophoresis
  • MLST multilocus sequence typing
  • the strain used for vesicle production can be selected according to a number of different characteristics that may be desired. For example, in addition to selection according to a level of GNAl 870 production, the strain may be selected according to: a desired PorA type (a "serosubtype", as described above), serogroup, serotype, and the like; decreased capsular polysaccharide production; and the like.
  • the production strain can produce any desired PorA polypeptide, and may express one or more PorA polypeptides (either naturally or due to genetic engineering).
  • Exemplary strains includes those that produce a PorA polypeptide which confers a serosubtype of Pl.7,16; Pl.19,15; Pl.7,1; Pl.5,2; P1.22a,14; Pl.14 ; Pl.5, 10; Pl.7,4; Pl.12,13; as well as variants of such PorA polypeptides which may or may not retain reactivity with conventional serologic reagents used in serosubtyping.
  • PorA polypeptides characterized according to PorA variable region (VR) typing (see, e.g., Russell et al.
  • PorA polypeptides as characterized by PorA serosubtypes include
  • the production strain can be a capsule deficient strain.
  • Capsule deficient strains can provide vesicle-based vaccines that provide for a reduced risk of eliciting a significant autoantibody response in a subject to whom the vaccine is administered (e.g., due to production of antibodies that cross-react with sialic acid on host cell surfaces).
  • "Capsule deficient” or “deficient in capsular polysaccharide” as used herein refers to a level of capsular polysaccharide on the bacterial surface that is lower than that of a naturally-occurring strain or, where the strain is genetically modified, is lower than that of a parental strain from which the capsule deficient strain is derived.
  • a capsule deficient strain includes strains that are decreased in surface capsular polysaccharide production by at least 10%, 20%, 25%, 30%, 40%, 50%, 60%, 75%, 80%, 85%, 90% or more, and includes strains in which capsular polysaccharide is not detectable on the bacterial surface (e.g., by whole cell ELISA using an anti-capsular polysaccharide antibody).
  • Capsule deficient strains include those that are capsule deficient due to a naturally-occurring or recombinantly-generated genetic modification.
  • Naturally-occurring capsule deficient strains see, e.g., Dolan-Livengood et al. J. Infect. Dis. (2003) 187(10): 1616-28), as well as methods of identifying and/or generating capsule-deficient strains (see, e.g., Fisseha et al. (2005) Infect. Immun. 73(7):4070-4080; Stephens et al. (1991) Infect Immun 59(ll):4097-102; Frosch et al. (1990) MoI Microbiol. 1990 4(7):1215-
  • Modification of a Neisserial host cell to provide for decreased production of capsular polysaccharide may include modification of one or more genes involved in capsule synthesis, where the modification provides for, for example, decreased levels of capsular polysaccharide relative to a parent cell prior to modification.
  • Such genetic modifications can include changes in nucleotide and/or amino acid sequences in one or more capsule biosynthesis genes rendering the strain capsule deficient (e.g., due to one or more insertions, deletions, substitutions, and the like in one or more capsule biosynthesis genes).
  • Capsule deficient strains can lack or be non-functional for one or more capsule genes.
  • Of particular interest are strains that are deficient in sialic acid biosynthesis.
  • strains having a defect in sialic acid biosynthesis can be defective in any of a number of different genes in the sialic acid biosynthetic pathway.
  • strains that are defective in a gene product encoded by the N-acetylglucosamine-6-phosphate 2-epimerase gene known as synX AAF40537.1 or siaA AAA20475
  • a capsule deficient strain is generated by disrupting production of a functional synX gene product (see, e.g., Swartley et al. (1994) J Bacteriol. 176(5):1530-
  • Capsular deficient strains can also be generated from naturally-occurring strains using non-recombinant techniques, e.g., by use of bactericidal anti-capsular antibodies to select for strains that reduced in capsular polysaccharide.
  • the strains can be selected so as to differ in on or more strain characteristics, e.g., to provide for vesicles that differ in PorA type and/or GNAl 870 variant group.
  • vesicles can be produced according to the invention using a naturally-occurring or modified non-naturally-occurring Neisserial strain that produces vesicles with sufficient GNAl 870 protein that, when administered to a subject, provide for production of anti-GNA1870 antibodies.
  • the Neisserial strain used to produce vesicles according to the invention can be naturally occurring strains that express a higher level of GNAl 870 relative to strains that express no detectable or a low level of GNAl 870.
  • RMl 090 is an example of a strain that produces a low level of GNAl 870.
  • Naturally occurring strains that produce GNAl 870 at a level that is 1.5, 2, 2,5 3, 3.5, 4, 4.5, 5, 5.5, 6, 6,5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 -fold or greater over GNA1870 production in a low GNA1870-producing strain, such as RM1090, are of particular interest.
  • Examples of naturally-occurring strains that express a high level of GNA1870 include ET-5 strains such as H44/76, Cu385 and MC58.
  • the strain produces a level of GNAl 870 that is greater than that produced in RM1090, and can be at least 1.5, 2, 2,5 3, 3.5, 4, 4.5, 5, 5.5, 6, 6,5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 -fold or greater than that in RM1090.
  • the Neisserial strain is modified by recombinant or non-recombinant techniques to provide for a sufficiently high level of GNAl 870 production.
  • Such modified strains generally are produced so as to provide for an increase in GNAl 870 production that is 1.5, 2, 2,5 3, 3.5, 4, 4.5, 5, 5.5, 6, 6,5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 -fold or greater over GNAl 870 production in the unmodified parental cell or over GNAl 870 production of the strain RMl 090.
  • Any suitable strain can be used in this embodiment, including strains that produce low or undetectable levels of GNAl 870 prior to modification and strains that naturally produce high levels of GNAl 870 relative to strains that express no detectable or a low level of GNAl 870.
  • Modified strains can be generated by non-recombinant techniques such as, for example, exposure to chemicals, radiation, or other DNA modifying or damaging agent, and the like. Modified strains having a desired protein expression profile, particularly with respect to GNAl 870 production, can be identified through screening for strains producing a desired level of GNAl 870 (e.g., an increased level of GNAl 870 as compared to the unmodified parental strain or a low GNAl 870 producer (such as RMl 090), or a level similar to that of a strain that produces GNAl 870 at acceptably high levels).
  • a desired level of GNAl 870 e.g., an increased level of GNAl 870 as compared to the unmodified parental strain or a low GNAl 870 producer (such as RMl 090), or a level similar to that of a strain that produces GNAl 870 at acceptably high levels.
  • modified strains are produced using recombinant techniques, usually by introduction of nucleic acid encoding a GNAl 870 polypeptide or manipulation of an endogenous GNAl 870 gene to provide for increased expression of endogenous GNAl 870.
  • Methods for determining GNAl 870 production levels are known in the art.
  • Such methods include, for example, Western blot (optionally with analysis assisted by densitometry scan), flow cytometric (e.g., FACS) analysis using anti-GNA1870 antibody, detection of GNAl 870 RNA levels, and the like.
  • Strains that have higher levels of GNAl 870 production, either naturally or due to genetic modification, are sometimes referred to herein as GNAl 870 "over-expressers” or are said to "overexpress” GNAl 870.
  • Neisserial host cells genetically modified to provide for increased expression of an endogenous GNA1870
  • Endogenous GNAl 870 expression can be increased by altering in situ the regulatory region controlling the expression of GNAl 870.
  • Methods for providing for increased expression of an endogenous Neisserial gene are known in the art (see, e.g., WO 02/09746).
  • the nucleic acid sequences of genes encoding genomic GNAl 870 variants and subvariants are known, providing for ready adaptation of such methods in the upregulation of endogenous GNAl 870 expression.
  • the endogenous GNAl 870 may be of any desired variant group (e.g., v.1 , v.2, v.3, and the like) or subvariant of GNAl 870.
  • a "canonical" v.l GNAl 870 polypeptide of strain MC58 is of particular interest. Also of interest is a subvariant GNAl 870 polypeptide of strain NZ98/294, and v.2 GNAl 870 polypeptide of strain 2996.
  • Modification of a Neisserial host cell to provide for increased production of endogenous GNAl 870 may include partial or total replacement of all of a portion of the endogenous gene controlling GNAl 870 expression, where the modification provides for, for example, enhanced transcriptional activity relative to the unmodified parental strain.
  • Increased transcriptional activity may be conferred by variants (point mutations, deletions and/or insertions) of the endogenous control regions, by naturally occurring or modified heterologous promoters or by a combination of both.
  • the genetic modification confers a transcriptional activity greater than that of the unmodified endogenous transcriptional activity (e.g., by introduction of a strong promoter), resulting in an enhanced expression of GNAl 870.
  • Typical strong promoters that may be useful in increasing GNAl 870 transcription production can include, for example, the promoters of porA, porB, lbpB, tbpB, pi 10, hpuAB, igtF, Opa, pi 10, 1st, and hpuAB.
  • PorA, RMp and PorB are of particular interest as constitutive, strong promoters.
  • PorB promoter activity is contained in a fragment corresponding to nucleotides -1 to -250 upstream of the initation codon of porB.
  • double cross-over homologous recombination technology to introduce a promoter in a region upstream of the coding sequence, e.g., about 1000 bp, from about 30-970 bp, about 200-600 bp, about 300-500 bp, or about 400 bp upstream (5') of the initiation ATG codon of the GNA1870-encoding nucleic acid sequence to provide for up-regulation.
  • a promoter in a region upstream of the coding sequence, e.g., about 1000 bp, from about 30-970 bp, about 200-600 bp, about 300-500 bp, or about 400 bp upstream (5') of the initiation ATG codon of the GNA1870-encoding nucleic acid sequence to provide for up-regulation.
  • Optimal placement of the promoter can be determined through routine use of methods available in the art.
  • a highly active promoter e.g., PorA, PorB or Rmp promoters
  • the PorA promoter can be optimized for expression as described by van der Ende et al. Infect Immun 2000;68:6685-90.
  • Insertion of the promoter can be accomplished by, for example, PCR amplification of the upstream segment of the targeted GNAl 870 gene, cloning the upstream segment in a vector, and either inserting appropriate restriction sites during PCR amplification, or using naturally occurring restriction sites to insert the PorA promoter segment.
  • an about 700 bp upstream segment of the GNA 1870 gene can be cloned.
  • a PorA promoter segment is inserted.
  • An antibiotic (e.g., erythromycin) resistance cassette can be inserted within the segment further upstream of the PorA promoter and the construct was used to replace the wild-type upstream GNAl 870 segment by homologous recombination.
  • Another approach involves introducing a GNAl 870 polypeptide-encoding sequence downstream of an endogenous promoter that exhibits strong transcriptional activity in the host cell genome.
  • the coding region of the Rmp gene can be replaced with a coding sequence for a GNAl 870 polypeptide.
  • This approach takes advantage of the highly active constitutive Rmp promoter to drive expression.
  • Neisserial strains can be genetically modified to over-express GNAl 870 by introduction of a construct encoding a GNAl 870 polypeptide into a Neisserial host cell.
  • the GNAl 870 introduced for expression is referred to herein as an "exogenous" GNAl 870.
  • the host cell produces an endogenous GNAl 870, the exogenous GNAl 870 may have the same or different amino acid sequence compared to the endogenous GNAl 870.
  • the strain used as the host cell in this embodiment can produce any level of
  • GNAl 870 (e.g., high level, intermediate level, or low level GNAl 870 production).
  • a strain that is selected for low level or no detectable GNAl 870 production, or that is modified to exhibit no detectable, or a low level, of GNAl 870 production.
  • the host cell may be genetically modified so that the endogenous GNAl 870 gene is disrupted so that GNAl 870 is not produced or is not present in the cell envelope (and thus is not present at detectable levels in a vesicle prepared from such a modified cell).
  • the host cell produces an intermediate or high level of GNAl 870 (e.g., relative to a level of GNAl 870 produced by, for example, RMl 090).
  • the host cell can be genetically modified to express any suitable GNAl 870 polypeptide, including GNAl 870 variants or subvariants.
  • GNAl 870 variants or subvariants As described in more detail below, the amino acid sequences of many GNAl 870 polypeptides are known; alignment of these sequences provides guidance as to residues that are conserved among the variants, thus providing guidance as to amino acid modifications (e.g., substitutions, insertions, deletions) that can be made.
  • GNAl 870 polypeptide encompasses naturally- occurring and synthetic (non-naturally occurring) polypeptides which share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or greater sequence identity at the nucleotide or amino acid level with a naturally-occurring GNAl 870 polypeptide, and which are capable of eliciting antibodies that specifically bind a naturally-occurring GNAl 870 polypeptide present on a whole cell Neisserial bacterium.
  • GNAl 870 polypeptide also encompasses fusion proteins, e.g., a GNAl 870 polypeptide having a heterologous polypeptide at the N- and/or C-terminus.
  • the host cell can be genetically modified to express at least 1 GNAl 870 polypeptide, and can be modified to express 2, 3, 4 or more GNAl 870 polypeptides in the same host cell.
  • a single host cell can be genetically modified to express at least one variant 1 GNAl 870 polypeptide, at least one variant 2 GNAl 870 polypeptide, and at least one variant 3 GNAl 870 polypeptide.
  • the different GNAl 870 polypeptides may be expressed from different promoters so as to allow a range of expression. For example, varying both the base composition and number of bases between the —10 and —35 regions of the PorA promoter should result in a wide range of expression of the desired recombinant protein (van der Ende et al. Infect Immun 2000;68:6685-90).
  • Nucleic acids encoding a GNAl 870 polypeptide for use in the invention are known in the art. Suitable GNAl 870 polypeptides are described in, for example, WO 2004/048404; Masignani et al. 2003 J Exp Med 197:789-799; Fletcher et al. Infect Immun 2004 2088-2100; Welsch et al. J Immunol 2004 172:5606-5615; and WO 99/57280. Nucleic acid (and amino acid sequences) for GNAl 870 variants and subvariants are also provided in GenBank as accession nos.: NC_003112, GenelD: 904318 (NCBI Ref. NP_274866) (from N.
  • AY548371 (AAT01290.1) (from N. meningitidis strain CU385); AY548370 (AAT01289.1) (from N. meningitidis strain H44/76); AY548377 (AAS56920.1) (from N. meningitidis strain M4105); AY548376 (AAS56919.1) (from N. strain M1390); AY548375 (AAS56918.1) (from N. meningitidis strain N98/254); AY548374 (AAS56917.1) (from N. meningitidis strain M6190); AY548373 (AAS56916.1) (from N. meningitidis strain 4243); and AY548372 (AAS56915.1) (from N. meningitidis strain BZ83).
  • Fig. 7 is an alignment of exemplary amino acid sequences of GNAl 870 variants 1, 2 and 3 from N. meningitidis strains MC58, 951-5945, and M1239, respectively (WO 2004/048404).
  • the immature GNAl 870 protein includes a leader sequence of about 19 residues, with each variant usually containing an N-terminal cysteine to which a lipid moeity can be covalently attached. This cysteine residue is usually lipidated in the naturally- occurring protein. "1" indicates that first amino acid of the mature protein, with amino acids indicated by negative numbers part of the leader sequence. Grey and black backgrounds indicate conserved and identical amino acid residues, respectively.
  • GNAl 870 polypeptides can be lipidated or non-lipidated. It is generally preferred that the GNAl 870 be lipidated, so as to provide for positioning of the polypeptide in the membrane.
  • Lipidated GNA1870 can be prepared by expression of the,GNA1870 polypeptide having the N-terminal signal peptide to direct lipidation by diacylglyceryl transferase, followed by cleavage by lipoprotein-specific (type II) signal peptidase.
  • the GNAl 870 polypeptide useful in the invention includes non-naturally occurring (artificial or mutant) GNAl 870 polypeptides that differ in amino acid sequence from a naturally-occurring GNAl 870 polypeptide, but which are present in the membrane of aNesserial host so that vesicles prepared from the host contain GNAl 870 in a form that provides for presentation of epitopes of interest, preferably a bactericidal epitope, and provides for an anti-GNA1870 antibody response.
  • the GNAl 870 polypeptide is a variant 1 (v.l) or variant 2 (v.2) or variant 3 (v.3) GNAl 870 polypeptide, with subvariants of v.l v,2 and v.3 being of interest, including subvariants of v.l (see, e.g., Welsch et al. J Immunol 2004 172:5606-5615).
  • the GNA1870 polypeptide comprises an amino acid sequence of a GNAl 870 polypeptide that is most prevalent among the strains endemic to the population to be vaccinated.
  • GNAl 870 polypeptides useful in the invention also include fusion proteins, where the fusion protein comprises a GNAl 870 polypeptide having a fusion partner at its N- terminus or C-terminus.
  • Fusion partners of interest include, for example, glutathione S transferase (GST), maltose binding protein (MBP), His-tag, and the like, as well as leader peptides from other proteins, particularly lipoproteins (e.g., the amino acid sequence prior to the N-terminal cysteine may be replaced with another leader peptide of interest).
  • GNAl 870 polypeptide-encoding nucleic acids can be identified using techniques well known in the art, where GNAl 870 polypeptides can be identified based on amino acid sequences similarity to a known GNAl 870 polypeptide. Such GNAl 870 polypeptides generally share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or greater sequence identity at the nucleotide or amino acid level. Sequence identity can be determined using methods for alignment and comparison of nucleic acid or amino acid sequences, which methods are well known in the art. Comparison of longer sequences may require more sophisticated methods to achieve optimal alignment of two sequences.
  • Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman and Wunsch (1970) J. MoL Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. (USA) 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, WI), or by inspection, and the best alignment (i.e. resulting in the highest percentage of sequence similarity over the comparison window) generated by the various methods is selected.
  • nucleic acids or polypeptide sequences refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection.
  • Polypeptides of interest include those having at least 60%, 70%, 75%, 80%, 85%, 90%, 95% or more nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection.
  • the region sharing sequence identity exists over a region of the sequences that is at least about 10, 20, 30, 40, 50, 60, 70, 80, or 100 contiguous residues in length.
  • identity of the sequences is determined by comparison of the sequences over the entire length of the coding region of a reference polypeptide.
  • test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated.
  • sequence comparison algorithm calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.
  • Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. MoI. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (see generally, Current Protocols in Molecular Biology, F.M.
  • This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al, supra).
  • These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them.
  • the word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always ⁇ 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative- scoring residue alignments; or the end of either sequence is reached.
  • the BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.
  • the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Her ⁇ koff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)).
  • the BLAST algorithm In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)).
  • One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
  • a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
  • a further indication that two nucleic acid sequences or polypeptides share sequence identity is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid, as described below.
  • a polypeptide typically share sequence identity with a second polypeptide, for example, where the two polypeptides differ only by conservative substitutions.
  • Another indication that two nucleic acid sequences share sequence identity is that the two molecules hybridize to each other under stringent conditions. The selection of a particular set of hybridization conditions is selected following standard methods in the art (see, for example, Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, (1989) Cold Spring Harbor, N.Y.).
  • stringent hybridization conditions hybridization at 50 0 C or higher and 0.1 x SSC (15 mM sodium chloride/1.5 rnM sodium citrate). Another example of stringent hybridization conditions is overnight incubation at 42 0 C in a solution: 50 % formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5 x Denhardf s solution, 10% dextran sulfate, and 20 mg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1 x SSC at about 65 0 C.
  • Stringent hybridization conditions are hybridization conditions that are at least as stringent as the above representative conditions, where conditions are considered to be at least as stringent if they are at least about 80% as stringent, typically at least about 90% as stringent as the above specific stringent conditions.
  • Other stringent hybridization conditions are known in the art and may also be employed to identify nucleic acids of this particular embodiment of the invention.
  • residue positions which are not identical differ by conservative amino acid substitutions.
  • Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains.
  • a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine
  • a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine
  • a group of amino acids having amide-containing side chains is asparagine and glutamine
  • a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan
  • a group of amino acids having basic side chains is lysine, arginine, and histidine
  • a group of amino acids having sulfur-containing side chains is cysteine and methionine.
  • Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine- tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.
  • Methods for transfer of genetic material into a Neisserial host include, for example, conjugation, transformation, electroporation, calcium phosphate methods and the like.
  • the method for transfer should provide for stable expression of the introduced GNA1870-encoding nucleic acid.
  • the GNA1870-encoding nucleic acid can be provided as a inheritable episomal element (e.g., plasmid) or can be genomically integrated.
  • Suitable vectors will vary in composition depending what type of recombination event is to be performed. Integrative vectors can be conditionally replicative or suicide plasmids, bacteriophages, transposons or linear DNA fragments obtained by restriction hydrolysis or PCR amplification.
  • Selection of the recombination event can be accomplished by means of selectable genetic marker such as genes conferring resistance to antibiotics (for instance kanamycin, erythromycin, chloramphenicol, or gentamycin), genes conferring resistance to heavy metals and/or toxic compounds or genes complementing auxotrophic mutations (for instance pur, leu, met, aro).
  • selectable genetic marker such as genes conferring resistance to antibiotics (for instance kanamycin, erythromycin, chloramphenicol, or gentamycin), genes conferring resistance to heavy metals and/or toxic compounds or genes complementing auxotrophic mutations (for instance pur, leu, met, aro).
  • the vector is an expression vector based on episomal plasmids containing selectable drug resistance markers that autonomously replicate in both E. coli and N. meningitidis.
  • a "shuttle vector” is the plasmid pFPIO (Pagotto et al. Gene 2000 244:13-19).
  • the antigenic compositions for use in the invention generally include vesicles prepared from Neisserial cells that express an acceptable level of GNAl 870, either naturally or due to genetic modification (e.g., due to expression of a recombinant GNAl 870).
  • vesicles is meant to encompass outer membrane vesicles as well as micro vesicles (which are also referred to as blebs).
  • the antigenic composition comprises outer membrane vesicles (OMV) prepared from the outer membrane of a cultured strain of Neisseria meningitidis spp.
  • OMVs may be obtained from a. Neisseria meningitidis grown in broth or solid medium culture, preferably by separating the bacterial cells from the culture medium (e.g. by filtration or by a low-speed centrifugation that pellets the cells, or the like), lysing the cells (e.g. by addition of detergent, osmotic shock, sonication, cavitation, homogenization, or the like) and separating an outer membrane fraction from cytoplasmic molecules (e.g.
  • outer membrane fractions may be used to produce OMVs.
  • the antigenic composition comprises microvesicles
  • MVs may be obtained by culturing a strain of Neisseria meningitidis in broth culture medium, separating whole cells from the broth culture medium (e.g. by filtration, or by a low-speed centrifugation that pellets only the cells and not the smaller blebs, or the like), and then collecting the MVs that are present in the cell-free culture medium (e.g. by filtration, differential precipitation or aggregation of MVs, or by a high-speed centrifugation that pellets the blebs, or the like).
  • Strains for use in production of MVs can generally be selected on the basis of the amount of blebs produced in culture (e.g., bacteria can be cultured in a reasonable number to provide for production of blebs suitable for isolation and administration in the methods described herein).
  • An exemplary strain that produces high levels of blebs is described in PCT Publication No. WO 01/34642.
  • strains for use in MV production may also be selected on the basis of NspA production, where strains that produce higher levels of NspA may be preferable (for examples of N. meningitides strains having different NspA production levels, see, e.g., Moe et al. (1999 Infect. Immun. 67: 5664).
  • the antigenic composition comprises vesicles from one strain, or from 2, 3, 4, 5 or more strains, which strains may be homologous or heterologous, usually heterologous, to one another with respect to one or both of GNAl 870 or PorA.
  • the vesicles are prepared from a strain that expresses 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more GNAl 870 proteins, which may be different variants (v.l, v.2, v.3) or subvariants (e.g., a subvariant of v.l, v.2, or v.3).
  • the antigenic compositions comprises a mixture of OMVs and MVs, which may be from the same or different strains.
  • vesicles from different strains can be administered as a mixture.
  • OMVs and MVs from the same or different strains can be administered as a mixture.
  • isolated antigens or particular combinations of antigens may be included in the antigenic compositions of the invention.
  • the vesicles are optionally treated to reduce endotoxin, e.g., to reduce toxicity following administration.
  • reduction of endotoxin can be accomplished by extraction with a suitable detergent (for example, BRIJ-96, sodium deoxycholate, sodium lauoylsarcosinate, Empigen BB, Triton X-IOO, TWEEN 20 (sorbitan monolaurate polyoxyethylene), TWEEN 80, at a concentration of 0.1-10%, preferably 0.5-2%, and SDS).
  • a detergent for example, BRIJ-96, sodium deoxycholate, sodium lauoylsarcosinate, Empigen BB, Triton X-IOO, TWEEN 20 (sorbitan monolaurate polyoxyethylene), TWEEN 80, at a concentration of 0.1-10%, preferably 0.5-2%, and SDS.
  • a detergent other than deoxycholate it is preferable to use a detergent other than deoxycholate.
  • the vesicles of the antigenic compositions are prepared without detergent.
  • detergent treatment is useful to remove endotoxin activity, it may deplete the native GNAl 870 lipoprotein by extraction during vesicle production.
  • strains that are relatively low producers of endotoxin lipopolysaccharide, LPS
  • LPS lipopolysaccharide
  • the vesicles can be prepared from Neisseria mutants in which lipooligosaccharide or other antigens that may be undesirable in a vaccine (e.g.
  • vesicles can be prepared from JV. meningitidis strains that contain genetic modifications that result in decreased or no detectable toxic activity of lipid A.
  • such strain can be genetically modified in lipid A biosynthesis (Steeghs et al. Infect Immun 1999;67:4988-93; van der Ley et al. Infect Immun 2001;69:5981-90; Steeghs et al. J Endotoxin Res 2004;10:113-9). Mutations in genes responsible for the terminal modifications steps lead to temperature-sensitive (htrB) or permissive (msbB) phenotypes.
  • Non-lauroylated (htrB mutant) or non-myristoylated (msbB mutant) lipid A are less toxic than the wild-type lipid A.
  • Mutations in the lipid A 4'-kinase encoding gene (lpxK) also decreases the toxic activity of lipid A.
  • [UU135J LPS toxic activity can also be altered by introducing mutations in genes/loci involved in polymyxin B resistance (such resistance has been correlated with addition of aminoarabinose on the 4' phosphate of lipid A).
  • pmrE that encodes a UDP-glucose dehydrogenase
  • the gene pmrF that is present in this region encodes a dolicol-phosphate manosyl transferase (Gunn J. S., Kheng, B. L., Krueger J., Kim K., Guo L., hackett M., Miller S. I. 1998. MoI. Microbiol. 27: 1171-1182).
  • PhoP-PhoQ regulatory system which is a phospho-relay two component regulatory system (e.g., PhoP constitutive phenotype, PhoP c ), or low Mg +"1" environmental or culture conditions (that activate the PhoP-PhoQ regulatory system) lead to the addition of aminoarabinose on the 4'-phosphate and 2-hydroxymyristate replacing myristate (hydroxylation of myristate).
  • This modified lipid A displays reduced ability to stimulate E-selectin expression by human endothelial cells and TNF- ⁇ secretion from human monocytes.
  • Polymyxin B resistant strains are also suitable for use in the invention, as such strains have been shown to have reduced LPS toxicity (see, e.g., van der Ley et al. 1994. In: Proceedings of the ninth international pathogenic Neisseria conference. The Guildhall, Winchester, England).
  • synthetic peptides that mimic the binding activity of polymyxin B may be added to the antigenic compositions to reduce LPS toxic activity (see, e.g., Rustici et al. 1993, Science 259:361-365; Porro et al. Prog Clin Biol Res. 1998;397:315-25).
  • Endotoxin can also be reduced through selection of culture conditions. For example, culturing the strain in a growth medium containing 0.1 mg-100 mg of aminoarabinose per liter medium provides for reduced lipid toxicity (see, e.g., WO 02/097646).
  • Immunogenic compositions used as vaccines comprise an immunologically effective amount of antigen, particularly an immunologically effective amount of GNAl 870, as well as any other compatible components, as needed.
  • immunologically effective amount is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective to elicit for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of the individual to be treated (e.g., non-human primate, primate, human, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating clinician's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.
  • Dosage regimen may be a single dose schedule or a multiple dose schedule
  • unit dosage form refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of the antigenic compositions of the present invention in an amount sufficient to produce the desired effect, which compositions are provided in association with a pharmaceutically acceptable excipient (e.g., pharmaceutically acceptable diluent, carrier or vehicle).
  • the vaccine may be administered in conjunction with other immunoregulatory agents.
  • compositions to be administered are provided in a pharmaceutically acceptable diluent such as an aqueous solution, often a saline solution, a semi-solid form (e.g., gel), or in powder form.
  • a pharmaceutically acceptable diluent such as an aqueous solution, often a saline solution, a semi-solid form (e.g., gel), or in powder form.
  • diluents can be inert, although the compositions of the invention may also include an adjuvant.
  • Suitable adjuvants include, but are not necessarily limited to, alum, aluminum phosphate, aluminum hydroxide, MF59 (4.3% w/v squalene, 0.5% w/v Tween 80, 0.5% w/v Span 85), CpG-containing nucleic acid (where the cytosine is unmethylated), QS21, MPL, 3DMPL, extracts from Aquilla, ISCOMS, LT/CT mutants, ⁇ oly(D,L-lactide- co-glycolide) (PLG) microparticles, Quil A, interleukins, and the like.
  • thr-MDP N-acetyl-muramyl-L-threonyl-D-isoglutamine
  • CGP 11637 N- acetyl-nor-muramyl-L-alanyl-D-isoglutamine
  • nor-MDP N- acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-( 1 '-2'-dipalmitoyl-sn-glycero-3 - hydroxyphosphoryloxy)-ethylamine
  • CGP 19835A referred to as MTP-PE
  • RIBI which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion.
  • the effectiveness of an adjuvant may be determined by measuring the amount
  • compositions include, but are not limited to: (1) oil-in- water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59TM (W090/14837; Chapter 10 in Vaccine design: the subunit and adjuvant approach, eds.
  • oil-in- water emulsion formulations with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components
  • MF59TM W090/14837
  • Chapter 10 in Vaccine design the subunit and adjuvant approach, eds.
  • Span 85 (optionally containing MTP-PE) formulated into submicron particles using a microfluidizer, (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L 121, and thr-MDP either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) REBITM adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components such as monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (DETOXTM); (2) saponin adjuvants, such as QS21 or STIMULONTM (Cambridge
  • cytokines such as interleukins (e.g. EL-I, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 (WO99/44636), etc.), interferons (e.g. gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.; (5) monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL) e.g.
  • MPL monophosphoryl lipid A
  • 3dMPL 3-O-deacylated MPL
  • WO99/52549 (9) apolyoxyethylene sorbitan ester surfactant in combination with an octoxynol (WO01/21207) or a polyoxyethylene alkyl ether or ester surfactant in combination, with at least one additional non-ionic surfactant such as an octoxynol (WO01/21152); (10) a saponin and an immunostiraulatory oligonucleotide (e.g. a CpG oligonucleotide) (WO00/62800); (11) an immunostimulant and a particle of metal salt e.g. WO00/23105; (12) a saponin and an oil-in-water emulsion e.g.
  • an immunostiraulatory oligonucleotide e.g. a CpG oligonucleotide
  • an immunostimulant and a particle of metal salt e.g. WO00/23105
  • WO99/11241 (13) a saponin (e.g. QS21) + 3dMPL + IM2 (optionally + a sterol) e.g. WO98/57659; (14) other substances that act as immunostimulating agents to enhance the efficacy of Hie composition.
  • Muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-25 ace ⁇ yl-normuramyl-L- alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-aIanyl-D-isoglu1an ⁇ iyl-L-alanine-2-(l -2'- dipalrnitoyl-OT-gIycero-3-hydroxyphosphoryloxy)-etliylamine MIP-PE), etc.
  • the antigenic compositions may be combined with a conventional pharmaceutically acceptable excipient, such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium, carbonate, and the like.
  • the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like.
  • concentration of antigen in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs.
  • the resulting compositions may be in the form of a solution, suspension, tablet, pill, capsule, powder, gel, cream, lotion, ointment, aerosol or the like.
  • the protein concentration of antigenic compositions of the invention in the pharmaceutical formulations can vary widely, i.e. from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
  • the methods of the invention provide for administration of one or more antigenic compositions of the invention to a mammalian subject (e.g., a human) so as to elicit a protective immune response against more than one strain of Neisseria species bacteria, and thus protection against disease caused by such bacteria.
  • a mammalian subject e.g., a human
  • the methods of the invention can provide for an immunoprotective immune response against a 1, 2, 3, A, or more strains of Neisseria meningitidis species, where the strains differ in at least one of serogroup, serotype, serosubtype, or GNAl 870 polypeptide (e.g., different GNAl 870 variants and/or subvariants).
  • compositions of the invention can be administered orally, nasally, nasopharyngeally, parenterally, enterically, gastrically, topically, transdermally, subcutaneously, intramuscularly, in tablet, solid, powdered, liquid, aerosol form, locally or systemically, with or without added excipients.
  • parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in such publications as Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pennsylvania (1980).
  • oral administration can require protection of the compositions from digestion. This is typically accomplished either by association of the composition with an agent that renders it resistant to acidic and enzymatic hydrolysis or by packaging the composition in an appropriately resistant carrier. Means of protecting from digestion are well known in the art.
  • compositions are administered to an animal that is at risk from acquiring a Neisseria! disease to prevent or at least partially arrest the development of disease and its complications.
  • An amount adequate to accomplish this is defined as a "therapeutically effective dose.” Amounts effective for therapeutic use will depend on, e.g., the antigenic composition, the manner of administration, the weight and general state of health of the patient, and the judgment of the prescribing physician. Single or multiple doses of the antigenic compositions may be administered depending on the dosage and frequency required and tolerated by the patient, and route of administration.
  • the antigenic compositions described herein can comprise a mixture of vesicles (e.g., OMV and MV), which vesicles can be from the same or different strains.
  • the antigenic compositions can comprise a mixture of vesicles from 2, 3, 4, 5 or more strains, where the vesicles can be OMV, MV or both.
  • the antigenic compositions are administered in an amount effective to elicit an immune response, particularly a humoral immune response, in the host. Amounts for the immunization of the mixture generally range from about 0.001 mg to about 1.0 mg per 70 kilogram patient, more commonly from about 0.001 mg to about 0.2 mg per 70 kilogram patient. Dosages from 0.001 up to about 10 mg per patient per day may be used, particularly when the antigen is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ.
  • Substantially higher dosages are possible in oral, nasal, or topical administration.
  • the initial administration of the mixture can be followed by booster immunization of the same of different mixture, with at least one booster, more usually two boosters, being preferred.
  • the antigenic compositions used to prime and boost are prepared from strains of Neisseria that possess variant immunodominant antigens (the main antigens that are routinely detected by antisera from different host animals that have been infected with Neisseria; representative examples include Porin A, Porin B, pilin, NspA, phospholipids, polysaccharides, lipopolysaccharides, pilins, OmpA, Opa, Ope, etc.) and/or variant GNAl 870 proteins.
  • the strains also may vary with respect to the capsule molecule, as reflected by their serogroup.
  • Serotype and serosubtype classification is currently determined by detecting which of a panel of known monoclonals, which are known to recognize specific Porin molecules, bind to an unknown strain (Sacchi et al., 1998, Clin. Diag. Lab. Immunol. 5:348). It is probable that other such monoclonals will be identified.
  • the use of any novel serotypes and serosubtypes which may be defined by any new monoclonals are specifically contemplated by the invention.
  • serotypes and serosubtypes may be defined, not only by interaction with monoclonal antibodies, but also structurally by the absence and/or presence of defined peptide residues and peptide epitopes (Sacchi et al., 2000, J. Infect. Dis. 182:1169). Serotype and serosubtype classification schemes that are based on structural features of the Porins (known or that may be discovered at a later date) are specifically encompassed by the invention.
  • the antigenic compositions administered are prepared from 2, 3, 4, 5 or more strains, which strains may be homologous or heterologous, usually heterologous, to one another with respect to one or both of GNAl 870 or PorA.
  • the vesicles are prepared from strains express different GNAl 870 proteins, which GNA1870 proteins may be different variants (v.l, v.2, v.3) or subvariants (e.g., a subvariant of v.l, v.2, or v.3).
  • the vesicles are prepared from strains that are heterologous to one another respect to PorA.
  • vesicles are prepared from Neisseria! strains that are genetically diverse to one another (e.g., the strains belong to different serotypes and/or serosubtypes; express different PorA proteins; express different GNAl 870 variants or subvariants; and/or may also optionally belong to different capsular serogroups).
  • the vesicles can be used to prepare an antigenic composition that is a mixture of vesicles prepared from at least 2, 3, 4, or more of such genetically diverse strains.
  • GNAl 870 protein and/or PorA of the second Neisserial strain from which antigenic compositions are prepared and administered is/are different from that of the first strain used to produce vesicles.
  • the second, third, and further administered antigenic compositions can optionally be prepared from Neisserial strains are genetically diverse to the second strain (e.g., the strains belong to different serotypes and/or serosubtypes; express different GNAl 870 proteins; express different PorA proteins; and/or belong to different capsular serogroups).
  • a third strain used for preparing a third antigenic composition may be genetically diverse to the first and second strains used to prepare the first and second antigenic compositions, but may, in some embodiments, not be genetically diverse with respect to the first strain.
  • the antigenic compositions may be obtained from one or more strains of Neisseria, particular Neisseria meningitidis, that are genetically engineered by known methods (see, e.g. U.S. Pat. No. 6,013,267) to express one or more nucleic acids that encode GNAl 870.
  • the host cell may express an endogenous GNAl 870 polypeptide or may modified or selected so as not to express any detectable endogenous GNAl 870 polypeptide.
  • the GNAl 870 polypeptide expressed in the host cell by recombinant techniques can be of the same or different variant type as an endogenous GNAl 870 polypeptide.
  • the host cells may be further modified to express additional antigens of interest, such as Porin A, Porin B, NspA, pilin, or other Neisserial proteins, hi addition, the antigen compositions of the invention can comprise additional Neisserial antigens such as those exemplified in PCT Publication Nos.
  • the antigen compositions are typically administered to a mammal that is immunologically na ⁇ ve with respect to Neisseria, particularly with respect to Neisseria meningitidis.
  • the mammal is a human child about five years or younger, and preferably about two years old or younger, and the antigen compositions are administered at any one or more of the following times: two weeks, one month, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 months, or one year or 15, 18, or 21 months after birth, or at 2, 3, 4, or 5 years of age.
  • administration to any mammal is preferably initiated prior to the first sign of disease symptoms, or at the first sign of possible or actual exposure to Neisseria.
  • the invention also contemplates immunoprotective antibodies generated by immunization with an antigenic composition of the invention, and methods of use.
  • Such antibodies can be administered to an individual (e.g., a human patient) to provide for passive immunity against a Ne ⁇ sserial disease, either to prevent infection or disease from occurring, or as a therapy to improve the clinical outcome in patients with established disease (e.g. decreased complication rate such as shock, decreased mortality rate, or decreased morbidity, such as deafness).
  • Antibodies administered to a subject that is of a species other than the species in which they are raised are often immunogenic.
  • murine or porcine antibodies administered to a human often induce an immunologic response against the antibody.
  • the immunogenic properties of the antibody are reduced by altering portions, or all, of the antibody into characteristically human sequences thereby producing chimeric or human antibodies, respectively.
  • Chimeric antibodies are immunoglobulin molecules comprising a human and non-human portion. More specifically, the antigen combining region (or variable region) of a humanized chimeric antibody is derived from a non-human source (e.g. murine), and the constant region of the chimeric antibody (which confers biological effector function to the immunoglobulin) is derived from a human source. The chimeric antibody should have the antigen binding specificity of the non-human antibody molecule and the effector function conferred by the human antibody molecule.
  • a large number of methods of generating chimeric antibodies are well known to those of skill in the art (see, e.g., U.S. Patents Nos.
  • recombinant DNA vector is used to transfect a cell line that produces an antibody against a peptide of the invention.
  • the novel recombinant DNA vector contains a "replacement gene” to replace all or a portion of the gene encoding the immunoglobulin constant region in the cell line (e.g. a replacement gene may encode all or a portion of a constant region of a human immunoglobulin, or a specific immunoglobulin class), and a "target sequence” which allows for targeted homologous recombination with immunoglobulin sequences within the antibody producing cell.
  • a replacement gene to replace all or a portion of the gene encoding the immunoglobulin constant region in the cell line
  • a replacement gene may encode all or a portion of a constant region of a human immunoglobulin, or a specific immunoglobulin class
  • target sequence which allows for targeted homologous recombination with immunoglobulin sequences within the antibody producing cell.
  • a recombinant DNA vector is used to transfect a cell line that produces an antibody having a desired effector function (e.g. a constant region of a human immunoglobulin), in which case, the replacement gene contained in the recombinant vector may encode all or a portion of a region of an antibody and the target sequence contained in the recombinant vector allows for homologous recombination and targeted gene modification within the antibody producing cell.
  • a desired effector function e.g. a constant region of a human immunoglobulin
  • the resulting chimeric antibody may define the same antigen and/or have the same effector function yet be altered or improved so that the chimeric antibody may demonstrate a greater antigen specificity, greater affinity binding constant, increased effector function, or increased secretion and production by the transfected antibody producing cell line, etc.
  • this invention provides for fully human antibodies.
  • Human antibodies consist entirely of characteristically human polypeptide sequences.
  • the human antibodies of this invention can be produced by a wide variety of methods (see, e.g., Larrick et al., U.S. Patent No. 5,001,065).
  • the human antibodies of the present invention are produced initially in trioma cells (descended from three cells, two human and one mouse). Genes encoding the antibodies are then cloned and expressed in other cells, particularly non-human mammalian cells.
  • trioma technology has been described by Ostberg et al. (1983), Hybridoma 2: 361-367, Ostberg, U.S. Patent No. 4,634,664, and Engelman et al., U.S. Patent No. 4,634,666. Triomas have been found to produce antibody more stably than ordinary hybridomas made from human cells.
  • antibodies can be provided in a pharmaceutical composition comprising an effective amount of an antibody and a pharmaceutical excipients (e.g., saline).
  • the pharmaceutical composition may optionally include other additives (e.g., buffers, stabilizers, preservatives, and the like).
  • An effective amount of antibody is generally an amount effective to provide for protection against Neisserial disease or symptoms for a desired period, e.g. , a period of at least about 2 days to 10 days or 1 month to 2 months).
  • the antigenic compositions of the invention can also be used for diagnostic purposes.
  • the antigenic compositions can be used to screen pre-immune and immune sera to ensure that the vaccination has been effective.
  • Antibodies can also be used in immunoassays to detect the presence of particular antigen molecules associated with Neisserial disease.
  • Group C strain RM1090 (C:2a:5-1,2) and mutants described below that were derived from this strain, and group B strain H44/76 and mutants described below that were derived from this strain, were used to prepare the outer membrane vesicle (OMV) vaccines.
  • Strain RMl 090 naturally expresses low levels of a GNAl 870 variant 2 protein.
  • the RM1090 strain in which the GNA1870 gene was inactivated (RMl 090 ⁇ GNA1870, described below) was used for over-expression of GNAl 870 variant 1.
  • Strain H44/76 is a relatively high expresser of GNAl 870 variant 1.
  • strains naturally express sub- variants of the GNAl 870 variant 1 protein and were selected as test organisms to determine the breadth of vaccine-induced anti-GNA1870 variant 1 protective immunity. These strains are genetically diverse, as defined by electrophoretic type and/or multilocus sequencing type, and they also express several different PorA VR sequence types. Variant 1 strains were chosen because they account for about 60% of disease-producing group B isolates (Masignani et al. J Exp Med 2003; 197:789-99).
  • Strain Cu385 and strain H44/76 express GNAl 870 variant 1 with an identical amino acid sequence to that of strain MC58 (Welsch et al. J Immunol 2004; 172: 5606- 15), the gene used to express the recombinant GNAl 870 variant 1 protein in E. coli, and also used in the shuttle vector to over-express GNAl 870 in the N. meningitidis vaccine strain RMl 090 (see below). The remaining seven strains express subvariants of GNAl 870 variant 1 with slight sequence variations from the variant of GNA 1870 protein encoded by the gene from strain MC58 (Masignani et al. 2003, supra ).
  • strain Cu385 was highly susceptible to complement-mediated bactericidal activity of antibodies elicited in mice immunized with a recombinant GNAl 870 protein vaccine (Table 1).
  • JV. meningitidis strains BZ198, M1390, M6190 and NZ98/294 were selected because they were resistant to bactericidal activity of antisera prepared against the recombinant GNAl 870 vaccine (bactericidal titers ⁇ l:10).
  • pFP12-GNA 1870 shuttle vector construct Over-expression of GNAl 870 in JV. meningitidis was accomplished using the shuttle vector FP 12, which has an origin of replication from a naturally-occurring plasmid in JV. gonorrhoeae and has been shown to transform E. coli and JV. meningitidis stably (Pagotto et al. Gene 2000;244:13-9).
  • the variant 1 GNA1870 gene including the putative FUR box promoter from JV.
  • meningitidis strain MC58 was amplified from genomic DNA by PCR using the following primers: GNA1870FURSphIF 5', 5"- ATCGGCATGCGCCGTTCGGACGACATTTG-S” and GNAl 870FURStUlR 3' 5"- AAGAAGGCCTTTATTGCTTGGCGGCAAGGC-S”.
  • the PCR product was then digested with Sphl and Stul restriction endonucleases and ligated into pFP12 plasmid digested with Sphl and Stul, which removed the GFP gene.
  • the resulting plasmid, pFP12-GNA1870 was transformed and propagated in E. coli strain TOPlO competent cells (Invitrogen), which was grown in Luria-Bertani medium at 37° C under chloramphenicol selection (50 ⁇ g/ml).
  • GNAl 870 gene was inactivated (RMl 090 ⁇ GNA1870) was made by homologous recombination by transformation with plasmid pBSUDGNA1870ERM using erythromycin selection (5 ⁇ g/ml).
  • a mutant over-expressing GNAl 870 3-4 colonies of the RM1090 ⁇ GNA1870 knockout strain were selected from a chocolate agar plate that had been grown overnight. The colonies of bacteria were mixed with 3 ⁇ g of the plasmid pFP12- GNAl 870 in 20 ⁇ l EB buffer (Qiagen), plated onto a chocolate agar plate, and incubated for 5 hrs at 37 0 C.
  • the larger culture was grown at 37°C with vigorous shaking to an OD 620 of 0.8 to 1.0. Phenol was added (0.5% wt/vol), and the broth was left at 4°C overnight to kill the bacteria. The bacterial cells were pelleted by centrifugation (10,000 X g) for 30 min at 4 0 C 5 and frozen and stored at -20 0 C until used for preparation of the outer membrane vesicle vaccines.
  • K meningitidis membrane fractions for OMVs were prepared as previously described without the use of detergents to avoid extraction of the GNAl 870 lipoprotein (Moe et al. 2002, supra).
  • the frozen bacterial cells were suspended in 40 ml of PBS and sonicated on ice with a sonifier fitted with a microtip (Branson, Danbury, Conn) for four 15-s bursts, which was sufficient to release membrane blebs but not to cause complete lysis of the bacteria.
  • the bacterial suspensions were cooled on ice between the bursts. Cell debris was removed by centrifugation at 5,000 X g for 15 min, and the membrane fraction remaining in the supernatant was obtained by ultracentrifugation at 100,000 X g for 1 h at
  • MVs were used, which are obtained from blebs released by the bacteria into the supernatant as described in (Moe et al. 2002, supra); see also WO 02/09643 .
  • H44/76 and mutant thereof, the frozen bacterial cells were resuspended in 20 ml PBS buffer, and sonicated with four 15-s bursts.
  • Cell debris was removed by centrifugation (16,000 X g) for 30 min at 4°C, and the cell membranes, which were enriched with outer membrane proteins, were collected from the soluble fraction by centrifugation (100,000 X g) for 2 hours.
  • the protein concentrations were determined by the DC protein assay (Bio-Rad, Richmond, CA.) and the BCA Protein Assay Kit (Pierce, Rockford, IL).
  • the OMV preparations were analyzed by 15% SDS-PAGE (12.5% SDS- PAGE for the H44/76 preparations) as described by Laemmli (Nature 1970;227:680-5) employing a Mini-Protean II electrophoresis apparatus (Bio-Rad), and Western blot.
  • Samples were suspended in sample buffer (0.06 M Tris*HCl, pH 6.8, 10% (v/v) glycerol, 2% (w/v) SDS, 5% (v/v) 2-mercaptoethanol, 10 ⁇ g/ml bromophenol blue) and heated to 100 0 C for 5 min. before loading directly onto the gel.
  • sample buffer (0.06 M Tris*HCl, pH 6.8, 10% (v/v) glycerol, 2% (w/v) SDS, 5% (v/v) 2-mercaptoethanol, 10 ⁇ g/ml bromophenol blue
  • Bound antibody was detected using rabbit anti-mouse IgG+ A+M- horseradish peroxidase conjugated polyclonal antibody (Zymed, South San Francisco, CA) and "Western Lightning" chemiluminescence reagents (PerkinElmer Life Sciences, Inc., Boston, MA).
  • the detecting anti-GNA1870 antiserum was from mice immunized sequentially with one injection each of 10 ⁇ g of recombinant GNAl 870 v.l (gene from N. meningitidis strain MC58), followed by a dose of recombinant v.3 protein (gene from strain M1239), followed by a dose of recombinant v.2 protein (gene from strain 2996). Each injection was separated by 3- to 4-weeks.
  • the recombinant protein vaccine was expressed in E. coli as previously described using a GNAl 870 DNA sequence encoding six COOH-terminal histidines (His tag) and devoid of the N-terminal sequence coding for the putative leader peptide (Welsch et al. J Immunol 2004; 172:5606- 15).
  • This non-lipidated HisTag GNAl 870 protein was used since it provides for greater ease of preparation than the recombinant lipoprotein, and data from earlier studies indicated that the non-lipidated antigen given with Freund's complete and incomplete adjuvants elicited strong bactericidal antibody responses in mice against the majority of strains tested.
  • each mouse received a dose of 1.25 ⁇ g of total protein present in OMV and 170 ⁇ g of aluminum phosphate. Three injections were given separated by three weeks. Blood was collected by cardiac puncture three weeks after the third dose. The sera were separated by centrifugation and stored frozen at -70 0 C until use. [00185] Absorption of anti-GNA1870 antibodies. To test the contribution of anti-GNA1870
  • GNAl 870 antibodies to antibody functional activity we absorbed serum pools to remove anti-GNA1870 antibodies.
  • 100 ⁇ l of serum pools diluted 1:2 in PBS buffer containing 10 niM imidazole was added to a column that contained 250 ⁇ l of Ni-NTA Sepharose (Qiagen, Valencia, CA) that had been complexed with 200 ⁇ g of recombinant GNA1870-HisTag protein or, as a negative control, recombinant NadA-HisTag protein (Comanducci et al. J Exp Med 2002;195:1445-54; Hou et al. 2005, supra).
  • the solid-phase antigen consisted of rGNAl870 v.l or v.2 proteins.
  • the secondary antibody was a 1 :2000 dilution of alkaline phosphatase-conjugated rabbit anti- mouse IgM+G+A (Zymed).
  • the serum titer was defined as the dilution giving an OD 4 0 5 of 0.5 after a 30-min incubation with substrate.
  • Complement-mediated bactericidal antibody activity was performed as previously described (Moe et al. 2002, supra) using mid-log phase bacteria grown in Mueller Hinton broth supplemented with 0.25% glucose.
  • the final reaction mixture contained different dilutions of test sera, 20% (v/v) human complement, and Gey's buffer containing 1% BSA.
  • the complement source was human serum from a healthy adult with no detectable intrinsic bactericidal activity (Granoff et al. J Immunol 1998;160:5028-36; Welsch et al. 2003, supra).
  • Serum bactericidal titers were defined as the serum dilution resulting in a 50% decrease in CFU per ml after 60 min. of incubation of bacteria in the reaction mixture, as compared with control CFU per ml at time 0.
  • bacteria incubated with the negative control antibody and complement showed a 150 to 200% increase in CFU/mL during the 60 min. of incubation.
  • anti-GNAl 870 antibodies to bind to the surface of live N. meningitidis was determined by flow cytometric detection of indirect fluorescence assay, performed as described previously (Granoff et al. J Immunol 2001;167:3487-3496). Positive controls included mouse monoclonal antibodies specific for the group C polysaccharide capsule (1076.1(Garcia-Ojeda et al. Infect Immun 2000;68:239-46)), PorA Pl.2 (Granoff et al. J Immunol 2001;167:3487 ⁇ 3496), and GNAl 870 variant 1 (JAR3)( Welsch et al.
  • EXAMPLE 1 SURFACE-ACCESSIBILITY OF GNA1870 ONiV. MENINGITIDIS STRAIN RM1090.
  • the strain transformed with the shuttle vector encoding GNAl 870 showed strong binding with both the polyclonal and monoclonal anti-GNAl 870 antibodies.
  • GNAl 870 is exposed on the surface of the RMl 090 strain transformed with the pFP12-GNA1870 shuttle vector.
  • the positive control anticapsular and anti-PorA P 1.16
  • monoclonal antibodies bound to H44/76 wildtype strain and to a mutant of strain H44/76 that over-expresses GNAl 870 (both shown in row 1).
  • the positive control antibodies also bound to H44/76 ⁇ GNA1870 (shown in row 2).
  • the OMV prepared from the strain transformed with the shuttle vector containing the GNAl 870 gene showed decreased expression of proteins resolving between 29 and 32 kDa.
  • GNAl 870 is not readily apparent in any of the OMV preparations including the OMV prepared from the mutant strain over- expressing GNAl 870 (lane 5).
  • 1 ⁇ g of the recombinant GNA 1870 variant protein is shown in Lane 6).
  • Fig. 2A Western blot with a polyclonal mouse antiserum raised against v.
  • the H44/76 OMV preparations were analyzed by Western blot using polyclonal antiserum to GNAl 870 (Fig. 2B).
  • the amount of OMV loaded onto the gel was standardized based on total protein content of the preparations.
  • GNAl 870 was expressed in the membrane preparations from the wildtype strain and was increased in the corresponding preparation from the mutant engineered to over-express this protein.
  • the increase in GNAl 870 was modest (approximately 3 -fold)
  • Table 2 and Fig. 5 summarize the serum anti-GNAl 870 antibody responses of the different groups of mice as measured by ELISA.
  • the highest antibody responses to the variant 1 protein in Table 2 were in mice immunized with the recombinant GNAl 870 v.l vaccine only, or with the recombinant GNAl 870 v.l vaccine given as a mixture with an OMV vaccine (titers against the variant 1 protein of 1:120,000 and 1:300,000, respectively).
  • the mice immunized with OMV prepared from strain RM 1090 over-expressing variant 1 GNAl 870 had a 4- to 10-fold lower anti-GNA 1870 titer (1:32,000).
  • mice immunized with OMV prepared from the wild-type RMl 090 strain had undetectable or negligible anti-GNAl 870 antibody responses as measured against either the variant 1 or 2 proteins. This result suggests that in the absence of over-expression, GNAl 870 in OMV from the wild-type strain is poorly immunogenic.
  • mice were immunized with H44/76 OMV (1.25 ⁇ g of total protein) or 5 ⁇ g of rGNAl 870 given with aluminum phosphate. Serum samples were obtained 3 weeks after the third dose and pooled (2 pools per vaccine group, each pool prepared from 4 to 5 mice). As shown in Fig. 5, control mice immunized with the aluminum adjuvant alone had no detectable anti-GNA1870 antibody (GMT ⁇ l:10, bar 1), whereas mice immunized with rGNA1870 showed the highest responses (GMT 1 :23,500, bar 2).
  • the vaccines consisted of 5 ⁇ g of total protein absorbed with A1 2 (PO4) 3 .
  • the OMV + rGNAl 870 vaccine consisted of a mixture of 2.5 ⁇ g of OMV and 2.5 ⁇ g of rGNAl 870 (v.l).
  • b Serum dilution in an ELISA giving an OD of 0.5 after 30 mins incubation with substrate. Data shown are the respective geometric means of titers measured in 2 serum pools from each vaccine group. Each pool contained equal volumes of sera from 4 to 5 immunized mice.
  • Figure 3A summarizes the serum bactericidal antibody responses of the different groups of mice as measured against four of the test strains.
  • Mice immunized with the recombinant GNAl 870 protein vaccine alone, or with the recombinant GNAl 870 vaccine in combination with an OMV vaccine, or with the OMV over-expressing GNAl 870 developed high bactericidal titers against strain Cu385 that were not significantly different from each other (compare bars 4, 5 and 6 of upper panel).
  • strain Cu385 expresses the canonical GNAl 870 v. 1 protein (identical amino acid sequence as that of strain MC58, the gene used to express the recombinant GNAl 870 protein), and was known from our previous study to be highly susceptible to bactericidal activity of antibody elicited in mice by the recombinant GNAl 870 vaccine (Table 1).
  • Cu385 has a heterologous PorA serosubtype (Pl.19,15) to that of the vaccine strain RM1090 (Pl.5,2), and, therefore, strain Cu385 was expected to be resistant to bactericidal activity of antibodies raised against the control OMV vaccine that did not over-express GNAl 870 variant 1 (Tappero et al. JAMA 1999;281 : 1520-7; Moe et al. 2002, supra). .
  • Figure 3 A also shows the corresponding serum bactericidal titers measured against strain M6190 (second panel from the top) that expresses a sub-variant of v. 1 GNAl 870 protein as compared with that of the engineered vaccine strain.
  • Both strains express PorA molecules that are heterologous with that of the RMl 090 vaccine strain (Table I) 5 and were not killed by sera from mice immunized with OMV vaccines prepared from the RM1090 wild-type or GNAl 870 knockout strains (bars 2 and 3, geometric mean titers ⁇ l:10).
  • FIG. 3B summarizes the serum bactericidal antibody responses against six strains, including H44/76, which were used to prepare the OMV vaccine.
  • strain H44/76 Five of the six strains have PorA serosubtypes heterologous to that of H44/76. Strain H44/76 also expresses a GNAl 870 variant 1 protein sequence identical to that of strain MC58, which contains the gene used to clone and express the recombinant GNAl 870 protein vaccine. All of the vaccine preparations except the negative control aluminum adjuvant elicited high serum bactericidal antibody responses when measured against the H44/76 vaccine strain (Fig. 3B 5 Panel A).
  • mice immunized with the OMV vaccine with over-expressed GNAl 870 had high bactericidal antibody responses against strain 4243, low but detectable bactericidal responses against strains NZ98/254, BZl 98, and Zl 092, and no detectable bactericidal activity against M6190 (titer ⁇ 1 :10).
  • all strains were readily killed by complement together with positive control antibodies to the respective PorA and/or polysaccharide capsules.
  • EXAMPLE 4 ACTIVATION OF C3B COMPLEMENT DEPOSITION ON THE SURFACE OF LIVE ENCAPSULATED N. MENINGITIDIS CELLS.
  • the panels in columns 3 to 6 of Fig. 4A show the effect of adding complement to dilutions of serum pools obtained from groups of immunized mice immunized with the different vaccines.
  • a Ni-NTA affinity column loaded with His-tagged recombinant GNAl 870 was used to absorb anti-GNA1870 antibodies from a serum pool prepared from mice immunized with H44/76 OMV with over-expressed GNAl 870. As shown in Table 3, by ELISA, 98% of the anti-GNA1870 antibodies were removed by this column as compared with that of serum absorbed with a negative control column containing the Ni-NTA matrix only. After absorption on the negative control column, bactericidal activity against strain 4243 was similar to that of the original non-absorbed serum pool, while adsorption of the anti-GNA1870 antibodies resulted in complete loss of bactericidal activity.
  • a pool prepared from sera from mice immunized with H44/76 OMV with overexpressed GNAl 870 was adsorbed on a column containing a Ni-NTA matrix (Qiagen) that had been incubated over night with 50 ⁇ g/ml recombinant His-tagged GNAl 870. The flow through was collected and concentrated to the original volume.
  • the control column contained Ni-NTA matrix without the His-tagged protein.
  • the OMV vaccine prepared from the RM1090 N. meningitis strain that is engineered to over-expresses GNAl 870 showed decreased expression of several other cell envelope proteins as compared with the respective proteins in OMV prepared from the wild- type vaccine RM1090 strain, or the RM1090 ⁇ GNA1870 knockout strain (Fig. 2A, Panel A). Therefore, it was possible that the higher functional activity of the antisera from mice immunized with OMV that over-expressed GNAl 870 resulted from antibodies elicited by antigens other than GNAl 870.
  • Strain M6190 1000 600 600 a A serum pool was prepared from five mice immunized with the OMV vaccine from strain RMl 090 engineered to over-express GNAl 870. The antiserum was absorbed on a recombinant GNAl 870 affinity column or, as a negative control, an affinity column containing recombinant NadA (See methods). The pass- through fractions were combined and concentrated to their original serum volume by membrane filtration (see methods). b Serum dilution in the flow cytometric complement activation assay that elicited a 10-fold increase in immunofluorescence as compared with negative control serum (See Figure 4).
  • Table 4 also summarizes the bactericidal titers of the absorbed serum pools as measured against strains Cu385 and M6190. Absorption of the anti-GNA1870 antibodies completely removed the bactericidal activity against strain Cu385 but had no significant effect on the titer against strain M6190. This latter result was expected since strain M6190 expresses a PorA with has a homologous serosubtype to PorA expressed by the RM 1090 vaccine strain and the bactericidal anti-PorA antibodies would not be removed by the GNAl 870 or NadA affinity columns.
  • FIG. 6 shows the geometric means of the CFU/ml in blood obtained 4- to 6-hours after the challenge. All 10 rats treated with a 1 : 15 dilution of the serum pool from negative control mice immunized with aluminum phosphate alone had bacteremia with a geometric mean CFU/ml of ⁇ 10 5 (Panel A, bar 1).
  • the serum pool from the mice immunized with the OMV vaccine that over-expressed GNAl 870 conferred protection (PO.0002 compared with the geometric mean of rats treated with a 1:15 dilution of the negative control serum) but there was no significant protective activity by the higher dilution of the serum pools from the mice immunized with any of the other 3 vaccine groups tested, including the serum from mice given the recombinant GNAl 870 vaccine (bar 7, P>0.10).
  • EXAMPLE 9 IMMUNIZATION OF MICE WITH A VESICLE VACCINE PREPARED FROM STRAIN RM1090 THAT OVER-EXPRESSES NEISSERIAL SURFACE PROTEIN A (NSPA) IS NOT ASSOCIATED WITH ENHANCED SERUM BACTERICIDAL ANTIBODY RESPONSES.
  • a microvesicle vaccine was prepared from strain RMl 090 in which the gene for NspA in the wildtype strain had been inactivated.
  • a second vesicle vaccine was prepared from the RMl 090 NspA-knockout strain transformed with the shuttle vector pFP12 containing the NspA gene from strain 8047.
  • SDS PAGE the resulting vesicles from the strain transformed with the shuttle vector contained 10- fold increased expression of the NspA protein as compared with the RMl 090 wildtype strain (data not shown).
  • mice were immunized with 3 doses of the vesicle vaccines given with aluminum phosphate, and serum was collected 3 weeks after the last immunization.
  • Table 5 summarizes the serum bactericidal antibody responses as measured against four test strains, BZl 98, NZ98/254, Cu385 and Z1090.
  • Microvesicles were prepared as described by Moe et al (Infection Immunity 2002:70:6021-6031) from a NspA-knockout the knockout strain transformed with shuttle vector pFP12 containing the
  • NspA gene from strain 8047. Mice were immunized with three injections and bled ⁇ 3 weeks after the last injection. The titers shown are from pooled serum from 9 to 10 mice in each vaccine group.
  • the respective anti-NspA antibody titers as measured by ELISA were ⁇ l:50 (aluminum phosphate group), 1:700 (vesicles from RM1090 NspA knockout strain) and 1:19,000 (vesicles from RM1090 strain over-expressing NspA).
  • b Lowest concentration giving 50% killing of bacteria after 1 hr. incubation with human complement c Highest dilution of serum giving 50% killing of bacteria after 1 hr. incubation with human complement d Expressed in the NspA knockout background

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.

Description

GNA1870-BASED VESICLE VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BYNElSSERLi MENINGITIDIS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the priority benefit of U.S. provisional application serial no. 60/647,911, filed January 27, 2005, which application is incorporated by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with government support under Public Health
Service grant nos. ROl AI46464, R21 AI061533, from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, and T32-HL007951, from the National Heart, Lung and Blood Institute of the National Institutes of Health. The government may have certain rights in this invention.
FIELD OF THE INVENTION
[0003] This invention relates to broad-spectrum vaccines for the prevention of diseases caused by Neisseria meningitidis.
BACKGROUND OF THE INVENTION
[0004] Neisseria meningitidis is a Gram-negative bacterium which colonizes the human upper respiratory tract and is responsible for worldwide sporadic and cyclical epidemic outbreaks of, most notably, meningitis and sepsis. The attack and morbidity rates are highest in children under 2 years of age. Like other Gram negative bacteria, Neisseria meningitidis typically possess a cytoplasmic membrane, a peptidoglycan layer, an outer membrane which together with the capsular polysaccharide constitute the bacterial wall, and pili which project into the outside environment. Encapsulated strains of Neisseria meningitidis are a major cause of bacterial meningitis and septicemia in children and young adults (Rosenstein et al. J Infect Dis 1999;180:1894-901).
[0005] Humans are the only known reservoir for Neisseria meningitidis spp.
Accordingly, Neisseria! species have evolved a wide variety of highly effective strategies to evade the human immune system. These include expression of a polysaccharide capsule that is structurally identical with host polysialic acid (i.e. serogroup B) and high antigenic mutability for the immunodominant noncapsular epitopes, i.e. epitopes of antigens that are present at the surface in relatively large quantities, are accessible to antibodies, and elicit a strong antibody response.
[0006] The prevalence and economic importance of invasive Neisseria meningitidis infections have driven the search for effective vaccines that can confer immunity across serotypes, and particularly across group B serotypes or serosubtypes. However, many efforts to develop broad spectrum vaccines have been hampered by the wide variety of highly effective strategies used by Neisserial species to evade the human immune system. [0007] Capsular-based vaccines are available for prevention of disease caused by group A, C, Y and W-135 strains (reviewed in Granoff et al. Meningococcal Vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. 4th ed. Philadelphia: W. B. Saunders Company, 2003). However, there is no vaccine approved for use in the U.S. or Europe for prevention of disease caused by group B strains, which account for about 30% of disease in North America (Lingappa et al. Vaccine 2001;19:4566-75; Raghunathan et al. Annu Rev Med 2004;55:333- 5) and more than two-thirds of cases in Europe (Cartwright et al. Vaccine 2001;19:4347-56; Trotter et al. Lancet 2004;364:365-7). One reason for the lack of a group B capsular-based vaccine is that the group B capsule can elicit an autoantibody response in humans (Finne et al. Lancet 1983;2:355-7), and the polysaccharide is poorly immunogenic, even when conjugated to carrier proteins (Jennings et al. J Immunol 1981; 127: 1011-8). There also are potential safety issues for a capsular-based group B vaccine that is capable of eliciting autoreactive group B anticapsular antibodies. Therefore, recent group B meningococcal vaccine research has focused on the use of non-capsular antigens. [0008] Outer membrane vesicle (OMV) vaccines have been proven to elicit protective immunity against group B meningococcal disease in humans (reviewed in Jodar et al. Lancet 2002;359:1499-1508). Recently an OMV vaccine was licensed and introduced in New Zealand in response to a public health intervention to halt a group B epidemic that has been ongoing for more than a decade (Thomas et al. N Z Med J 2004;l 17:U1016; Desmond et al. Nurs N Z 2004;10:2; Baker et al. J Paediatr Child Health 2001 ;37:S 13-9). Other vesicle-based approaches to immunization have been described (see, e.g., Cartwright K et al, 1999, Vaccine; 17:2612-2619; de Kleinjn et al, 2000, Vaccine, 18:1456-1466; Rouupe van der Voort ER, 2000, Vaccine, 18:1334-1343; Tappero et al., 1999, JAMA 281:1520; Rouupe van der Voort ER, 2000, Vaccine, 18:1334-1343;US 2002/0110569; WO 02/09643). [0009] Immunization of children and adults with meningococcal outer membrane vesicle (OMV) vaccines induces serum bactericidal antibodies, a serological correlate of protection against disease (Goldschneider et al51969, J. Exp. Med. 129:1307). The efficacy of OMV vaccines for prevention of meningococcal B disease also has been demonstrated directly in older children and adults in randomized, prospective clinical trials, and in retrospective case-control studies. Thus, the clinical effectiveness of outer membrane vesicle vaccines is not in dispute. Such vaccines are licensed for use in children in New Zealand, and close to licensure in Norway for use in older children and adults, and are in late-stage clinical development for licensure in other European countries. An OMV vaccine prepared by the Finley Institute in Cuba also is available commercially and has been given to millions of children in South America.
[0010] However, the serum bactericidal antibody response to OMV vaccines tends to be strain specific (Tappero et al., 1999, JAMA 281:1520; and Rouupe van der Voort ER, 2000, Vaccine, 18:1334-1343). Moreover, currently available OMV vaccines are also limited in that the bactericidal antibody responses are largely directed against surface-exposed loops of a major porin protein, PorA (Tappero et al. JAMA 1999;281 : 1520-7), which is antigenically variable (Sacchi et al. J Infect Dis 2000; 182:1169-76). Because of the immunodominance of PorA, the immunity induced is predominantly specific to the strains from which the membrane vesicles were obtained (Tappero et al., 1999, JAMA 281 : 1520; Martin SL et al, 2000, Vaccine, 18:2476-2481). Thus, OMV vaccines are useful for prevention of disease in epidemic situations caused by a predominant meningococcal strain with a single PorA serosubtype, such as the P 1.4 epidemic strain in New Zealand (Baker et al. 2001, supra). However, there is considerable PorA diversity among strains causing endemic disease such as that found in the U.S (Sacchi et al. 2000, supra). Furthermore, even minor amino acid polymorphisms can decrease susceptibility of strains to the bactericidal activity of antibodies to PorA (Martin et al. Vaccine 2000; 18:2476-81). [0011] The completion of genome sequencing projects for several Neisseria meningitidis strains provided a catalogue of all potential meningococcal protein antigens. Through a combination of bioinformatics, microarray technology, proteomics and immunologic screening, a large number of new meningococcal vaccine candidates have been identified (Pizza et al. Science 2000;287:1816-20; De Groot et al. Expert Rev Vaccines 2004;3 :59-76). Among these numerous candidates is Genome derived Neisserial Antigen 1870 (GNAl 870). GNAl 870, which is also known as NMB 1870 (WO 2004/048404) or LP2086 (see, e.g., Fletcher et al. Infect Immun 2004 72:2088-2100), is an approximately 27 IcDa lipoprotein expressed in all K meningitidis strains tested (Masignani et al. J Exp Med 2003;197:789~99; Giuliani et al. Infect. Immun 2005; 73:1151-60; Welsch et al. J Immunol 2004; 172:5606-15).
[0012] N. meningitidis strains can be sub-divided into three GNAl 870 variant groups
(v.l, v.2, and v.3) based on amino acid sequence variability and immunologic cross- reactivity (Masignani et al. J Exp Med 2003; 197:789-99). Variant 1 strains account for about 60% of disease-producing group B isolates (Masignani et al. 2003, supra). Within each variant group, there is on the order of about 92% or greater conservation of amino acid sequence.
[0013] Mice immunized with recombinant GNAl 870 developed high serum bactericidal antibody responses against strains expressing GNAl 870 proteins of the homologous variant group (Masignani et al. 2003, supra; Welsch et al. 2004, supra). However, a number of strains that expressed sub-variants of the respective GNAl 870 protein were resistant to anti-GNA1870 complement-mediated bacteriolysis. Although the cause of this phenomenon is not known, conceivably this may be due to minor GNAl 870 polymorphisms, or due to strain differences in the accessibility of critical GNAl 870 epitopes on the surface of the bacteria that result in decreased binding and/or complement activation by the anti-GNA1870 antibodies. The recombinant GNAl 870 protein vaccine used in the above immunogenicity studies was expressed in E. coli as a His-Tag protein devoid of the leader peptide. The recombinant protein also lacked the motif necessary for post- translational lipidation, which may decrease immunogenicity (Fletcher et al. Infect Immun 2004;72:2088-100).
[0014] The vaccine potential of a combination of recombinant PorA and recombinant
GNAl 870 has been explored (Fletcher et al. Infect Immun 2004, 72:2088-1200). There was no apparent interference in the antibody responses to the two antigens when the combination vaccine was given to mice. However, the recombinant combination required restoration of conformation PorA epitopes, which are necessary for eliciting ant-PorA bactericidal antibodies (See, for example, Christodoulides et al, Microbiology, 1998;144: 3027-37 and Muttilainen et al, Microb Pathog 1995;18:423-36). Also, the combination recombinant vaccine was not shown to enhance anti-GNA1870 bactericidal antibodies against N. meningitidis strains expressing subvariants of the GNAl 870 protein used in the vaccine. [0015] O'Dwyer et al. (Infect Immun 2004;72:6511-80) describes preparation of an outer membrane vesicle (OMV) vaccine from a commensal N. flavescens strain that was genetically engineered to express Neisserial surface protein A (NspA), a highly conserved meningococcal membrane protein vaccine candidate that is not naturally-expressed by N. flavescens. The immunized mice developed NspA-specific serum opsonophagocytic activity. Also, after absorption of antibodies to the OMV, the residual anti-NspA antibodies conferred passive protection to mice given a lethal challenge of an encapsulated N. meningitidis strain. However, the antibodies elicited by the modified JV. flavescens OMV vaccine in this study were not shown to give superior protection to those elicited by the OMV from N. flavescens that did not express the heterologous antigen. Also, the modified iV. flavescens OMV did not elicit serum bactericidal antibody responses whereas in previous studies, mice immunized with recombinant NspA expressed in E. coli vesicles (Moe et al. Infect Immun 1999;67: 5664-75; Moe et al. Infect Immun 2001;69:3762-71), or reconstituted in liposomes (Martin et al. In: Thirteenth International Pathogenic Neisseria Conference. Oslo: Nordberg Aksidenstrykkeri AS, 2002), developed serum bactericidal antibody. PCT publication No. WO 02/09746 and US Publication No. US 20040126389 also describes OMV prepared from strains engineered to over-express aNeisserial antigen, with NspA, Omp85, pili (PiIQ, PiIC), PorA, PorB, Opa, Tbρ2, TbpA, TbpB, Hsf, PIdA, HasR, FrpA/C, FrpB, Hap, LbpA/LbpB, FhaB, Iipo02, MItA, and ctrAi listed as specific examples of such antigens. [0016] The present invention overcomes the disadvantages of prior art approaches to vaccination and elicits protective immunity against a broad spectrum of Neisseria meningitidis strains, notably (but not exclusively) including strains belonging to serogroup B.
LITERATURE
[0017] Bjune et al. NIPH Ann 1991;14:125-30; discussion 130-2; Chen et al. In:
Thirteenth International Pathogenic Neisseria Conference Nordberg Aksidenstrykkeri AS, 2002; Christodoulides et al. Microbiology 1998;144 ( Pt 11):3027-37; Claassen et al. Vaccine 1996;14:1001-8; de Kleijn et al. Vaccine 2000;18:1456-66.; Frasch et al. Meningococcal vaccines: methods and protocols. Totowa, New Jersey: Humana Press, 2001:81-107; Fukasawa et al. FEMS Immunol Med Microbiol 2004;41:205-10; Hoist et al. Vaccine 2003 ;21:734-7; Humphries Vaccine 2004;22: 1564-9; Jansen et al. FEMS Immunol Med Microbiol 2000;27:227-33; Kijet et al. In: Thirteen international Pathogenic Neisseria Conference Nordberg Aksidenstrykkeri, 2002; Martin et al. Vaccine 2000;l 8:2476-81; McGuinness et al. Lancet 1991;337:514-7.; Morley et al. Vaccine 2001;20:666-87; Muttilainen et al. Microb Pathog 1995;18:423-36; Parmar et al. Biochim Biophys Acta 1999;1421 :77-90; Newcombe et al. Infect Immun 2004;72:338-44; O'Dwyer et al. Infect Immυn 2004;72:6511-8; Oliver et al. Infect Immun 2002;70:3621-6 Peeters et al. Vaccine 1996;14:1009-15.; Peeters et al. Vaccine 1999;17:2702-12; Rouppe van der Voort et al. Vaccine 2000;18:1334-43; Sanchez et al. Vaccine 2002;20:2964-71; Steeghs et al. EMBO J 2001;20:6937-45; Steeghs et al. J Endotoxin Res 2004;10:l 13-9; Troncoso et al. FEMS Immunol Med Microbiol 2000;27: 103-9; Vandeputte et al. J Biol Chem 2003; van der Ley P et al. Vaccine 1995;13:401-7; Claassen et al. Vaccine 1996;14:1001-8; Peeters et al. Vaccine 1996; 14:1009-15 ; Cantini et al. J Biol Chem. 2005 Dec 31; [Epub ahead of print].
SUMMARY OF THE INVENTION
[0018] The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.
In one aspect, the invention features compositions comprising antigenic vesicles prepared from a first Neisseria species bacterium, wherein the Neisseria species bacterium produces a level of a GNAl 870 polypeptide sufficient to provide for production of a vesicle that, when administered to a subject, elicits anti-GNA1870 antibodies; and a pharmaceutically acceptable carrier. The vesicle can be outer membrane vesicles (OMVs), microvesicles (MV), or a mixture of OMVs and MVs. The Neisseria species bacterium can be a naturally occurring bacterium, or genetically modified in GNAl 870 polypeptide production (e.g., to provide for expression of a GNAl 870 polypeptide from a heterologous promoter, to express an exogenous GNAl 870 polypeptide, and the like). The GNAl 870 polypeptide can be endogenous to the host cell. In some embodiments, the Neisseria species bacterium is genetically modified to disrupt production of an endogenous GNAl 870 polypeptide, and is genetically modified to produce a GNAl 870 polypeptide from a nucleic acid exogenous to the host cell. In other embodiments, the Neisseria species bacterium is genetically modified to produce at least two different GNAl 870 polypeptides (e.g., GNAl 870 polypeptides of different variant groups (v.l, v.2, and v.3). In further related embodiments, the Neisseria species bacterium is deficient in production of capsular polysaccharide.
[0019] In one embodiment, the composition further comprises an antigenic vesicle prepared from a second Neisseria species bacterium, wherein the second Neisseria species bacterium produces a level of a GNAl 870 polypeptide sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNA1870 antibodies, and wherein the second Neisseria species bacterium is genetically diverse to the first Neisseria species bacterium (e.g., the first and second bacteria differ in at least one of serogroup, serotype, or serosubtype). In further related embodiments, the GNAl 870 polypeptide of the second Neisseria species bacterium is different from the GNAl 870 polypeptide of the first Neisseria species bacterium.
[0020] In another embodiment, the composition further comprises an antigenic vesicle prepared from a third Neisseria species bacterium, wherein the second Neisseria species bacterium produces a level of a GNAl 870 polypeptide sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNA1870 antibodies, and wherein the third Neisseria species bacterium is genetically diverse to the first Neisseria species bacterium (e.g., differ in at least one of serogroup, serotype, or serosubtype). In related embodiments the GNAl 870 polypeptides of the first, second and third Neisseria species bacterium are different.
[0021] In an embodiment of specific interest, the composition comprises a first antigenic vesicle prepared from a first Neisseria meningitidis bacterium genetically modified to overexpress a GNAl 870 polypeptide; a second antigenic vesicle prepared from a second Neisseria meningitidis bacterium genetically modified to overexpress a GNAl 870 polypeptide; and a pharmaceutically acceptable carrier; wherein the GNAl 870 polypeptide of the first and second bacterium are different GNAl 870 polypeptide variant groups, and the first and second bacteria produce different PorA polypeptides. In a related embodiment, the composition further comprises a third antigenic vesicle prepared from a third Neisseria meningitidis bacterium genetically modified to overexpress a GNAl 870 polypeptide, wherein the GNAl 870 polypeptide of the third bacterium is of a different GNAl 870 polypeptide variant group than that of the first and second bacteria, and wherein the third bacterium produces a PorA polypeptide different from the PorA polypeptide of the first and second bacteria. In further related embodiments, the vesicles are prepared without use of a detergent.
[0022] In another aspect the invention features a method of producing an antigenic composition by culturing a Neisseria species bacterium producing a GNAl 870 polypeptide, wherein the GNAl 870 polypeptide is produced at a level sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNA1870 antibodies; preparing vesicles from the cultured bacterium; and combining the vesicles with a pharmaceutically acceptable carrier to produce an antigenic composition suitable for administration to a subject. The first and second vesicles can be, independently, an outer membrane vesicle (OMV) or a microvesicle (MV). The Neisseria species bacterium can be a naturally occurring bacterium and thus express an endogenous GNAl 870, or genetically modified in GNAl 870 polypeptide production (e.g., to provide for expression of a GNAl 870 polypeptide from a heterologous promoter, to express an exogenous GNAl 870 polypeptide, and the like). The GNAl 870 polypeptide can be endogenous to the host cell. In some embodiments, the Neisseria species bacterium is genetically modified to disrupt production of an endogenous GNAl 870 polypeptide. In other embodiments, the Neisseria species bacterium is genetically modified to produce at least two different GNAl 870 polypeptides . (e.g., GNAl 870 polypeptides of different variant groups (v.l, v.2, and v.3). In other embodiments, the Neisseria species bacterium is genetically modified to disrupt production of an endogenous full-length GNAl 870 polypeptide, and produces a GNAl 870 polypeptide from a nucleic acid exogenous to the host cell. In further related embodiments, the Neisseria species bacterium is deficient in production of capsular polysaccharide. [0023] In another aspect the invention features a method of eliciting an immune response against Neisseria by administering to a mammal an immunologically effective amount of a composition comprising a first antigenic preparation comprising vesicles prepared from a first Neisseria species bacterium, wherein the Neisseria species bacterium produces a level of a GNAl 870 polypeptide sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNAl 870 antibodies; wherein said administering is sufficient to elicit an immune response to a GNAl 870 polypeptide present in the vesicles. The vesicles can be outer membrane vesicles (OMVs), microvesicles (MVs), or a mixture of OMVs and MVs. The Neisseria species bacterium can be a naturally occurring bacterium and thus express an endogenous GNAl 870, or genetically modified in GNAl 870 polypeptide production (e.g., to provide for expression of a GNAl 870 polypeptide from a heterologous promoter, to express an exogenous GNAl 870 polypeptide, and the like). The GNAl 870 polypeptide can be endogenous to the host cell. In some embodiments, the Neisseria species bacterium is genetically modified to disrupt production of an endogenous GNAl 870 polypeptide. In other embodiments, the Neisseria species bacterium has been engineered to over-express GNAl 870. In still further embodiments, the GNAl 870 polypeptide is a chimeric protein (a fusion protein), wherein the chimeric protein contains at least an antigenic portion of GNAl 870 for presentation on vesicles (e.g., OMVs, MVs). In further related embodiments, the Neisseria species bacterium is deficient in production of capsular polysaccharide. [0024] In other embodiments, the Neisseria species bacterium is genetically modified to produce at least two different GNAl 870 polypeptides (e.g., GNAl 870 polypeptides of different variant groups (v.l, v.2, and v.3). In other embodiments, the Neisseria species bacterium is genetically modified to disrupt production of an endogenous full-length GNAl 870 polypeptide, and produces a GNAl 870 polypeptide from a nucleic acid exogenous to the host cell.
[0025] In related embodiments, the composition administered in the method comprises an immunologically effective amount of a second antigenic preparation comprising vesicles prepared from a second Neisseria species bacterium, wherein the second Neisseria species bacterium produces a level of a GNA 1870 polypeptide sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNA1870 antibodies, and wherein the second Nesseria species bacterium is genetically diverse to the first Neisseria species bacterium (e.g., the first and second bacteria are of a different serogroup, serotype, or serosubtype). The GNA1870 polypeptide of the second Neisseria species bacterium can be different from the GNAl 870 polypeptide of the first Neisseria species bacterium.
[0026] In further related embodiments, the composition further comprises a third isolated antigenic preparation comprising vesicles prepared from a third Neisseria species bacterium, wherein the second Neisseria species bacterium produces a level of a GNAl 870 polypeptide sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNAl 870 antibodies, and wherein the third Neisseria species bacterium is genetically diverse to the first or second Neisseria species bacterium (e.g.,. the first, second and third Neisseria species bacteria are genetically diverse in that they differ in at least one of serogroup, serotype, or serosubtype). The GNAl 870 polypeptides of the first, second and third Neisseria species bacteria can be different.
[0027] The method can provide for eliciting a protective immune response in the subject against more than one strain of Neisseria, particularly N. meningitidis, more particularly serogroup B Neisseria meningitidis.
[0028] The antigenic compositions described herein can elicit a combination of optimal anti-GNAl 870, anti-PorA, and/or anti-OpC bactericidal antibody responses and, thereby, confer broad protection against meningococcal disease. [0029] Vaccines prepared from GNAl 870 over-expressing strains as described herein can elicit an antibody response that is bactericidal for Neisserial strains that share the GNAl 870 variant and/or PorA of the strain from which the vesicles were prepared, as well as an antibody response that is bactericidal for Neisserial strains that have a GNAl 870 subvariant and have a heterologous PorA relative to the vesicle production strain. [0030] Vaccines prepared from GNAl 870 over-expressing strains can also decrease the likelihood of selection and emergence of disease-causing JV. meningitidis strains in the population with decreased expression of PorA. These mutants are of particular concern if conventional OMV vaccines are widely used in the population. Because expression of PorA is phase-variable (van der Ende et al, J. Bacteriology 1995:177:2475-2480), and mutants deficient in PorA expression are relatively common and can be readily selected by killing JV. meningitidis with anti-PorA antibody and complement. PorA-deficient strains also are virulent and capable of causing disease.
[0031] The present disclosure also provides methods that can be advantageous with respect to the ease of preparation of an effective vaccine composition relative to preparation of a vaccine involving a recombinant polypeptide, or a combination vaccine formulation that incorporates multiple individual antigens, or a recombinant protein such as PorA that require renaturation of conformational epitopes to elicit bactericidal antibody. [0032] Aspects, features, and advantages of the invention will be readily apparent to the ordinarily skilled artisan upon reading the present disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure IA shows the results of a flow cytometry experiment measuring binding of anti-GNA1870 antibodies on the surface of live encapsulated JV. meningitidis cells of strain RM1090 and RM1090 mutants as determined by indirect fluorescence. Row A. RM1090ΔGNA1870 strain. Row B. RM1090 wild-type strain. Row C. RM1090 strain transformed with shuttle vector pFP12 containing the GNAl 870 gene. Column 1. Negative control serum (1:10 dilution) from mice immunized with aluminum phosphate alone. Column 2. Positive control anti-group C polysaccharide mAb (lOμg/ml). Column 3. Positive control anti-PorA mAb (anti-Pl.2, 1:500 dilution). Column 4. Anti-GNA1870 (v. 1) mAb (2 μg/ml). Column 5. Polyclonal anti-GNA1870 antisera prepared against v. 1, 2 and 3 recombinant proteins (1:10 dilution). Column 6. Same as column 5 but a 1:250 dilution of serum.
[0034] Figure IB shows the binding of antibodies to the surface of live Group B JV. meningitidis cells as determined by indirect fluorescence cytometry. Row 1 : wildtype H44/76 strain (grey area); H44/76 mutant over-expressing GNAl 870 (black area). Row 2. H44/76ΔGNA1870. Panel A, anti-adjuvant negative control antiserum 1:10 dilution; Panel B, anti-PorA niAb (Pl.16) 1:500 dilution; Panel C, anticapsular mAb 10 μg/ml; Panel D, anti-rGNA1870 mAb JAR3 10 μg/ml; Panel E, anti-rGNA1870 polyclonal antiserum 1:10 dilution; Panel F, same as Panel E with a 1 :250 dilution.
[0035] Figure 2A provides results of SDS PAGE and Western blot analysis of
OMVs. Panel A is a photograph of a Commassie-stained SDS PAGE. Lanes 1 to 5, OMV preparations (about 5 μg of protein in each lane except in lane 5 where 10 μg was loaded). Lane 1, wild-type (WT) strain RMl 090; lane 2, WT strain transformed with shuttle vector pFP12 without the GNA1870 gene; lane 3. RM1090ΔGNA1870 knockout (KO); lane 4, RM1090ΔGNA1870 KO transformed with pFP12 without the GNAl 870 gene; lane 5, RM1090ΔGNA1870 KO transformed with shuttle vector ρFP12-GNA1870 containing the GNAl 870 gene; lane 6, rGNA1870 (about 1 μg). Panels B and C are photographs of Western blots using polyclonal anti-GNA1870 antisera from mice immunized with variant 1, 2 and 3 rGNA1870 proteins. Panel B: The sensitivity of detection of this antiserum was slightly higher for the variant 2 (v.2) recombinant GNAl 870 protein as compared with the variant 1 recombinant GNAl 870 protein (v.l). Panel C: Lane 1, recombinant GNAl 870 v.l; Lane 2, OMV from WT RM1090; Lane 3, OMV from RM1090ΔGNA1870; Lane 4, OMV from RM1090 transformed with the pFP12 shuttle vector containing the GNA1870 gene. The over-expression of GNAl 870 v.l in the RM1090ΔGNA 1870 strain transformed with the shuttle vector is greater than the native expression level of GNAl 870 in the wild-type strain (lane 2).
[0036] Figure 2B provides results of Western-Blot analysis of OMV vaccines probed with anti-rGNA1870 polyclonal antibody. Wildtype, OMV prepared from wildtype H44/76 strain; ΔGNA1870, OMV prepared from a mutant of H44/76 in which the gene encoding GNAl 870 had been inactivated; OE GNAl 870, OMV from a mutant of H44/76 engineered to over-express GNAl 870; rGNA1870, purified His-Tag GNAl 870 expressed in E. coli. [0037] Figure 3 A shows graphs of the serum bactericidal titers of mice as measured against four representative encapsulated N. meningitidis strains: Cu385, M6190, Z1092 and NZ98/254. The vaccine groups were: bar 1, aluminum phosphate adjuvant alone; bar 2, OMV vaccine from RMl 090 wild-type; bar 3, OMV vaccine from RM1090ΔGNA1870; bar
4, mixture of OMV vaccine from RM1090ΔGNA1870 + recombinant GNAl 870 protein; bar
5, OMV vaccine from RMl 090 over-expressed GNAl 870; bar 6, recombinant GNAl 870 protein. Bars that show the 95% confidence intervals about the geometric means represent vaccine groups where sera were assayed from 9 to 10 individual animals. Bars with asterisks (*) represent geometric means of results from assaying two serum pools from each vaccine group (each pool from sera of 4- to 5 different mice).
[0038] Figure 3B shows graphs of the serum bactericidal activity (1/GMT ± SD) of sera from mice immunized with H44/76 OMV vaccines. Serum pools were prepared as described in legend to Fig. 3 A. Groups of mice immunized with (1) Adjuvant, (2) rGNA1870, (3) H44/76 wildtype (4) H44/76 ΔGNA1870 (5) H44/76 OE GNAl 870. Although not shown on panels, all strains were killed by complement plus positive control anticapsular and/or anti-PorA monoclonal antibodies.
[0039] Figure 4A is a series of graphs showing activation of human C3b and iC3b complement deposition on the surface of live encapsulated JV. meningitidis cells as determined by indirect fluorescence flow cytometry. Row A. Strain NZ98/254. Row B. Strain M1390. Column 1, complement plus a positive control group B anticapsular MAb, 25 μg/ml (open area) or a 1 :40 dilution of a serum pool from negative control mice immunized with aluminum phosphate alone (closed area). Column 2, complement plus anti-GNA1870 MAb JAR3, 1 μg/ml (open) or heat-inactivated complement + the anti-GNA1870 MAb, 5 μg/ml (closed). Columns 3, 4 and 5, complement plus 1:100 dilution of serum pools from mice immunized with: column 3 (rGNA1870 vaccine); Column 4 (OMV vaccine from RMl 090 WT strain); or column 5 (a mixture of rGNA1870 vaccine and OMV vaccine from strain RM1090ΔGNA1870). Column 6, complement plus dilutions of a serum pool from mice immunized with OMV vaccine from strain RM1090 over-expressing GNAl 870 (open area, 1:100 dilution and gray area 1:400 dilution). For comparison, panels in column 6 also show data from complement plus a 1 : 100 dilution of a serum pool from mice immunized with OMV vaccine from strain RM1090ΔGNA1870 (closed area). [0040] Figure 4B is a series of graphs showing activation of human C3b and iC3b complement deposition on the surface of live encapsulated TV. meningitidis cells as determined by indirect fluorescence flow cytometry. Strains NZ 98/254, BZ198, Z1092 and M6190. Panel A, open area: complement plus anticapsular mAb (25 μg/ml for Group B strains NZ98/254, BZ198, and M61903, and 1 μg/ml for Group A strain Z1092); filled area: complement plus 1:100 dilution of anti-adjuvant antisera. Panel B, open area: complement plus anti-rGNA1870 mAb JAR3 25 μg/ml; filled area: complement plusl: 100 dilution of polyclonal anti-rGNA1870 antisera. Panel C, complement plus 1:100 dilution of antisera against OMV from wildtype H44/76; Panel D, open area: complement plus 1 : 100 dilution of antisera prepared against OMV with over-expressed GNAl 870 that had been absorbed with a negative control column (Ni-NTA only); filled area: complement plus 1 :25 dilution of antisera prepared against OMV with over-expressed GNAl 870 after absorption with a solid phase GNAl 870 column.
[0041] Figure 5 is a bar graph showing serum anti-GNA1870 antibody responses as measured by ELISA (GMT ± SD). The antigen on the plate was rGNA1870 variant 1. The secondary antibody was alkaline phosphatase-conjugated goat anti-mouse IgG+ A+M. The bars represent the respective geometric mean titers of 2 antiserum pools (4-5 mice per pool) from groups of mice immunized with (1) Adjuvant; (2) rGNA1870; (3) H44/76 wildtype OMV; (4) H44/76 ΔGNA1870 OMV; (5) H44/76 OE GNAl 870 OMV. [0042] Figure 6 provides graphs showing results of analysis of passive protection in the infant rat meningococcal bacteremia model. At time 0, infant rats were treated intraperitoneally (IP) with dilutions of serum pools from immunized mice (N= 9 to 10 individual sera per pool) and challenged two hours later with group B strain NZ98/294 (about 60,000 CFU/rat given IP). Quantitative blood cultures were obtained 4 to 6 hours after the bacterial challenge. Panel A: 1 :15 serum dilutions. Panel B: 1:60 serum dilutions. Bar 1 : Serum from mice immunized with aluminum phosphate only; bar 2: Anticapsular mAb (10 μg/rat); bar 3: Anti-GNA1870 mAb (10 μg/rat); bar 4: Serum from mice immunized with OMV vaccine from RM1090 ΔGNA1870; bar 5: Serum from mice immunized with mixture of OMV vaccine from RM1090ΔGNA plus recombinant GNAl 870 protein vaccine; bar 6: Serum from mice immunized with OMV vaccine from RM1090 over- expressing GNAl 870; bar 7: Serum from mice immunized with recombinant GNAl 870 protein vaccine.
[0043] Figure 7 is an alignment of exemplary amino acid sequences of GNAl 870 variants 1, 2 and 3 fromiV. meningitidis strains MC58, 951-5945, and M1239, respectively. "1" indicates that first amino acid of the mature protein, with amino acids indicated by negative numbers part of the leader sequence. Grey and black backgrounds indicate conserved and identical amino acid residues, respectively.
[0044] Figures. 8A-8H provide amino acid sequences of exemplary GNAl 870 polypeptides useful in the invention, including an amino acid sequence alignments of selected exemplary GNAl 870 polypeptides (Fig. 8H). [0045] Figure 9 provides alignments of the amino acid sequences of exemplary PorA
VRl family prototype (Panel A) and the amino acid sequences of exemplary PorA VR2 family prototype (Panel B).
[0046] Before the present invention and specific exemplary embodiments of the invention are described, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
[0047] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either both of those included limits are also included in the invention.
[0048] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. AU publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.
[0049] It must be noted that as used herein and in the appended claims, the singular forms "a", "and", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an antigen" includes a plurality of such antigens and reference to "the vesicle" includes reference to one or more vesicles and equivalents thereof known to those skilled in the art, and so forth.
[0050] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed. DETAILED DESCRIPTION OF THE INVENTION
[0051] The present invention is based on the discovery that an OMV vaccine prepared from a mutant JV. /πeningitidis strain engineered to over-express GNAl 870 elicits broader bactericidal antibody responses in mice than a recombinant GNAl 870 (rGNA1870) protein vaccine or an OMV prepared from a naturally-occurring strain, or a combination of a recombinant protein vaccine and an OMV vaccine.
[0052] OMV vaccines have been administered safely to millions of humans, and are proven to be efficacious against developing meningococcal disease. As noted in the introduction section, their principal limitation is that they elicit strain-specific bactericidal antibody responses. Also there is concern that if OMV vaccines are used widely in the population that the immune response may select for emergence of "escape mutants" of JV. meningitidis strains (i.e., strains with mutations in PorA amino acid sequence of surface- accessible loops or with decreased expression of PorA). In short, the invention provides that, by selection of a prevalent PorA serosubtype and preparing a mutant that over-expresses GNAl 870, it is possible to prepare a vesicle-based vaccine (e.g., OMV, MV) that elicits a combination of optimal anti-GNA1870 and anti-PorA bactericidal antibody responses and, thereby, confers broad protection against meningococcal disease. Use of such a vaccine also has a lower risk than a convention OMV vaccine for selection of disease-producing PorA- deficient mutant strains in the population.
[0053] In addition, vesicles prepared from a strain over-expressing GNAl 870 have an altered protein profile compared with vesicles prepared from a strain that expresses a relatively lower level of GNAl 870. As discussed in more detail in the Examples, OMV prepared from GNAl 870 over-expressing strains showed decreased expression of a number of other cell envelope proteins as compared with OMV prepared from the wild-type vaccine RM1090 strain, or the RM1090 ΔGNA1870 knockout strain. While the ability of antisera from mice immunized with OMV over-expressing GNAl 870 to elicit bactericidal antibody to strain Cu385 or activate C3b deposition on strain NZ98/294 was a result of antibodies elicited by GNAl 870, the decrease in these other outer cell envelope proteins may serve to further enhance the immunogenicity and protective immune response elicited by vesicles prepared from GNAl 870 over-expressing strains (e.g., due to "unmasking" of other antigens in the vesicle). [0054] The examples provided herein illustrate the breadth of protection elicited by immunization with an OMV vaccine prepared from a iV. meningitidis strain that over- expresses (e.g., is genetically engineered to over-express) GNAl 870. Functional activities of the anti-GNA1870 antibodies elicited by the OMV vaccine that over-expressed GNAl 870 were greater than that of the antibodies elicited by the recombinant GNAl 870 vaccine, or a combination of recombinant GNAl 870 and OMV prepared from the wildtype strain. For example, despite a lower magnitude of the anti-GNA1870 antibody response as measured by ELISA (Table 2), sera from mice immunized with the OMV vaccine prepared from the strain engineered to over-express GNAl 870 showed higher bactericidal activity against strain Zl 092 than that of sera from mice immunized with the recombinant protein GNAl 870 vaccine, or with OMV vaccines prepared from the wild-type or GNAl 870 knock-out RMl 090 strains, or with OMV vaccine mixed with the recombinant GNAl 870 protein vaccine (Fig. 3).
[0055] Furthermore, even in the absence of strong bactericidal activity, the antibodies elicited by the OMV vaccine that over-expressed GNAl 870 gave greater C3b deposition on the surface of strains NZ98/254 or Ml 390 (Fig. 4A5 column 6) than antibodies raised to the other vaccines, and the former also conferred greater passive protection against bacteremia in infant rats challenged with strain NZ98/254 (Fig. 6, Panels A-B). The ability to activate C3b deposition on strain NZ98/254 was lost after absorption of anti-GNA1870 antibodies (Table 3). In short, the modified OMV vaccine conferred broader protective activity than the GNAl 870 recombinant protein or the OMV vaccine from the wild-type vaccine strain as a result of the ability of the modified OMV vaccine to elicit both serosubtype-specific bactericidal activity against strains expressing a homologous PorA molecule to that of the vaccine strain, and anti-GNA1870 antibodies with greater functional activity against strains expressing sub-variants of the GNAl 870 variant 1 protein than elicited by recombinant GNAl 870 vaccine.
[0056] The modified OMV vaccine prepared from a GNAl 870 over-expressing strain was advantageous over recombinant GNAl 870 against strains expressing sub-variants of the variant 1 GNAl 870 protein and/or expressing a homologous PorA serosubtype. Interestingly, mice immunized with a vesicle vaccine prepared from a N. meningitidis strain (RMl 090) engineered to over-express NspA had more 10-fold higher ELISA anti-NspA antibody titers but lower serum bactericidal titers against some N. meningitidis strains such as Cu385 or Zl 092 than control mice immunized with a control vesicle vaccine prepared from strain RMl 090 in which the gene encoding NspA had been inactivated (Table 5). O'Dwyer et al. also observed lack of serum bactericidal activity in mice vaccinated with an
OMV vaccine prepared from a N. flavescens strain engineered to over-express NspA (Infect. Innun. 2004;72:6511-80). Thus, the present findings showing enhanced bactericidal and protective antibody responses to an OMV vaccine over-expressing GNAl 870 are surprising. [0057] Over-expression of GNAl 870 v.1 in strain H44/76 resulted in ~3-fold more
GNAl 870 in the OMV as compared with the naturally-higher amounts of GNAl 870 in OMV prepared from the H44176 wildtype strain. In contrast with our previous study of mice immunized with OMV from wildtype strain RMl 090, mice immunized with OMV prepared from wildtype H44/76 developed anti-GNA1870 antibody responses as measured by ELISA (Figure 5). However, the group of mice given OMV from the strain with over- expressed GNAl 870 had ~10-fold higher titers. The titers measured by ELISA did not correlate well with antibody functional activity. For example, the highest serum anti- GNAl 870 titers were in mice immunized with the recombinant GNAl 870 vaccine but the bactericidal and C3b deposition activity of serum from mice immunized with the recombinant protein were limited to strain H44/76. Susceptibility of this strain was expected because virtually all N. meningitides strains with genetic lineage of ET 5 are high expressers of the canonical GNAl 870 v. 1 protein (identical amino acid sequence to that of MC58) and these strains are highly susceptible to complement-mediated bactericidal activity of anti- GNAl 870 antibodies (Masignani et al. 2003,suρra; Welsch et al. 2004, supra). The remaining five N. meningitidis test strains in our study express lower amounts of GNAl 870 than strain H44/76, and the respective proteins are subvariants of GNAl 870 v.l. The five strains also have heterologous PorA molecules to that of the H44/76 vaccine strain. These five strains were resistant to bactericidal activity and complement activation by antibodies elicited by the recombinant GNAl 870 vaccine, or by the anti-PorA antibodies elicited by the OMV vaccines. In contrast, four of the five strains were susceptible to bactericidal activity and/or complement deposition activity of sera from mice immunized with H44/76 OMV vaccine with over-expressed GNAl 870. Activation of C3b on the surface of live bacteria have led to predicted passive protection of infant rats against meningococcal bacteremia (Welsch et al. J Infect Dis 2003;188:1730-40; Welsch et al J Immunol 2004;172:5606-15; Hou et al. J Infect Dis 2005;192:580-90; Moe et al. Infect Immun 2002;70:6021-31). The OMV vaccine with over-expressed GNA 1870 consists of a complex mixture of antigens and would be expected to elicit antibody to a number of antigenic targets. However, in absorption experiments, the antibody functional activity against these strains was directed against GNAl 870 (Table 3). [0058] Remarkably, an OMV vaccine prepared from a mutant strain with only a modest increase in GNAl 870 level elicited higher and broader GNA1870-specific bactericidal antibody responses and/or greater C3 deposition than an OMV vaccine prepared from a wildtype strain selected to have relatively high expression of GNAl 870. Thus, even a slight change in the ratio of GNAl 870 to total protein in the OMV vaccine preparation appears to determine whether or not there is an antibody response to GNAl 870. Further, the quality of the antibodies elicited by the OMV vaccine with over-expressed GNAl 870 is superior to that of antibodies elicited by the recombinant GNAl 870 vaccine. For example the recombinant vaccine elicited higher ELISA antibody binding titers than those elicited by the OMV vaccine with over-expressed GNAl 870, but the antibodies to the recombinant protein had lower bactericidal and complement activation activity. Defining the mechanisms by which the modified GNA1870-OMV vaccine elicits serum antibodies with broader functional activity than the recombinant protein or control OMV vaccine will require further study.
[0059] The present invention thus provides methods and compositions for eliciting an immune response that is broadly reactive with diverse disease-producing JV. meningitidis strains. The invention circumvents the problem of immunodominance of antigenically variable domains of PorA in vesicle-or PorA-based vaccines by enhancing the antibody response to GNAl 870 and, possibly, to other common antigens in the vaccine strains. Importantly, the methods of the invention elicit serum bactericidal antibody, the only proven serologic correlate of protection in humans (Goldschneider et al. 1969, supra), against strains of Neisseria expressing serosubtype epitopes that were not used in the vaccine preparations. Further, the method elicits serum bactericidal antibody against strains that are not killed by antibody to a conserved protein such as Neisserial surface protein A, a candidate meningococcal vaccine (Martin et al., 2000. J. Biotechnol. 83:27-31; Moe et al. (1999 Infect. Immun. 67: 5664; Moe et al. Infect Immun. 2001 69:3762). Without being held to theory, the vaccine and immunization regimen of the invention provides its unexpected advantages in broad spectrum protective immunity by eliciting antibodies that are specific for both conserved and non-conserved antigens.
DEFINITIONS
[0060] The term "protective immunity" means that a vaccine or immunization schedule that is administered to a mammal induces an immune response that prevents, retards the development of, or reduces the severity of a disease that is caused by Neisseria meningitidis, or diminishes or altogether eliminates the symptoms of the disease. [0061] The phrase "a disease caused by a strain of serogroup B of Neisseria meningitidis" encompasses any clinical symptom or combination of clinical symptoms that are present in an infection with a member of serogroup B of Neisseria meningitidis. These symptoms include but are not limited to: colonization of the upper respiratory tract (e.g. mucosa of the nasopharynx and tonsils) by a pathogenic strain of serogroup B of Neisseria meningitidis, penetration of the bacteria into the mucosa and the submucosal vascular bed, septicemia, septic shock, inflammation, haemmorrhagic skin lesions, activation of fibrinolysis and of blood coagulation, organ dysfunction such as kidney, lung, and cardiac failure, adrenal hemorrhaging and muscular infarction, capillary leakage, edema, peripheral limb ischaemia, respiratory distress syndrome, pericarditis and meningitis. [0062] The phrase "broad spectrum protective immunity" means that a vaccine or immunization schedule elicits "protective immunity" against at least one or more (or against at least two, at least three, at least four, at least five, against at least eight, or at least against more than eight) strains of Neisseria meningitidis, wherein each of the strains belongs to a different serosubtype as the strains used to prepare the vaccine. The invention specifically contemplates and encompasses a vaccine or vaccination regimen that confers protection against a disease caused by a member of serogroup B of Neisseria meningitidis and also against other serogroups, particularly serogroups A, C, Y and W-135. [0063] The phrase "specifically binds to an antibody" or "specifically immunoreactive with", when referring to an antigen such as a polysaccharide, phospholipid, protein or peptide, refers to a binding reaction which is based on and/or is probative of the presence of the antigen in a sample which may also include a heterogeneous population of other molecules. Thus, under designated immunoassay conditions, the specified antibody or antibodies bind(s) to a particular antigen or antigens in a sample and do not bind in a significant amount to other molecules present in the sample. Specific binding to an antibody under such conditions may require an antibody or antiserum that is selected for its specificity for a particular antigen or antigens.
[0064] The phrase "in a sufficient amount to elicit an immune response to epitopes present in said preparation" means that there is a detectable difference between an immune response indicator measured before and after administration of a particular antigen preparation. Immune response indicators include but are not limited to: antibody titer or specificity, as detected by an assay such as enzyme-linked immunoassay (ELISA), bactericidal assay, flow cytometry, immunoprecipitation, Ouchter-Lowny immunodiffusion; binding detection assays of, for example, spot, Western blot or antigen arrays; cytotoxicity assays, etc.
[0065] A "surface antigen" is an antigen that is present in a surface structure of
Neisseria meningitidis (e.g. the outer membrane, inner membrane, periplasmic space, capsule, pili, etc.).
[0066] The phrase "genetically diverse" as used in the context of genetically diverse strains of Neisseria meningitidis, refers to strains that differ from one another in the amino acid sequence of at least one, and usually at least two, more usually at least three polypeptides, particularly antigenic polypeptides. Genetic diversity of strains can be accomplished by selecting strains that differ in at least one or more, preferably at least two or more, of serogroup, serotype, or serosubtype (e.g., two strains that differ in at least one of the proteins selected from outer membrane, PorA and PorB proteins, are said to genetically diverse with respect to one another). Genetic diversity can also be defined by, for example, multi-locus sequence typing and/or multi-locus enzyme typing (see, e.g., Maiden et al.,
1998, Proc. Natl. Acad. Set USA 95:3140; Pizza et al. 2000 Science287:1816), multi-locus enzyme electrophoresis, and other methods known in the art.
[0067] "Serogroup" as used herein refers to classification of Neisseria meningitides by virtue of immunologically detectable variations in the capsular polysaccharide. About 12 serogroups are known: A, B, C, X, Y, Z, 29-E, W- 135, H, I, K and L. Any one serogroup can encompass multiple serotypes and multiple serosubtypes.
[0068] "Serotype" as used herein refers to classification of Neisseria meningitides strains based on monoclonal antibody defined antigenic differences in the outer membrane protein Porin B. A single serotype can be found in multiple serogroups and multiple serosubtypes.
[0069] "Serosubtype" as used herein refers classification of Neisseria meningitides strains based on antibody defined antigenic variations on an outer membrane protein called
Porin A, or upon VR typing of amino acid sequences deduced from DNA sequencing
(Sacchi et al., 2000, J. Infect. Dis. 182:1169; see also the Multi Locus Sequence Typing web site). Most variability between PorA proteins occurs in two (loops I and IV) of eight putative, surface exposed loops. The variable loops I and IV have been designated VRl and
VR2, respectively. A single serosubtype can be found in multiple serogroups and multiple serotypes.
[0070] "Enriched" means that an antigen in an antigen composition is manipulated by an experimentalist or a clinician so that it is present in at least a three-fold greater concentration by total weight, usually at least 5-fold greater concentration, more preferably at least 10-fold greater concentration , more usually at least 100-fold greater concentration than the concentration of that antigen in the strain from which the antigen composition was obtained. Thus, if the concentration of a particular antigen is 1 microgram per gram of total bacterial preparation (or of total bacterial protein), an enriched preparation would contain at least 3 micrograms per gram of total bacterial preparation (or of total bacterial protein). [0071] The term "heterologous" refers to two biological components that are not found together in nature. The components may be host cells, genes, or regulatory regions, such as promoters. Although the heterologous components are not found together in nature, they can function together, as when a promoter heterologous to a gene is operably linked to the gene. Another example is where a Neisserial sequence is heterologous to a Neisserial host of a different strain. "Heterologous" as used herein in the context of proteins expressed in two different bacterial strains, e.g., "heterologous PorA" or "heterologous GNAl 870", indicates that the proteins in question differ in amino acid sequence. For example, a first Neisserial strain expressing PorA 1.5-2,10 and a second Neisserial strain expressing PorA 7- 2,4 are said to have "heterologous PorA proteins" or are "heterologous with respect to PorA".
[0072] The term "immunologically naive with respect to Neisseria meningitidis" denotes an individual (e.g., a mammal such as a human patient) that has never been exposed (through infection or administration) to Neisseria meningitidis or to an antigen composition derived from Neisseria meningitidis in sufficient amounts to elicit protective immunity, or if exposed, failed to mount a protective immune response. (An example of the latter would be an individual exposed at a too young age when protective immune responses may not occur. Molages et al., 1994, Infect. Immun. 62: 4419-4424). It is further desirable (but not necessary) that the "immunologically naϊve" individual has also not been exposed to a Neisserial species other than Neisseria meningitidis (or an antigen composition prepared from a Neisserial species), particularly not to a cross-reacting strain of Neisserial species (or antigen composition). Individuals that have been exposed (through infection or administration) to a Neisserial species or to an antigen composition derived from that Neisserial species in sufficient amounts to elicit an immune response to the epitopes exhibited by that species, are "primed" to immunologically respond to the epitopes exhibited by that species. NEISSERIAL STRAINS EXPRESSING GNA1870 FOR USE IN VESICLE PRODUCTION
[0073] In general, the invention involves production of vesicles (microvesicles or outer membrane vesicles) from a naturally-occurring or genetically modified Neisserial strain that produces a level of GNAl 870 protein sufficient to provide for vesicles that, when administered to a subject, evoke serum anti-GNA1870 antibodies. The anti-GNA1870 antibodies produced facilitate immunoprotection against 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more Neisserial strains, which strains can be genetically diverse (or "heterologous") with respect to, for example, serogroup, serotype, serosubtype (e.g., as determined by PorA protein), Sequence type, electrophoretic type, GNAl 870 variant, and/or GNAl 870 subvariant. [0074] Any of a variety of Neisseria spp. strains that produce or can be modified to produce GNAl 870, and, optionally, which produce or can be modified to produce other antigens of interest, such as PorA, can be used in the methods of the invention. Characteristics of suitable strains with respect to GNAl 870 production are discussed in more detail below.
[0075] Pathogenic Neisseria spp. or strains derived from pathogenic Neisseria spp., particularly strains pathogenic for humans or derived from strains pathogenic or commensal for humans, are of particular interest. Exemplary Nessserial spp. include N. meningitidis, N. flavescens N. gonorrhoeae, N. lactamica, N. polysaccharea, N. cinerea, N. mucosa, N. subflava, N. sicca, N. elongata, and the like. "Derived from" in the context of bacterial strains is meant to indicate that a strain was obtained through passage in vivo, or in in vitro culture, of a parental strain and/or is a recombinant cell obtained by modification of a parental strain.
[0076] N. meningitidis strains are of particular interest in the present invention. N. meningitidis strains can be divided into serologic groups, serotypes and subtypes on the basis of reactions with polyclonal (Frasch, C. E. and Chapman, 1973, J. Infect. Dis. 127: 149-154) or monoclonal antibodies that interact with different surface antigens. Serogrouping is based on immunologically detectable variations in the capsular polysaccharide. About 12 serogroups (A, B, C, X, Y, Z, 29-E, and W-135) are known. Strains of the serogroups A, B, C, Y and W-135 account for nearly all meningococcal disease.
[0077] Serotyping is based on monoclonal antibody defined antigenic differences in an outer membrane protein called Porin B (PorB). Antibodies defining about 21 serotypes are currently known (Sacchi et al, 1998, CUn. Diag. Lab. Immunol. 5:348). Serosubtyping is based on antibody defined antigenic variations on an outer membrane protein called Porin A (PorA). Antibodies defining about 18 serosubtypes are currently known. Serosubtyping is especially important in Neisseria meningitidis strains where immunity may be serosubtype specific. Most variability between PorA proteins occurs in two (loops I and IV) of eight putative, surface exposed loops. The variable loops I and IV have been designated VRl and VR2, respectively. Since more PorA VRl and VR2 sequence variants exist that have not been defined by specific antibodies, an alternative nomenclature based on VR typing of amino acid sequence deduced from DNA sequencing has been proposed (Sacchi et al., 2000, J Infect. Dis. 182:1169; see also the Multi Locus Sequence Typing web site). Lipopolysaccharides can also be used as typing antigens, giving rise to so-called immunotypes: Ll, L2, etc.
[0078] N. meningitidis also may be divided into clonal groups or subgroups, using various techniques that directly or indirectly characterize the bacterial genome. These techniques include multilocus enzyme electrophoresis (MLEE), based on electrophoretic mobility variation of an enzyme, which reflects the underlying polymorphisms at a particular genetic locus. By characterizing the variants of a number of such proteins, genetic "distance" between two strains can be inferred from the proportion of mismatches. Similarly, clonality between two isolates can be inferred if the two have identical patterns of electrophoretic variants at number of loci. More recently, multilocus sequence typing (MLST) has superseded MLEE as the method of choice for characterizing the microorganisms. Using MLST, the genetic distance between two isolates, or clonality is inferred from the proportion of mismatches in the DNA sequences of 11 housekeeping genes in Neisseria meningitidis strains (Maiden et al., 1998, Proc. Natl Acad. ScL USA 95:3140).
[0079] The strain used for vesicle production can be selected according to a number of different characteristics that may be desired. For example, in addition to selection according to a level of GNAl 870 production, the strain may be selected according to: a desired PorA type (a "serosubtype", as described above), serogroup, serotype, and the like; decreased capsular polysaccharide production; and the like. [0080] For example, the production strain can produce any desired PorA polypeptide, and may express one or more PorA polypeptides (either naturally or due to genetic engineering). Exemplary strains includes those that produce a PorA polypeptide which confers a serosubtype of Pl.7,16; Pl.19,15; Pl.7,1; Pl.5,2; P1.22a,14; Pl.14 ; Pl.5, 10; Pl.7,4; Pl.12,13; as well as variants of such PorA polypeptides which may or may not retain reactivity with conventional serologic reagents used in serosubtyping. [0081] Also of interest are PorA polypeptides characterized according to PorA variable region (VR) typing (see, e.g., Russell et al. Emerging Infect Dis 2004 10:674-678; Sacchi CT, et al, Clin Diagn Lab Immunol 1998;5:845-55; Sacchi et al, J. Infect Dis 2000;182:l 169-1176). A substantial number of distinct VR types have been identified, which can be classified into VRl and VR2 family "prototypes". A web-accessible database describing this nomenclature and its relationship to previous typing schemes is found at neisseria.org/nm/typing/pora. Alignments of exemplary PorA VRl and VR2 types. is provided in Russell et al. Emerging Infect Dis 2004 10:674-678, and provided in Fig. 9 for the convenience of the reader.
[0082] Exemplary PorA polypeptides as characterized by PorA serosubtypes include
Pl.5,2; P1.5a,2a; P1.5a,2c; P1.5a,2c; P1.5a,2c; P1.5b,10; P1.5b,10; P1.5b,C; Pl.7,16; P1.7d,l; P1.7d,l; P1.7d,l; P1.7d,l; P1.7b,3; P1.7b,4; P1.7b,4; Pl.12,16; P1.12a,13a; Pl.22,9; Pl.23,14; Pl.23,14; Pl.19,15; PLB5I; P1.C,1; P1.E,A; P1.E,A; P1.E,A; ; Pl.5,2; Pl.5,2; P1.5a,10a; P1.5b,10; P1.5b,10; P1.5b,10b; Pl.7,16; Pl.7,16; P1.7b,l; P1.7b,13e; P1.7b,4; P1.7b,4; P1.7d,l; P1.7d,l; P1.7b,13a; Pl.23,3; Pl.23,3; Pl.23,3; Pl.19,15; Pl.19,1; Pl.19,15; Pl.19,15; Pl.19,15; Pl.19,15; Pl.19,15; Pl.19,15; Pl.19,15; PLE5A; PLE5A; Pl.E,16a; Pl.E,4a; Pl.E54a; Pl.Ea,3; Pl.Eb,9; Pl.Eb,9; Pl.Eb,9; Pl.Eb,9; Pl.Eb,9; P1.F,16; P1.7a,l; P1.7b,3; P1.7d,l; Pl.Ea,3; P1.5b,10; P1.5b,10; P1.5b,10; P1.5b,10; P1.5b,10; P1.5b,10; P1.5b,10b; P1.5b,10; P1.22,14a; ; P1.F,16; Pl.D,2d; P1.D,2; Pl.D,2d; P1.19c,2c; PLD5IOf; PLA5IOe; PLA5IOg; PLA5IO; Pl.19,15; Pl.19,15; Pl.19,15; Pl.19,15; P1.7b,16; P1.7,16b; Pl.7,16; Pl.19,15; Pl.Eb,9; P1.5,2e; PLE5A; P1.7b,13d; Pl.Ea,3; P1.7,16b; PLEc5I; P1.7b,4; P1.7b54; P1.759; Pl.19,15; Pl.19,15; Pl.19,15; P1.19,15a; P1.19a,15b; Pl.19,15; P1.5b,16; P1.19b,13a; Pl.5,16; Pl.5,2; P1.5,2b; P1.7b,16; P1.7,16b; P1.7b,3; Pl.Ea,3; P1.5a,2c; P1.F,16; P1.5a,9; P1.7c,10c; P1.7b,13a; P1.7,13a; P1.7a,10; Pl.20,9; P1.22,B; P1.5b,del; P1.5b,10; P1.7,13a; P1.12a,13f; P1.12a,13; P1.12a,13a; P1.12a,13a; P1.12a,13; P1.12a,13; Pl.E,13b; P1.7b,13a; P1.7b,13; Pl.5,2; Pl.5,2; Pl.Ea,3; Pl.22,9; Pl.5,2; Pl.5,2; Pl.19,15; P1.552; P1.12b513a; P1.5c,10a; P1.7e,16e; Pl.B,16d; Pl.F,16e; Pl.F,16e; P1.7b,13e; Pl.B,16d; P1.7e516e; P1.7b,13g; PLB,16f; ; P1.7,16c; P1.22,14b; P1.22,14c; P1.7,14; P1.7,14; and Pl.23,14.
[0083] Amino acid sequences of exemplary PorA polypeptides are found at
GenBank accession nos. X57182, X57180, U92941, U92944, U92927, U92931, U92917, U92922, X52995, X57184, U92938, U92920, U92921, U92929, U92925, U92916, X57178, AF051542, X57181, U92919, U92926, X57177, X57179, U92947, U92928, U92915,
X57183, U92943, U92942, U92939, U92918, U92946, U92496, U97260, U97259, AF042541, U92923, AF051539, AF051538, U92934, AF029088, U92933, U97263, U97261, U97262, U92945, AF042540, U92935, U92936, U92924, AF029086, AF020983, U94958, U97258, U92940, AF029084, U92930, U94959, U92948, AF016863, AF029089, U92937, AF029087, U92932, AF029090, AF029085, AF051540, AF051536, AF052743, AF054269, U92495, U92497, U92498, U92499, U92500, U92501, U92502, U92503, AF051541, X12899, Z48493, Z48489, Z48485, Z48494, Z48487, Z48488, Z48495, Z48490, Z48486, Z48491, Z48492, X66478, X66479, X66477, X66480, X81110, X79056, X78467, X81111, X78802, Z14281/82, Z14273/74, Z14275/76, Z14261/62, Z14265/66, Z14277/78, Z14283/84, Z14271/72, Z14269/70, Z14263/64, Z14259/60, Z14257/58, Z14293/94, Z14291/92, Z14279/80, Z14289/90, Z14287/88, Z14267/68, Z14285/86, L02929, X77423, X77424, X77433, X77426, X77428, X77430, X77427, X77429, X77425, X77432, X77431, X77422, Z48024/25, Z48032/33, Z48020/21, Z48022/23, Z48028/29, Z48016/17, Z48012/13, Z48014/15, Z48018/19, Z48026/27, U31060, U31061, U31062, U31063, U31064, U31065, U31066, U31067, U93898, U93899, U93900, U93901, U93902, U93903, U93904, U93905, U93906, U93907, and U93908.,
[0084] Alternatively or in addition, the production strain can be a capsule deficient strain. Capsule deficient strains can provide vesicle-based vaccines that provide for a reduced risk of eliciting a significant autoantibody response in a subject to whom the vaccine is administered (e.g., due to production of antibodies that cross-react with sialic acid on host cell surfaces). "Capsule deficient" or "deficient in capsular polysaccharide" as used herein refers to a level of capsular polysaccharide on the bacterial surface that is lower than that of a naturally-occurring strain or, where the strain is genetically modified, is lower than that of a parental strain from which the capsule deficient strain is derived. A capsule deficient strain includes strains that are decreased in surface capsular polysaccharide production by at least 10%, 20%, 25%, 30%, 40%, 50%, 60%, 75%, 80%, 85%, 90% or more, and includes strains in which capsular polysaccharide is not detectable on the bacterial surface (e.g., by whole cell ELISA using an anti-capsular polysaccharide antibody).
[0085] Capsule deficient strains include those that are capsule deficient due to a naturally-occurring or recombinantly-generated genetic modification. Naturally-occurring capsule deficient strains (see, e.g., Dolan-Livengood et al. J. Infect. Dis. (2003) 187(10): 1616-28), as well as methods of identifying and/or generating capsule-deficient strains (see, e.g., Fisseha et al. (2005) Infect. Immun. 73(7):4070-4080; Stephens et al. (1991) Infect Immun 59(ll):4097-102; Frosch et al. (1990) MoI Microbiol. 1990 4(7):1215-
1218) are known in the art. [0086] Modification of a Neisserial host cell to provide for decreased production of capsular polysaccharide may include modification of one or more genes involved in capsule synthesis, where the modification provides for, for example, decreased levels of capsular polysaccharide relative to a parent cell prior to modification. Such genetic modifications can include changes in nucleotide and/or amino acid sequences in one or more capsule biosynthesis genes rendering the strain capsule deficient (e.g., due to one or more insertions, deletions, substitutions, and the like in one or more capsule biosynthesis genes). Capsule deficient strains can lack or be non-functional for one or more capsule genes. [0087] Of particular interest are strains that are deficient in sialic acid biosynthesis.
Such strains can provide for production of vesicles that have reduced risk of eliciting anti- sialic acid antibodies that cross-react with human sialic acid antigens, and can further provide for improved manufacturing safety. Strains having a defect in sialic acid biosynthesis (due to either a naturally occurring modification or an engineered modification) can be defective in any of a number of different genes in the sialic acid biosynthetic pathway. Of particular interest are strains that are defective in a gene product encoded by the N-acetylglucosamine-6-phosphate 2-epimerase gene (known as synX AAF40537.1 or siaA AAA20475), with strains having this gene inactivated being of especial interest. For example, in one embodiment, a capsule deficient strain is generated by disrupting production of a functional synX gene product (see, e.g., Swartley et al. (1994) J Bacteriol. 176(5):1530-
4).
[0088] Capsular deficient strains can also be generated from naturally-occurring strains using non-recombinant techniques, e.g., by use of bactericidal anti-capsular antibodies to select for strains that reduced in capsular polysaccharide.
[0089] Where the invention involves use of two or more strains (e.g., to produce antigenic compositions of vesicles from different strains, as discussed below in more detail), the strains can be selected so as to differ in on or more strain characteristics, e.g., to provide for vesicles that differ in PorA type and/or GNAl 870 variant group.
GNAl 870 production in Neisserial host cells
[0090] In general as noted above, vesicles can be produced according to the invention using a naturally-occurring or modified non-naturally-occurring Neisserial strain that produces vesicles with sufficient GNAl 870 protein that, when administered to a subject, provide for production of anti-GNA1870 antibodies. 10091] In one embodiment, the Neisserial strain used to produce vesicles according to the invention can be naturally occurring strains that express a higher level of GNAl 870 relative to strains that express no detectable or a low level of GNAl 870. RMl 090 is an example of a strain that produces a low level of GNAl 870. Naturally occurring strains that produce GNAl 870 at a level that is 1.5, 2, 2,5 3, 3.5, 4, 4.5, 5, 5.5, 6, 6,5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 -fold or greater over GNA1870 production in a low GNA1870-producing strain, such as RM1090, are of particular interest. Examples of naturally-occurring strains that express a high level of GNA1870 include ET-5 strains such as H44/76, Cu385 and MC58. For a discussion of strains that express low or undetectable levels of GNAl 870, intermediate levels of GNA1870, or high levels of GNA1870 see Masignani et al. 2003, J Exp Med 197:789-199. In particular embodiments, the strain produces a level of GNAl 870 that is greater than that produced in RM1090, and can be at least 1.5, 2, 2,5 3, 3.5, 4, 4.5, 5, 5.5, 6, 6,5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 -fold or greater than that in RM1090. [0092] In another embodiment, the Neisserial strain is modified by recombinant or non-recombinant techniques to provide for a sufficiently high level of GNAl 870 production. Such modified strains generally are produced so as to provide for an increase in GNAl 870 production that is 1.5, 2, 2,5 3, 3.5, 4, 4.5, 5, 5.5, 6, 6,5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 -fold or greater over GNAl 870 production in the unmodified parental cell or over GNAl 870 production of the strain RMl 090. Any suitable strain can be used in this embodiment, including strains that produce low or undetectable levels of GNAl 870 prior to modification and strains that naturally produce high levels of GNAl 870 relative to strains that express no detectable or a low level of GNAl 870.
[0093] Modified strains can be generated by non-recombinant techniques such as, for example, exposure to chemicals, radiation, or other DNA modifying or damaging agent, and the like. Modified strains having a desired protein expression profile, particularly with respect to GNAl 870 production, can be identified through screening for strains producing a desired level of GNAl 870 (e.g., an increased level of GNAl 870 as compared to the unmodified parental strain or a low GNAl 870 producer (such as RMl 090), or a level similar to that of a strain that produces GNAl 870 at acceptably high levels). [0094] Alternatively, and more usually, modified strains are produced using recombinant techniques, usually by introduction of nucleic acid encoding a GNAl 870 polypeptide or manipulation of an endogenous GNAl 870 gene to provide for increased expression of endogenous GNAl 870. [0095] Methods for determining GNAl 870 production levels are known in the art.
Such methods include, for example, Western blot (optionally with analysis assisted by densitometry scan), flow cytometric (e.g., FACS) analysis using anti-GNA1870 antibody, detection of GNAl 870 RNA levels, and the like. Strains that have higher levels of GNAl 870 production, either naturally or due to genetic modification, are sometimes referred to herein as GNAl 870 "over-expressers" or are said to "overexpress" GNAl 870.
Production of genetically modified Neisserial strains
[0096] As noted above, by introduction of nucleic acid encoding a GNAl 870 polypeptide or manipulation of an endogenous GNAl 870 gene to provide for increased expression of endogenous GNAl 870.
Neisserial host cells genetically modified to provide for increased expression of an endogenous GNA1870
[0097] Endogenous GNAl 870 expression can be increased by altering in situ the regulatory region controlling the expression of GNAl 870. Methods for providing for increased expression of an endogenous Neisserial gene are known in the art (see, e.g., WO 02/09746). Furthermore, the nucleic acid sequences of genes encoding genomic GNAl 870 variants and subvariants are known, providing for ready adaptation of such methods in the upregulation of endogenous GNAl 870 expression. [0098] The endogenous GNAl 870 may be of any desired variant group (e.g., v.1 , v.2, v.3, and the like) or subvariant of GNAl 870. A "canonical" v.l GNAl 870 polypeptide of strain MC58 is of particular interest. Also of interest is a subvariant GNAl 870 polypeptide of strain NZ98/294, and v.2 GNAl 870 polypeptide of strain 2996. [0099] Modification of a Neisserial host cell to provide for increased production of endogenous GNAl 870 may include partial or total replacement of all of a portion of the endogenous gene controlling GNAl 870 expression, where the modification provides for, for example, enhanced transcriptional activity relative to the unmodified parental strain. Increased transcriptional activity may be conferred by variants (point mutations, deletions and/or insertions) of the endogenous control regions, by naturally occurring or modified heterologous promoters or by a combination of both. In general the genetic modification confers a transcriptional activity greater than that of the unmodified endogenous transcriptional activity (e.g., by introduction of a strong promoter), resulting in an enhanced expression of GNAl 870. [UUlUUJ Typical strong promoters that may be useful in increasing GNAl 870 transcription production can include, for example, the promoters of porA, porB, lbpB, tbpB, pi 10, hpuAB, igtF, Opa, pi 10, 1st, and hpuAB. PorA, RMp and PorB are of particular interest as constitutive, strong promoters. PorB promoter activity is contained in a fragment corresponding to nucleotides -1 to -250 upstream of the initation codon of porB. [00101] Methods are available in the art to accomplish introduction of a promoter into a host cell genome so as to operably link the promoter to an endogenous GNAl 870- encoding nucleic acid. For example, double cross-over homologous recombination technology to introduce a promoter in a region upstream of the coding sequence, e.g., about 1000 bp, from about 30-970 bp, about 200-600 bp, about 300-500 bp, or about 400 bp upstream (5') of the initiation ATG codon of the GNA1870-encoding nucleic acid sequence to provide for up-regulation. Optimal placement of the promoter can be determined through routine use of methods available in the art.
[00102] For example, a highly active promoter (e.g., PorA, PorB or Rmp promoters) upstream of the targeted gene. As an example, the PorA promoter can be optimized for expression as described by van der Ende et al. Infect Immun 2000;68:6685-90. Insertion of the promoter can be accomplished by, for example, PCR amplification of the upstream segment of the targeted GNAl 870 gene, cloning the upstream segment in a vector, and either inserting appropriate restriction sites during PCR amplification, or using naturally occurring restriction sites to insert the PorA promoter segment. For example, an about 700 bp upstream segment of the GNA 1870 gene can be cloned. Using naturally occurring restriction enzyme sites located at an appropriate distance (e.g., about 400 bp) upstream of the GNAl 870 promoter within this cloned segment a PorA promoter segment is inserted. An antibiotic (e.g., erythromycin) resistance cassette can be inserted within the segment further upstream of the PorA promoter and the construct was used to replace the wild-type upstream GNAl 870 segment by homologous recombination.
[00103] Another approach involves introducing a GNAl 870 polypeptide-encoding sequence downstream of an endogenous promoter that exhibits strong transcriptional activity in the host cell genome. For example, the coding region of the Rmp gene can be replaced with a coding sequence for a GNAl 870 polypeptide. This approach takes advantage of the highly active constitutive Rmp promoter to drive expression. SSeisserial host cells genetically modified to express an exogenous GNA1870
[00104] Neisserial strains can be genetically modified to over-express GNAl 870 by introduction of a construct encoding a GNAl 870 polypeptide into a Neisserial host cell. The GNAl 870 introduced for expression is referred to herein as an "exogenous" GNAl 870. The host cell produces an endogenous GNAl 870, the exogenous GNAl 870 may have the same or different amino acid sequence compared to the endogenous GNAl 870. [00105] The strain used as the host cell in this embodiment can produce any level of
GNAl 870 (e.g., high level, intermediate level, or low level GNAl 870 production). Of particular interest is use of a strain that is selected for low level or no detectable GNAl 870 production, or that is modified to exhibit no detectable, or a low level, of GNAl 870 production. For example, the host cell may be genetically modified so that the endogenous GNAl 870 gene is disrupted so that GNAl 870 is not produced or is not present in the cell envelope (and thus is not present at detectable levels in a vesicle prepared from such a modified cell). In other embodiments, the host cell produces an intermediate or high level of GNAl 870 (e.g., relative to a level of GNAl 870 produced by, for example, RMl 090).
GNA1870 polypeptides
[00106] The host cell can be genetically modified to express any suitable GNAl 870 polypeptide, including GNAl 870 variants or subvariants. As described in more detail below, the amino acid sequences of many GNAl 870 polypeptides are known; alignment of these sequences provides guidance as to residues that are conserved among the variants, thus providing guidance as to amino acid modifications (e.g., substitutions, insertions, deletions) that can be made.
[00107] Accordingly, "GNAl 870 polypeptide" as used herein encompasses naturally- occurring and synthetic (non-naturally occurring) polypeptides which share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or greater sequence identity at the nucleotide or amino acid level with a naturally-occurring GNAl 870 polypeptide, and which are capable of eliciting antibodies that specifically bind a naturally-occurring GNAl 870 polypeptide present on a whole cell Neisserial bacterium. "GNAl 870 polypeptide" also encompasses fusion proteins, e.g., a GNAl 870 polypeptide having a heterologous polypeptide at the N- and/or C-terminus.
[00108] The host cell can be genetically modified to express at least 1 GNAl 870 polypeptide, and can be modified to express 2, 3, 4 or more GNAl 870 polypeptides in the same host cell. For example, a single host cell can be genetically modified to express at least one variant 1 GNAl 870 polypeptide, at least one variant 2 GNAl 870 polypeptide, and at least one variant 3 GNAl 870 polypeptide.
[00109] Where expression of multiple GNAl 870 polypeptides meets with difficulty due to toxicity to the host cell, the different GNAl 870 polypeptides may be expressed from different promoters so as to allow a range of expression. For example, varying both the base composition and number of bases between the —10 and —35 regions of the PorA promoter should result in a wide range of expression of the desired recombinant protein (van der Ende et al. Infect Immun 2000;68:6685-90).
[00110] Nucleic acids encoding a GNAl 870 polypeptide for use in the invention are known in the art. Suitable GNAl 870 polypeptides are described in, for example, WO 2004/048404; Masignani et al. 2003 J Exp Med 197:789-799; Fletcher et al. Infect Immun 2004 2088-2100; Welsch et al. J Immunol 2004 172:5606-5615; and WO 99/57280. Nucleic acid (and amino acid sequences) for GNAl 870 variants and subvariants are also provided in GenBank as accession nos.: NC_003112, GenelD: 904318 (NCBI Ref. NP_274866) (from N. meningitidis strain MC58); AY548371 (AAT01290.1) (from N. meningitidis strain CU385); AY548370 (AAT01289.1) (from N. meningitidis strain H44/76); AY548377 (AAS56920.1) (from N. meningitidis strain M4105); AY548376 (AAS56919.1) (from N. strain M1390); AY548375 (AAS56918.1) (from N. meningitidis strain N98/254); AY548374 (AAS56917.1) (from N. meningitidis strain M6190); AY548373 (AAS56916.1) (from N. meningitidis strain 4243); and AY548372 (AAS56915.1) (from N. meningitidis strain BZ83).
[00111] Fig. 7 is an alignment of exemplary amino acid sequences of GNAl 870 variants 1, 2 and 3 from N. meningitidis strains MC58, 951-5945, and M1239, respectively (WO 2004/048404). The immature GNAl 870 protein includes a leader sequence of about 19 residues, with each variant usually containing an N-terminal cysteine to which a lipid moeity can be covalently attached. This cysteine residue is usually lipidated in the naturally- occurring protein. "1" indicates that first amino acid of the mature protein, with amino acids indicated by negative numbers part of the leader sequence. Grey and black backgrounds indicate conserved and identical amino acid residues, respectively. Additional amino acid sequences of GNAl 870 polypeptides, including non-naturally occurring variants, is provided in Figs. 8A-8H and 9. [00112] The GNAl 870 can be lipidated or non-lipidated. It is generally preferred that the GNAl 870 be lipidated, so as to provide for positioning of the polypeptide in the membrane. Lipidated GNA1870 can be prepared by expression of the,GNA1870 polypeptide having the N-terminal signal peptide to direct lipidation by diacylglyceryl transferase, followed by cleavage by lipoprotein-specific (type II) signal peptidase. [00113] The GNAl 870 polypeptide useful in the invention includes non-naturally occurring (artificial or mutant) GNAl 870 polypeptides that differ in amino acid sequence from a naturally-occurring GNAl 870 polypeptide, but which are present in the membrane of aNesserial host so that vesicles prepared from the host contain GNAl 870 in a form that provides for presentation of epitopes of interest, preferably a bactericidal epitope, and provides for an anti-GNA1870 antibody response. In one embodiment, the GNAl 870 polypeptide is a variant 1 (v.l) or variant 2 (v.2) or variant 3 (v.3) GNAl 870 polypeptide, with subvariants of v.l v,2 and v.3 being of interest, including subvariants of v.l (see, e.g., Welsch et al. J Immunol 2004 172:5606-5615). In one embodiment, the GNA1870 polypeptide comprises an amino acid sequence of a GNAl 870 polypeptide that is most prevalent among the strains endemic to the population to be vaccinated. [00114] GNAl 870 polypeptides useful in the invention also include fusion proteins, where the fusion protein comprises a GNAl 870 polypeptide having a fusion partner at its N- terminus or C-terminus. Fusion partners of interest include, for example, glutathione S transferase (GST), maltose binding protein (MBP), His-tag, and the like, as well as leader peptides from other proteins, particularly lipoproteins (e.g., the amino acid sequence prior to the N-terminal cysteine may be replaced with another leader peptide of interest). . [00115] Other GNAl 870 polypeptide-encoding nucleic acids can be identified using techniques well known in the art, where GNAl 870 polypeptides can be identified based on amino acid sequences similarity to a known GNAl 870 polypeptide. Such GNAl 870 polypeptides generally share at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or greater sequence identity at the nucleotide or amino acid level. Sequence identity can be determined using methods for alignment and comparison of nucleic acid or amino acid sequences, which methods are well known in the art. Comparison of longer sequences may require more sophisticated methods to achieve optimal alignment of two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman and Wunsch (1970) J. MoL Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. (USA) 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, WI), or by inspection, and the best alignment (i.e. resulting in the highest percentage of sequence similarity over the comparison window) generated by the various methods is selected.
[00116] The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection. Polypeptides of interest include those having at least 60%, 70%, 75%, 80%, 85%, 90%, 95% or more nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection. Preferably, the region sharing sequence identity exists over a region of the sequences that is at least about 10, 20, 30, 40, 50, 60, 70, 80, or 100 contiguous residues in length. In a most preferred embodiment, identity of the sequences is determined by comparison of the sequences over the entire length of the coding region of a reference polypeptide.
[00117] For sequence comparison, typically one sequence acts as a reference sequence
(e.g., a naturally-occurring GNAl 870 polypeptide sequence), to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.
[00118] Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. MoI. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (see generally, Current Protocols in Molecular Biology, F.M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1995 Supplement) (Ausubel)). [00119] Examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1990) J. MoI. Biol. 215: 403-410 and Altschuel et al. (1977) Nucleic Acids Res. 25: 3389-3402, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al, supra).
[00120] These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative- scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Herήkoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)).
[00121] In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
[00122] A further indication that two nucleic acid sequences or polypeptides share sequence identity is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide typically share sequence identity with a second polypeptide, for example, where the two polypeptides differ only by conservative substitutions. Another indication that two nucleic acid sequences share sequence identity is that the two molecules hybridize to each other under stringent conditions. The selection of a particular set of hybridization conditions is selected following standard methods in the art (see, for example, Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, (1989) Cold Spring Harbor, N.Y.). An example of stringent hybridization conditions is hybridization at 500C or higher and 0.1 x SSC (15 mM sodium chloride/1.5 rnM sodium citrate). Another example of stringent hybridization conditions is overnight incubation at 420C in a solution: 50 % formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5 x Denhardf s solution, 10% dextran sulfate, and 20 mg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1 x SSC at about 650C. Stringent hybridization conditions are hybridization conditions that are at least as stringent as the above representative conditions, where conditions are considered to be at least as stringent if they are at least about 80% as stringent, typically at least about 90% as stringent as the above specific stringent conditions. Other stringent hybridization conditions are known in the art and may also be employed to identify nucleic acids of this particular embodiment of the invention.
[00123] Preferably, residue positions which are not identical differ by conservative amino acid substitutions. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine- tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine. Vector and methods for introducing genetic material into Neisserial host cells
[00124] Methods and compositions which can be readily adapted to provide for genetic modification of a Neisserial host cell to express an exogenous GNAl 870 polypeptide are known in the art. Exemplary vectors and methods are provided in WO 02/09746 and O'Dwyer et al. Infect Immun 2004;72: 6511-80.
[00125] Methods for transfer of genetic material into a Neisserial host include, for example, conjugation, transformation, electroporation, calcium phosphate methods and the like. The method for transfer should provide for stable expression of the introduced GNA1870-encoding nucleic acid. The GNA1870-encoding nucleic acid can be provided as a inheritable episomal element (e.g., plasmid) or can be genomically integrated. [00126] Suitable vectors will vary in composition depending what type of recombination event is to be performed. Integrative vectors can be conditionally replicative or suicide plasmids, bacteriophages, transposons or linear DNA fragments obtained by restriction hydrolysis or PCR amplification. Selection of the recombination event can be accomplished by means of selectable genetic marker such as genes conferring resistance to antibiotics (for instance kanamycin, erythromycin, chloramphenicol, or gentamycin), genes conferring resistance to heavy metals and/or toxic compounds or genes complementing auxotrophic mutations (for instance pur, leu, met, aro).
[00127] In one embodiment, the vector is an expression vector based on episomal plasmids containing selectable drug resistance markers that autonomously replicate in both E. coli and N. meningitidis. One example of such a "shuttle vector" is the plasmid pFPIO (Pagotto et al. Gene 2000 244:13-19).
PREPARATION OF NEISSERIA MENINGITIDIS VESICLES
[00128] The antigenic compositions for use in the invention generally include vesicles prepared from Neisserial cells that express an acceptable level of GNAl 870, either naturally or due to genetic modification (e.g., due to expression of a recombinant GNAl 870). As referred to herein "vesicles" is meant to encompass outer membrane vesicles as well as micro vesicles (which are also referred to as blebs).
[00129] In one embodiment, the antigenic composition comprises outer membrane vesicles (OMV) prepared from the outer membrane of a cultured strain of Neisseria meningitidis spp. OMVs may be obtained from a. Neisseria meningitidis grown in broth or solid medium culture, preferably by separating the bacterial cells from the culture medium (e.g. by filtration or by a low-speed centrifugation that pellets the cells, or the like), lysing the cells (e.g. by addition of detergent, osmotic shock, sonication, cavitation, homogenization, or the like) and separating an outer membrane fraction from cytoplasmic molecules (e.g. by filtration; or by differential precipitation or aggregation of outer membranes and/or outer membrane vesicles, or by affinity separation methods using ligands that specifically recognize outer membrane molecules; or by a high-speed centrifugation that pellets outer membranes and/or outer membrane vesicles, or the like); outer membrane fractions may be used to produce OMVs.
[00130] In another embodiment, the antigenic composition comprises microvesicles
(MV) or blebs that are released during culture of said Neisseria meningitidis spp. MVs may be obtained by culturing a strain of Neisseria meningitidis in broth culture medium, separating whole cells from the broth culture medium (e.g. by filtration, or by a low-speed centrifugation that pellets only the cells and not the smaller blebs, or the like), and then collecting the MVs that are present in the cell-free culture medium (e.g. by filtration, differential precipitation or aggregation of MVs, or by a high-speed centrifugation that pellets the blebs, or the like). Strains for use in production of MVs can generally be selected on the basis of the amount of blebs produced in culture (e.g., bacteria can be cultured in a reasonable number to provide for production of blebs suitable for isolation and administration in the methods described herein). An exemplary strain that produces high levels of blebs is described in PCT Publication No. WO 01/34642. In addition to bleb production, strains for use in MV production may also be selected on the basis of NspA production, where strains that produce higher levels of NspA may be preferable (for examples of N. meningitides strains having different NspA production levels, see, e.g., Moe et al. (1999 Infect. Immun. 67: 5664).
[00131] In another embodiment, the antigenic composition comprises vesicles from one strain, or from 2, 3, 4, 5 or more strains, which strains may be homologous or heterologous, usually heterologous, to one another with respect to one or both of GNAl 870 or PorA. In one embodiment, the vesicles are prepared from a strain that expresses 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more GNAl 870 proteins, which may be different variants (v.l, v.2, v.3) or subvariants (e.g., a subvariant of v.l, v.2, or v.3). In another embodiment, the antigenic compositions comprises a mixture of OMVs and MVs, which may be from the same or different strains. In such embodiments, vesicles from different strains can be administered as a mixture. Further, OMVs and MVs from the same or different strains can be administered as a mixture. In addition to vesicles (OMVs and/or MVs), isolated antigens or particular combinations of antigens may be included in the antigenic compositions of the invention.
Reduction of lipid toxicity
[00132] Where desired {e.g., where the strains used to produce vesicles are associated with endotoxin or particular high levels of endotoxin), the vesicles are optionally treated to reduce endotoxin, e.g., to reduce toxicity following administration. Although less desirable as discussed below, reduction of endotoxin can be accomplished by extraction with a suitable detergent (for example, BRIJ-96, sodium deoxycholate, sodium lauoylsarcosinate, Empigen BB, Triton X-IOO, TWEEN 20 (sorbitan monolaurate polyoxyethylene), TWEEN 80, at a concentration of 0.1-10%, preferably 0.5-2%, and SDS). Where detergent extraction is used, it is preferable to use a detergent other than deoxycholate. In some embodiment, vesicles are produced without use of detergent, e.g., without use of deoxycholate or other detergent.
[00133] In embodiments of particular interest, the vesicles of the antigenic compositions are prepared without detergent. Although detergent treatment is useful to remove endotoxin activity, it may deplete the native GNAl 870 lipoprotein by extraction during vesicle production. Thus it may be particularly desirable to decrease endotoxin activity using technology that does not require a detergent. In one approach, strains that are relatively low producers of endotoxin (lipopolysaccharide, LPS) are used so as to avoid the need to remove endotoxin from the final preparation prior to use in humans. For example, the vesicles can be prepared from Neisseria mutants in which lipooligosaccharide or other antigens that may be undesirable in a vaccine (e.g. Rmp) is reduced or eliminated. [00134] For example, vesicles can be prepared from JV. meningitidis strains that contain genetic modifications that result in decreased or no detectable toxic activity of lipid A. For example, such strain can be genetically modified in lipid A biosynthesis (Steeghs et al. Infect Immun 1999;67:4988-93; van der Ley et al. Infect Immun 2001;69:5981-90; Steeghs et al. J Endotoxin Res 2004;10:113-9). Mutations in genes responsible for the terminal modifications steps lead to temperature-sensitive (htrB) or permissive (msbB) phenotypes. Mutations resulting in a decreased (or no) expression of these genes (or decreased or no activity of the product of these genes) result in altered toxic activity of lipid A. Non-lauroylated (htrB mutant) or non-myristoylated (msbB mutant) lipid A are less toxic than the wild-type lipid A. Mutations in the lipid A 4'-kinase encoding gene (lpxK) also decreases the toxic activity of lipid A. [UU135J LPS toxic activity can also be altered by introducing mutations in genes/loci involved in polymyxin B resistance (such resistance has been correlated with addition of aminoarabinose on the 4' phosphate of lipid A). These genes/loci could be pmrE that encodes a UDP-glucose dehydrogenase, or a region of antimicrobial peptide-resistance genes common to many enterobacteriaciae which could be involved in aminoarabinose synthesis and transfer. The gene pmrF that is present in this region encodes a dolicol-phosphate manosyl transferase (Gunn J. S., Kheng, B. L., Krueger J., Kim K., Guo L., Hackett M., Miller S. I. 1998. MoI. Microbiol. 27: 1171-1182).
[00136] Mutations in the PhoP-PhoQ regulatory system, which is a phospho-relay two component regulatory system (e.g., PhoP constitutive phenotype, PhoPc), or low Mg+"1" environmental or culture conditions (that activate the PhoP-PhoQ regulatory system) lead to the addition of aminoarabinose on the 4'-phosphate and 2-hydroxymyristate replacing myristate (hydroxylation of myristate). This modified lipid A displays reduced ability to stimulate E-selectin expression by human endothelial cells and TNF-α secretion from human monocytes.
[00137] Polymyxin B resistant strains are also suitable for use in the invention, as such strains have been shown to have reduced LPS toxicity (see, e.g., van der Ley et al. 1994. In: Proceedings of the ninth international pathogenic Neisseria conference. The Guildhall, Winchester, England). Alternatively, synthetic peptides that mimic the binding activity of polymyxin B may be added to the antigenic compositions to reduce LPS toxic activity (see, e.g., Rustici et al. 1993, Science 259:361-365; Porro et al. Prog Clin Biol Res. 1998;397:315-25).
[00138] Endotoxin can also be reduced through selection of culture conditions. For example, culturing the strain in a growth medium containing 0.1 mg-100 mg of aminoarabinose per liter medium provides for reduced lipid toxicity (see, e.g., WO 02/097646).
Formulations
[00139] Immunogenic compositions used as vaccines comprise an immunologically effective amount of antigen, particularly an immunologically effective amount of GNAl 870, as well as any other compatible components, as needed. By "immunologically effective amount" is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective to elicit for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of the individual to be treated (e.g., non-human primate, primate, human, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating clinician's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. [00140] Dosage regimen may be a single dose schedule or a multiple dose schedule
(e.g., including booster doses) with a unit dosage form of the antigenic composition administered at different times. The term "unit dosage form," as used herein, refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of the antigenic compositions of the present invention in an amount sufficient to produce the desired effect, which compositions are provided in association with a pharmaceutically acceptable excipient (e.g., pharmaceutically acceptable diluent, carrier or vehicle). The vaccine may be administered in conjunction with other immunoregulatory agents.
[00141] The antigenic compositions to be administered are provided in a pharmaceutically acceptable diluent such as an aqueous solution, often a saline solution, a semi-solid form (e.g., gel), or in powder form. Such diluents can be inert, although the compositions of the invention may also include an adjuvant. Examples of known suitable adjuvants that can be used in humans include, but are not necessarily limited to, alum, aluminum phosphate, aluminum hydroxide, MF59 (4.3% w/v squalene, 0.5% w/v Tween 80, 0.5% w/v Span 85), CpG-containing nucleic acid (where the cytosine is unmethylated), QS21, MPL, 3DMPL, extracts from Aquilla, ISCOMS, LT/CT mutants, ρoly(D,L-lactide- co-glycolide) (PLG) microparticles, Quil A, interleukins, and the like. For experimental animals, one can use Freund's, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N- acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP), N- acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-( 1 '-2'-dipalmitoyl-sn-glycero-3 - hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion. The effectiveness of an adjuvant may be determined by measuring the amount of antibodies directed against the immunogenic antigen.
[00142] Further exemplary adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) oil-in- water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59™ (W090/14837; Chapter 10 in Vaccine design: the subunit and adjuvant approach, eds. Powell & Newman, Plenum Press 1995), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing MTP-PE) formulated into submicron particles using a microfluidizer, (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L 121, and thr-MDP either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) REBI™ adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components such as monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (DETOX™); (2) saponin adjuvants, such as QS21 or STIMULON™ (Cambridge Bioscience, Worcester, MA) may be used or particles generated tiherefrom such as ISCOMs (immunostimulating complexes), which ISCOMS may be devoid of additional detergent e.g. WO00/07621; (3) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (4) cytokines, such as interleukins (e.g. EL-I, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 (WO99/44636), etc.), interferons (e.g. gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.; (5) monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL) e.g. GB- 2220221 , EP-A-0689454, optionally in the substantial absence of alum when used with pneumococcal saccharides e.g. WO00/56358; (6) combinations of 3dMPL with, for example, QS21 and/oroil-in-water emulsions e.g. EP-A-0835318, EP-A-0735898, EP-A-0761231; (7) oligonucleotides comprising CpG motifs [Krieg Vaccine 2000, 19, 618-622; Krieg Curr opinMol Ther2001 3:15-24; Roman etal, Nat. Med, 1997, 3, 849-854; Weiner etm., PNAS USA, 1997, 94, 10833-10837; Davis etal, J. Immunol, 1998, 160, 870-876; Chu etω., J. Exp.Med, 1997, 186, 1623-1631; Lipford et al, Ear. J. Immunol, 1997, 27, 2340-2344; Moldoveami e/ al, Vaccine, 1988, 16, 1216-1224, Krieg etal, Nature, 1995, 374, 546-549; Klmmanet al, PNAS USA, 1996, 93, 2879-2883; Ballas etal, J. Immunol, 1996, 157, 1840-1845; Cowdery et al, J. Immunol, 1996, 156, 4570-4575; Halpern et α/, Cell Immunol, 1996, 167, 72-78; Yamamoto etal, Jpn. J. Cancer Res., 1988, 79, 866-873; Stacey et al, J. Immunol, 1996, 157,2116-2122; Messina etal, J. Immunol, 1991, 147, 1759-1764; Yi etal, J. Immunol, 1996, 157,4918-4925; Yi et al, J. Immunol, 1996, 157, 5394-5402; Yi et al, J. Immunol, 1998, 160, 4755-4761; and Yi et al, J. Immunol, 1998, 160, 5898-5906; International patent applications WO96/02555, W098/16247, WO98/18810, WO98/40100, WO98/55495, WO98/37919 and WO98/52581] i.e. containing at least one CG dinucleotide, where the cytosine is unmethylated; (8) apolyoxyethylene ether or a polyoxyethylene ester e.g. WO99/52549; (9) apolyoxyethylene sorbitan ester surfactant in combination with an octoxynol (WO01/21207) or a polyoxyethylene alkyl ether or ester surfactant in combination, with at least one additional non-ionic surfactant such as an octoxynol (WO01/21152); (10) a saponin and an immunostiraulatory oligonucleotide (e.g. a CpG oligonucleotide) (WO00/62800); (11) an immunostimulant and a particle of metal salt e.g. WO00/23105; (12) a saponin and an oil-in-water emulsion e.g. WO99/11241; (13) a saponin (e.g. QS21) + 3dMPL + IM2 (optionally + a sterol) e.g. WO98/57659; (14) other substances that act as immunostimulating agents to enhance the efficacy of Hie composition. Muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-25 aceτyl-normuramyl-L- alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-aIanyl-D-isoglu1an±iyl-L-alanine-2-(l -2'- dipalrnitoyl-OT-gIycero-3-hydroxyphosphoryloxy)-etliylamine MIP-PE), etc. [00143] The antigenic compositions may be combined with a conventional pharmaceutically acceptable excipient, such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium, carbonate, and the like. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of antigen in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs. The resulting compositions may be in the form of a solution, suspension, tablet, pill, capsule, powder, gel, cream, lotion, ointment, aerosol or the like.
[00144] The protein concentration of antigenic compositions of the invention in the pharmaceutical formulations can vary widely, i.e. from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
IMMUNIZATION
[00145] In general, the methods of the invention provide for administration of one or more antigenic compositions of the invention to a mammalian subject (e.g., a human) so as to elicit a protective immune response against more than one strain of Neisseria species bacteria, and thus protection against disease caused by such bacteria. In particular, the methods of the invention can provide for an immunoprotective immune response against a 1, 2, 3, A, or more strains of Neisseria meningitidis species, where the strains differ in at least one of serogroup, serotype, serosubtype, or GNAl 870 polypeptide (e.g., different GNAl 870 variants and/or subvariants). Of particular interest is induction of a protective immune response against multiple strains of Neisseria meningitidis of serogroup B, particularly where the strains differ in serosubtype (e.g., have heterologous PorAs). Also of particular interest is induction of a protective immune response against strains that are heterologous to one other in terms of PorA and/or GNAl 870.
[00146] The antigenic compositions of the invention can be administered orally, nasally, nasopharyngeally, parenterally, enterically, gastrically, topically, transdermally, subcutaneously, intramuscularly, in tablet, solid, powdered, liquid, aerosol form, locally or systemically, with or without added excipients. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in such publications as Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pennsylvania (1980). [00147] It is recognized that oral administration can require protection of the compositions from digestion. This is typically accomplished either by association of the composition with an agent that renders it resistant to acidic and enzymatic hydrolysis or by packaging the composition in an appropriately resistant carrier. Means of protecting from digestion are well known in the art.
[00148] The compositions are administered to an animal that is at risk from acquiring a Neisseria! disease to prevent or at least partially arrest the development of disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for therapeutic use will depend on, e.g., the antigenic composition, the manner of administration, the weight and general state of health of the patient, and the judgment of the prescribing physician. Single or multiple doses of the antigenic compositions may be administered depending on the dosage and frequency required and tolerated by the patient, and route of administration. [00149] The antigenic compositions described herein can comprise a mixture of vesicles (e.g., OMV and MV), which vesicles can be from the same or different strains. In another embodiment, the antigenic compositions can comprise a mixture of vesicles from 2, 3, 4, 5 or more strains, where the vesicles can be OMV, MV or both. [00150] The antigenic compositions are administered in an amount effective to elicit an immune response, particularly a humoral immune response, in the host. Amounts for the immunization of the mixture generally range from about 0.001 mg to about 1.0 mg per 70 kilogram patient, more commonly from about 0.001 mg to about 0.2 mg per 70 kilogram patient. Dosages from 0.001 up to about 10 mg per patient per day may be used, particularly when the antigen is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ. Substantially higher dosages (e.g. 10 to 100 mg or more) are possible in oral, nasal, or topical administration. The initial administration of the mixture can be followed by booster immunization of the same of different mixture, with at least one booster, more usually two boosters, being preferred. [00151] In one embodiment, the antigenic compositions used to prime and boost are prepared from strains of Neisseria that possess variant immunodominant antigens (the main antigens that are routinely detected by antisera from different host animals that have been infected with Neisseria; representative examples include Porin A, Porin B, pilin, NspA, phospholipids, polysaccharides, lipopolysaccharides, pilins, OmpA, Opa, Ope, etc.) and/or variant GNAl 870 proteins. The strains also may vary with respect to the capsule molecule, as reflected by their serogroup.
[00152] Serotype and serosubtype classification is currently determined by detecting which of a panel of known monoclonals, which are known to recognize specific Porin molecules, bind to an unknown strain (Sacchi et al., 1998, Clin. Diag. Lab. Immunol. 5:348). It is probable that other such monoclonals will be identified. The use of any novel serotypes and serosubtypes which may be defined by any new monoclonals are specifically contemplated by the invention. In addition, serotypes and serosubtypes may be defined, not only by interaction with monoclonal antibodies, but also structurally by the absence and/or presence of defined peptide residues and peptide epitopes (Sacchi et al., 2000, J. Infect. Dis. 182:1169). Serotype and serosubtype classification schemes that are based on structural features of the Porins (known or that may be discovered at a later date) are specifically encompassed by the invention.
[00153] In another embodiment, the antigenic compositions administered are prepared from 2, 3, 4, 5 or more strains, which strains may be homologous or heterologous, usually heterologous, to one another with respect to one or both of GNAl 870 or PorA. In one embodiment, the vesicles are prepared from strains express different GNAl 870 proteins, which GNA1870 proteins may be different variants (v.l, v.2, v.3) or subvariants (e.g., a subvariant of v.l, v.2, or v.3). In another embodiment, the vesicles are prepared from strains that are heterologous to one another respect to PorA.
[00154] In embodiments of particular interest, vesicles are prepared from Neisseria! strains that are genetically diverse to one another (e.g., the strains belong to different serotypes and/or serosubtypes; express different PorA proteins; express different GNAl 870 variants or subvariants; and/or may also optionally belong to different capsular serogroups). The vesicles can be used to prepare an antigenic composition that is a mixture of vesicles prepared from at least 2, 3, 4, or more of such genetically diverse strains. For example, GNAl 870 protein and/or PorA of the second Neisserial strain from which antigenic compositions are prepared and administered is/are different from that of the first strain used to produce vesicles.
[00155] The second, third, and further administered antigenic compositions can optionally be prepared from Neisserial strains are genetically diverse to the second strain (e.g., the strains belong to different serotypes and/or serosubtypes; express different GNAl 870 proteins; express different PorA proteins; and/or belong to different capsular serogroups). For example, a third strain used for preparing a third antigenic composition may be genetically diverse to the first and second strains used to prepare the first and second antigenic compositions, but may, in some embodiments, not be genetically diverse with respect to the first strain.
[00156] The invention also contemplates that the antigenic compositions may be obtained from one or more strains of Neisseria, particular Neisseria meningitidis, that are genetically engineered by known methods (see, e.g. U.S. Pat. No. 6,013,267) to express one or more nucleic acids that encode GNAl 870. The host cell may express an endogenous GNAl 870 polypeptide or may modified or selected so as not to express any detectable endogenous GNAl 870 polypeptide. The GNAl 870 polypeptide expressed in the host cell by recombinant techniques (i.e., the exogenous GNA1870 polypeptide) can be of the same or different variant type as an endogenous GNAl 870 polypeptide. [00157] The host cells may be further modified to express additional antigens of interest, such as Porin A, Porin B, NspA, pilin, or other Neisserial proteins, hi addition, the antigen compositions of the invention can comprise additional Neisserial antigens such as those exemplified in PCT Publication Nos. WO 99/24578, WO 99/36544; WO 99/57280, WO 00/22430, and WO 00/66791, as well as antigenic fragments of such proteins. [00158] The antigen compositions are typically administered to a mammal that is immunologically naϊve with respect to Neisseria, particularly with respect to Neisseria meningitidis. In a particular embodiment, the mammal is a human child about five years or younger, and preferably about two years old or younger, and the antigen compositions are administered at any one or more of the following times: two weeks, one month, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 months, or one year or 15, 18, or 21 months after birth, or at 2, 3, 4, or 5 years of age. [00159] In general, administration to any mammal is preferably initiated prior to the first sign of disease symptoms, or at the first sign of possible or actual exposure to Neisseria.
PASSIVE IMMUNITY
[00160] The invention also contemplates immunoprotective antibodies generated by immunization with an antigenic composition of the invention, and methods of use. Such antibodies can be administered to an individual (e.g., a human patient) to provide for passive immunity against a Neϊsserial disease, either to prevent infection or disease from occurring, or as a therapy to improve the clinical outcome in patients with established disease (e.g. decreased complication rate such as shock, decreased mortality rate, or decreased morbidity, such as deafness).
[00161] Antibodies administered to a subject that is of a species other than the species in which they are raised are often immunogenic. Thus, for example, murine or porcine antibodies administered to a human often induce an immunologic response against the antibody. The immunogenic properties of the antibody are reduced by altering portions, or all, of the antibody into characteristically human sequences thereby producing chimeric or human antibodies, respectively.
[00162] Chimeric antibodies are immunoglobulin molecules comprising a human and non-human portion. More specifically, the antigen combining region (or variable region) of a humanized chimeric antibody is derived from a non-human source (e.g. murine), and the constant region of the chimeric antibody (which confers biological effector function to the immunoglobulin) is derived from a human source. The chimeric antibody should have the antigen binding specificity of the non-human antibody molecule and the effector function conferred by the human antibody molecule. A large number of methods of generating chimeric antibodies are well known to those of skill in the art (see, e.g., U.S. Patents Nos. 5,502,167, 5,500,362, 5,491,088, 5,482,856, 5,472,693, 5,354,847, 5,292,867, 5,231,026, 5,204,244, 5,202,238, 5,169,939, 5,081,235, 5,075,431 and 4,975,369). An alternative approach is the generation of humanized antibodies by linking the CDR regions of non- human antibodies to human constant regions by recombinant DNA techniques. See Queen et al, Proc. Natl. Acad. Sci. USA 86: 10029-10033 (1989) and WO 90/07861. [00163] In one embodiment, recombinant DNA vector is used to transfect a cell line that produces an antibody against a peptide of the invention. The novel recombinant DNA vector contains a "replacement gene" to replace all or a portion of the gene encoding the immunoglobulin constant region in the cell line (e.g. a replacement gene may encode all or a portion of a constant region of a human immunoglobulin, or a specific immunoglobulin class), and a "target sequence" which allows for targeted homologous recombination with immunoglobulin sequences within the antibody producing cell.
[00164] In another embodiment, a recombinant DNA vector is used to transfect a cell line that produces an antibody having a desired effector function (e.g. a constant region of a human immunoglobulin), in which case, the replacement gene contained in the recombinant vector may encode all or a portion of a region of an antibody and the target sequence contained in the recombinant vector allows for homologous recombination and targeted gene modification within the antibody producing cell. In either embodiment, when only a portion of the variable or constant region is replaced, the resulting chimeric antibody may define the same antigen and/or have the same effector function yet be altered or improved so that the chimeric antibody may demonstrate a greater antigen specificity, greater affinity binding constant, increased effector function, or increased secretion and production by the transfected antibody producing cell line, etc.
[00165] In another embodiment, this invention provides for fully human antibodies.
Human antibodies consist entirely of characteristically human polypeptide sequences. The human antibodies of this invention can be produced by a wide variety of methods (see, e.g., Larrick et al., U.S. Patent No. 5,001,065). In one embodiment, the human antibodies of the present invention are produced initially in trioma cells (descended from three cells, two human and one mouse). Genes encoding the antibodies are then cloned and expressed in other cells, particularly non-human mammalian cells. The general approach for producing human antibodies by trioma technology has been described by Ostberg et al. (1983), Hybridoma 2: 361-367, Ostberg, U.S. Patent No. 4,634,664, and Engelman et al., U.S. Patent No. 4,634,666. Triomas have been found to produce antibody more stably than ordinary hybridomas made from human cells.
[00166] Methods for producing and formulation antibodies suitable for administration to a subject (e.g. , a human subject) are well known in the art. For example, antibodies can be provided in a pharmaceutical composition comprising an effective amount of an antibody and a pharmaceutical excipients (e.g., saline). The pharmaceutical composition may optionally include other additives (e.g., buffers, stabilizers, preservatives, and the like). An effective amount of antibody is generally an amount effective to provide for protection against Neisserial disease or symptoms for a desired period, e.g. , a period of at least about 2 days to 10 days or 1 month to 2 months). DIAGNOSTIC ASSAYS
[00167] The antigenic compositions of the invention, or antibodies produced by administration of such compositions, can also be used for diagnostic purposes. For instance, the antigenic compositions can be used to screen pre-immune and immune sera to ensure that the vaccination has been effective. Antibodies can also be used in immunoassays to detect the presence of particular antigen molecules associated with Neisserial disease.
EXAMPLES
[00168] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
MATERIALS AND METHODS
[00169] The following methods and materials were used in the Examples below.
[00170] Bacterial Strains. The nine N. meningitidis strains used in this study (six capsular group B, and one capsular group A and two capsular group C) are listed in Table 1. Strains were collected over a period of 25 years from patients hospitalized in Cuba, The Netherlands, Germany, New Zealand, or the United States. Based on electrophoretic cluster analyses and/or sequencing typing, the strains are genetically diverse.
Figure imgf000051_0001
[00171] Group C strain RM1090 (C:2a:5-1,2) and mutants described below that were derived from this strain, and group B strain H44/76 and mutants described below that were derived from this strain, were used to prepare the outer membrane vesicle (OMV) vaccines. Strain RMl 090 naturally expresses low levels of a GNAl 870 variant 2 protein. The RM1090 strain in which the GNA1870 gene was inactivated (RMl 090ΔGNA1870, described below) was used for over-expression of GNAl 870 variant 1. Strain H44/76 is a relatively high expresser of GNAl 870 variant 1. The remaining seven strains naturally express sub- variants of the GNAl 870 variant 1 protein and were selected as test organisms to determine the breadth of vaccine-induced anti-GNA1870 variant 1 protective immunity. These strains are genetically diverse, as defined by electrophoretic type and/or multilocus sequencing type, and they also express several different PorA VR sequence types. Variant 1 strains were chosen because they account for about 60% of disease-producing group B isolates (Masignani et al. J Exp Med 2003; 197:789-99).
[00172] Strain Cu385 and strain H44/76 express GNAl 870 variant 1 with an identical amino acid sequence to that of strain MC58 (Welsch et al. J Immunol 2004; 172: 5606- 15), the gene used to express the recombinant GNAl 870 variant 1 protein in E. coli, and also used in the shuttle vector to over-express GNAl 870 in the N. meningitidis vaccine strain RMl 090 (see below). The remaining seven strains express subvariants of GNAl 870 variant 1 with slight sequence variations from the variant of GNA 1870 protein encoded by the gene from strain MC58 (Masignani et al. 2003, supra ). In a previous study, strain Cu385 was highly susceptible to complement-mediated bactericidal activity of antibodies elicited in mice immunized with a recombinant GNAl 870 protein vaccine (Table 1). In contrast, JV. meningitidis strains BZ198, M1390, M6190 and NZ98/294 were selected because they were resistant to bactericidal activity of antisera prepared against the recombinant GNAl 870 vaccine (bactericidal titers <l:10).
[00173] pFP12-GNA 1870 shuttle vector construct. Over-expression of GNAl 870 in JV. meningitidis was accomplished using the shuttle vector FP 12, which has an origin of replication from a naturally-occurring plasmid in JV. gonorrhoeae and has been shown to transform E. coli and JV. meningitidis stably (Pagotto et al. Gene 2000;244:13-9). The variant 1 GNA1870 gene, including the putative FUR box promoter from JV. meningitidis strain MC58, was amplified from genomic DNA by PCR using the following primers: GNA1870FURSphIF 5', 5"- ATCGGCATGCGCCGTTCGGACGACATTTG-S" and GNAl 870FURStUlR 3' 5"- AAGAAGGCCTTTATTGCTTGGCGGCAAGGC-S". The PCR product was then digested with Sphl and Stul restriction endonucleases and ligated into pFP12 plasmid digested with Sphl and Stul, which removed the GFP gene. The resulting plasmid, pFP12-GNA1870, was transformed and propagated in E. coli strain TOPlO competent cells (Invitrogen), which was grown in Luria-Bertani medium at 37° C under chloramphenicol selection (50 μg/ml).
[00174] Transformation of N. meningitidis. The RMl 090 strain in which the
GNAl 870 gene was inactivated (RMl 090ΔGNA1870) was made by homologous recombination by transformation with plasmid pBSUDGNA1870ERM using erythromycin selection (5 μg/ml). For preparation of a mutant over-expressing GNAl 870, 3-4 colonies of the RM1090ΔGNA1870 knockout strain were selected from a chocolate agar plate that had been grown overnight. The colonies of bacteria were mixed with 3 μg of the plasmid pFP12- GNAl 870 in 20 μl EB buffer (Qiagen), plated onto a chocolate agar plate, and incubated for 5 hrs at 370C. Serial dilutions of the bacteria were re-cultured onto chocolate agar plates containing chloramphenicol (5 μg/ml). The culture plates were incubated overnight at 37°C, and the colonies were screened for GNAl 870 expression by a colony blot assay using mouse polyclonal anti-rGNAl 870 antibody. Positive individual colonies were selected and re- cultured onto chocolate agar plates containing chloramphenicol. The meningococcal bacterial cells were frozen in 2% skim milk (wt/vol), and stored at -80°C. [00175] An analogous procedure was used to transform strain H44/76 and a mutant thereof that over-expresses GNAl 870. Chromosomal gnal870 in strain H44/76 was inactivated by transformation with pBSUDgnal870erm (Hou et al. Infect Immun 2003;71:6844-49). The mutant (H44/76Δgnal870) was then transformed with plasmid pFP12-GNA1870 that encoded GNA1870 variant 1 from strain MC58. The transformants were selected on chocolate agar plates containing 5 μg/ml chloramphenicol. [00176] Membrane preparations. N. meningitidis were subcultured from frozen stock onto chocolate agar plates (Remel, Laztakas, Kans.). After overnight incubation at 37°C in 5% CO2, several colonies were selected and inoculated into about 6 ml of Mueller- Hinton broth containing 0.25% glucose and 0.02 niM CMP-NANA in an atomosphere containing 5% CO2 to an optical density at 620 nm (OD62o) of 0.1. All strains containing the introduced pFP12-GNAl 870 shuttle vector were grown in the presence of 5 μg/mL of chloramphenicol. The inoculated broth was incubated at 37°C and 5% CO2 with rocking until OD620 reached 0.6 to 0.7 (2 to 3 h). Six 6-ml starter cultures were used to inoculate 1 L of Mueller-Hinton broth. The larger culture was grown at 37°C with vigorous shaking to an OD620 of 0.8 to 1.0. Phenol was added (0.5% wt/vol), and the broth was left at 4°C overnight to kill the bacteria. The bacterial cells were pelleted by centrifugation (10,000 X g) for 30 min at 40C5 and frozen and stored at -200C until used for preparation of the outer membrane vesicle vaccines.
[00177] For the cultures containing strain H44/76 and the mutant thereof, six 7 ml starter cultures were used. The cells were transferred into 1 L of Mueller-Hinton broth without added chloramphenicol and were grown with vigorous shaking until OD620 reached 0.8 to 1.0. Phenol was added (0.5% wt/vol), and the culture was left at 370C for two hours and incubated overnight at 4°C to kill the bacteria. The cells were pelleted by centrifugation (11,000 X g) for 30 min at 4°C
[00178] K meningitidis membrane fractions for OMVs were prepared as previously described without the use of detergents to avoid extraction of the GNAl 870 lipoprotein (Moe et al. 2002, supra). In brief, the frozen bacterial cells were suspended in 40 ml of PBS and sonicated on ice with a sonifier fitted with a microtip (Branson, Danbury, Conn) for four 15-s bursts, which was sufficient to release membrane blebs but not to cause complete lysis of the bacteria. The bacterial suspensions were cooled on ice between the bursts. Cell debris was removed by centrifugation at 5,000 X g for 15 min, and the membrane fraction remaining in the supernatant was obtained by ultracentrifugation at 100,000 X g for 1 h at
40C, and re-suspended in 5 ml of PBS. These preparations were referred to as OMVs. Alternatively, MVs could be used, which are obtained from blebs released by the bacteria into the supernatant as described in (Moe et al. 2002, supra); see also WO 02/09643 . [00179] For H44/76 (and mutant thereof), the frozen bacterial cells were resuspended in 20 ml PBS buffer, and sonicated with four 15-s bursts. Cell debris was removed by centrifugation (16,000 X g) for 30 min at 4°C, and the cell membranes, which were enriched with outer membrane proteins, were collected from the soluble fraction by centrifugation (100,000 X g) for 2 hours.
[00180] Characterization of vaccines. The protein concentrations were determined by the DC protein assay (Bio-Rad, Richmond, CA.) and the BCA Protein Assay Kit (Pierce, Rockford, IL). The OMV preparations were analyzed by 15% SDS-PAGE (12.5% SDS- PAGE for the H44/76 preparations) as described by Laemmli (Nature 1970;227:680-5) employing a Mini-Protean II electrophoresis apparatus (Bio-Rad), and Western blot. Samples were suspended in sample buffer (0.06 M Tris*HCl, pH 6.8, 10% (v/v) glycerol, 2% (w/v) SDS, 5% (v/v) 2-mercaptoethanol, 10 μg/ml bromophenol blue) and heated to 1000C for 5 min. before loading directly onto the gel.
[00181] For Western blots, the gel was equilibrated with buffer (48 mM TrisΗCl, 39 mM glycine [pH 9.0] 20% (v/v) methanol) and transferred to a nitrocellulose membrane (Bio-Rad) using a Trans-Blot™ (Bio-Rad) semi-dry electrophoretic transfer cell. The nitrocellulose membranes were blocked with 2% (w/v) non-fat milk in PBS, and reacted with a 1:20,000 dilution of anti-rGNA1870- antiserum in PBS containing 1% (w/v) BSA and 1% (w/v) Tween-20. Bound antibody was detected using rabbit anti-mouse IgG+ A+M- horseradish peroxidase conjugated polyclonal antibody (Zymed, South San Francisco, CA) and "Western Lightning" chemiluminescence reagents (PerkinElmer Life Sciences, Inc., Boston, MA). The detecting anti-GNA1870 antiserum was from mice immunized sequentially with one injection each of 10 μg of recombinant GNAl 870 v.l (gene from N. meningitidis strain MC58), followed by a dose of recombinant v.3 protein (gene from strain M1239), followed by a dose of recombinant v.2 protein (gene from strain 2996). Each injection was separated by 3- to 4-weeks.
[00182] Immunization. The recombinant protein vaccine was expressed in E. coli as previously described using a GNAl 870 DNA sequence encoding six COOH-terminal histidines (His tag) and devoid of the N-terminal sequence coding for the putative leader peptide (Welsch et al. J Immunol 2004; 172:5606- 15). This non-lipidated HisTag GNAl 870 protein was used since it provides for greater ease of preparation than the recombinant lipoprotein, and data from earlier studies indicated that the non-lipidated antigen given with Freund's complete and incomplete adjuvants elicited strong bactericidal antibody responses in mice against the majority of strains tested.
[00183] The OMV preparations or recombinant GNAl 870 protein were diluted in
PBS and adsorbed with an equal volume of aluminum phosphate adjuvant (1% Alhydrogel final concentration [wt/vol; Superfos Biosector, Frederikssund, Denmark]) that had been incubated with PBS buffer). Groups of 4-6 week old female CDl mice (Charles River Breeding Laboratories, Raleigh, NC) (N=IO per group) were immunized intraperitoneally (IP). Each mouse received a dose containing 5 μg of total protein (for the mixture group, 2.5 μg each of OMV and rGNA1870). A total of three injections were given, each separated by 3-week intervals. Two weeks after the third dose, mice were bled by cardiac puncture and sacrificed. The sera were separated and stored frozen at -2O0C.
[00184] For the H44/76 preparations, each mouse received a dose of 1.25 μg of total protein present in OMV and 170 μg of aluminum phosphate. Three injections were given separated by three weeks. Blood was collected by cardiac puncture three weeks after the third dose. The sera were separated by centrifugation and stored frozen at -700C until use. [00185] Absorption of anti-GNA1870 antibodies. To test the contribution of anti-
GNAl 870 antibodies to antibody functional activity, we absorbed serum pools to remove anti-GNA1870 antibodies. In brief, 100 μl of serum pools diluted 1:2 in PBS buffer containing 10 niM imidazole was added to a column that contained 250 μl of Ni-NTA Sepharose (Qiagen, Valencia, CA) that had been complexed with 200 μg of recombinant GNA1870-HisTag protein or, as a negative control, recombinant NadA-HisTag protein (Comanducci et al. J Exp Med 2002;195:1445-54; Hou et al. 2005, supra). The columns were incubated overnight at 4° C, and washed with 500 μl of PBS buffer containing 10 mM imidazole. Five fractions (100 μl each) that passed through the column were combined and concentrated to the original 50 μl serum volumes by membrane filtration (Microcon YM-10, 10,000 MWCO, Millipore Corp., Bedford, MA). Based on an ELISA, more than 98-99% of the anti-GNA1870 antibodies were removed by the GNAl 870 column. [00186] Anti-GNA1870 antibody. ELISA was used to measure serum antibody titers to GNAl 870, which was performed as previously described (Welsch et al. J Immunol 2004;172:5606-l). The solid-phase antigen consisted of rGNAl870 v.l or v.2 proteins. The secondary antibody was a 1 :2000 dilution of alkaline phosphatase-conjugated rabbit anti- mouse IgM+G+A (Zymed). The serum titer was defined as the dilution giving an OD405 of 0.5 after a 30-min incubation with substrate. [00187] Complement-mediated bactericidal antibody activity. The bactericidal assay was performed as previously described (Moe et al. 2002, supra) using mid-log phase bacteria grown in Mueller Hinton broth supplemented with 0.25% glucose. The final reaction mixture contained different dilutions of test sera, 20% (v/v) human complement, and Gey's buffer containing 1% BSA. The complement source was human serum from a healthy adult with no detectable intrinsic bactericidal activity (Granoff et al. J Immunol 1998;160:5028-36; Welsch et al. 2003, supra). Serum bactericidal titers were defined as the serum dilution resulting in a 50% decrease in CFU per ml after 60 min. of incubation of bacteria in the reaction mixture, as compared with control CFU per ml at time 0. Typically, bacteria incubated with the negative control antibody and complement showed a 150 to 200% increase in CFU/mL during the 60 min. of incubation.
[00188] Binding of antibodies to the surface of live encapsulated N. meningitidis.
The ability of anti-GNAl 870 antibodies to bind to the surface of live N. meningitidis was determined by flow cytometric detection of indirect fluorescence assay, performed as described previously (Granoff et al. J Immunol 2001;167:3487-3496). Positive controls included mouse monoclonal antibodies specific for the group C polysaccharide capsule (1076.1(Garcia-Ojeda et al. Infect Immun 2000;68:239-46)), PorA Pl.2 (Granoff et al. J Immunol 2001;167:3487~3496), and GNAl 870 variant 1 (JAR3)( Welsch et al. J Immunol 2004; 172:5606-15) and a 1:300 dilution of FITC conjugated Goat anti-mouse (Fab')2 IgG (H+L) (Jackson Immuno Research Laboratories, West Grove, PA)_. [00189] Activation of human complement deposition on the surface of live encapsulated meningococci. Anti-GNAl 870 antibody-dependent deposition of C3b or iC3b on the bacterial surface of live TV! meningitidis bacteria was determined by flow cytometry, performed as previously described (Welsch et al. J Infect Dis 2003;188:1730-40). Washed, log-phase bacteria were incubated in a reaction mixture containing 5% (v/v) human complement and appropriate serum dilutions in veranol buffer. Complement deposition was detected with FITC-conjugated sheep anti-human complement C3c (BioDesign Intl., Saco, ME)5 which reacts with both C3b and iC3b. The complement source was the same human serum described above for the bactericidal assay.
[00190] Passive protection in infant rats. The ability of antiserum to confer passive protection against N. meningitidis group B bacteremia was tested in infant rats challenged IP with group B strain NZ98/254 Welsch et al. 2003, supra; Moe et al. Infect Immun 1999;67:5664-75; Moe et al. Infect Immun 2001;69:3762-71). In brief, 4-day old infant pups from litters of outbred Wistar rats (Charles River, Hollister, CA) were randomly redistributed to the nursing mothers. At time 0, groups of eight animals were administered antisera or antibodies IP that had been diluted in PBS containing 1% BSA. Two hours later, the animals were challenged IP with approximately 6 x 104 CFU of washed log-phase bacteria grown in Mueller-Hinton supplemented with 0.25% glucose and 10 μM CMP- NANA (Sigma, St. Louis, MO). Four to six hours after the bacterial challenge, blood specimens were obtained by cardiac puncture and aliquots of 1, 10 and 100 μl of blood were plated onto chocolate agar to ascertain CFU/ml.
EXAMPLE 1: SURFACE-ACCESSIBILITY OF GNA1870 ONiV. MENINGITIDIS STRAIN RM1090.
[00191] To determine whether the GNAl 80 protein expressed by the RMl 090 strain transformed with pFP12-GNA1870 is an integral part of the outer membrane and exposed on the cell surface, and to determine whether overexpressed GNAl 870 in strain H44/76 is anchored and surface-accessible in the outer membrane, binding of anti-GNA1870 and control antibodies to live encapsulated bacterial cells was measured by flow cytometry (Fig.
[00192] As shown in Fig. IA, positive control mAbs specific for group C capsular polysaccharide (column 2) or PorA (anti-Pl.2, column 3) showed strong binding to the parent RM1090 strain (row B) and to the two RM1090 mutant strains: a GNA1870 knockout transformed with the shuttle vector without the GNAl 870 gene (row A), and the knockout transformed with the shuttle vector encoding the GNAl 870 variant 1 protein (row C). With all three strains there was no significant binding with a 1 : 10 dilution of a negative control serum pool from mice immunized with aluminum phosphate alone (column 1). There also was no significant binding of anti-GNAl 870 monoclonal or polyclonal antibodies with the GNAl 870 knockout strain (Row A, columns 5 and 6, respectively). The wild-type RMl 090 strain, which naturally expresses low levels of a GNAl 870 v. 2 protein, had no detectable binding with an anti-GNAl 870 mAb specific for a v. 1 protein (Row B, column 4), and showed minimal binding above background with a polyclonal mouse antiserum (columns 5 and 6) prepared against recombinant v. 1, 2 and 3 GNAl 870 proteins (see below). In contrast, the strain transformed with the shuttle vector encoding GNAl 870 (variant 1) showed strong binding with both the polyclonal and monoclonal anti-GNAl 870 antibodies. Thus, GNAl 870 is exposed on the surface of the RMl 090 strain transformed with the pFP12-GNA1870 shuttle vector. [00193] As shown in Fig. 1 B5 the positive control anticapsular and anti-PorA (P 1.16) monoclonal antibodies bound to H44/76 wildtype strain and to a mutant of strain H44/76 that over-expresses GNAl 870 (both shown in row 1). The positive control antibodies also bound to H44/76 ΔGNA1870 (shown in row 2). As expected, there was no binding of the anti-GNA1870 monoclonal or polyclonal antibodies to the mutant strain H44/76 in which the gene encoding GNAl 870 had been inactivated (columns D to F). Incubation of the wildtype strain with the anti-GNA1870 antibodies showed good binding, a result that reflected the relatively high level of natural GNAl 870 expression in strain H4476. There was a modest increase in binding to the mutant strain that had been engineered to over- express GNAl 870, as evidenced by a small shift to the right of immune fluorescence. Thus, over-expression of GNA1870 resulted in a small increase in the amount of the protein in the outer membrane, and the protein is surface-exposed.
EXAMPLE 2. ANALYSIS OF OMV VACCINE
[00194] The major proteins in the OMV preparations from strain RM 1090 and the respective mutants were separated by SDS-PAGE and visualized by staining with Coomasie Blue (Fig. 2A, Panel A). As is typical of OMV prepared from JV. meningitidis, there were a limited number of major proteins resolving with apparent masses between 29 kDa (Opa/Opc) and 43 kDa (PorA). The OMV prepared from the wild-type strain (lane 1) and GNAl 870 knockout strain (lane 3) expressed similar respective amounts of each of these proteins. In contrast, OMV from the strains transformed with the pFP12 shuttle vector that did not contain the gene encoding GNAl 870 (lanes 2 and 4, respectively) showed decreased relative expression of three proteins migrating with apparent masses between 38 and 43 kDa. This result likely reflects in part decreased expression of the porin proteins by antibiotic selection from the presence of 5 μg/ml of chloramphenicol in the growth media (Tommassen et al. Infect Immun 1990;58:1355-9). Lane 5 shows OMV prepared from strain RM1090 transformed with the shuttle vector encoding GNAl 870. To better visualize the proteins, this lane was loaded with 2-fold more protein (about 10 μg) than in lanes 1 to 4. As compared with the other OMV preparations, the OMV prepared from the strain transformed with the shuttle vector containing the GNAl 870 gene showed decreased expression of proteins resolving between 29 and 32 kDa. By SDS PAGE, GNAl 870 is not readily apparent in any of the OMV preparations including the OMV prepared from the mutant strain over- expressing GNAl 870 (lane 5). (For comparison, 1 μg of the recombinant GNA 1870 variant protein is shown in Lane 6). [00195] In Fig. 2A, Western blot with a polyclonal mouse antiserum raised against v.
1, 2 and 3 GNAl 870 recombinant proteins was used to evaluate expression of GNAl 870 in the different vaccine preparations. As shown in Panel B, the antiserum was slightly more reactive with the rGNAl 870 v.2 protein than the v.1 recombinant protein. Even with this bias, the OMV prepared from RM1090 transformed with pFP12-GNA1870 showed increased reactivity by Western blot as compared with the OMV prepared from the wild-type RM1090 strain that naturally expresses a v. 2 protein (Fig. 2A, Panel C). In contrast, the negative control OMV from the GNA1870 knockout mutant (RM1090ΔGNA1870) had no detectable reactivity. The results of densitometry measurements indicated that expression of the v. 1 GNAl 870 protein in the strain transformed with the shuttle vector was approximately 10-fold higher than that of the v. 2 protein expressed naturally by the wild- type parent RMl 090 strain.
[00196] The H44/76 OMV preparations were analyzed by Western blot using polyclonal antiserum to GNAl 870 (Fig. 2B). The amount of OMV loaded onto the gel was standardized based on total protein content of the preparations. As expected, GNAl 870 was expressed in the membrane preparations from the wildtype strain and was increased in the corresponding preparation from the mutant engineered to over-express this protein. However, the increase in GNAl 870 was modest (approximately 3 -fold)
EXAMPLE 3: ANALYSIS OF SERUM ANTIBODY RESPONSES
[00197] Table 2 and Fig. 5 summarize the serum anti-GNAl 870 antibody responses of the different groups of mice as measured by ELISA. The highest antibody responses to the variant 1 protein in Table 2 were in mice immunized with the recombinant GNAl 870 v.l vaccine only, or with the recombinant GNAl 870 v.l vaccine given as a mixture with an OMV vaccine (titers against the variant 1 protein of 1:120,000 and 1:300,000, respectively). The mice immunized with OMV prepared from strain RM 1090 over-expressing variant 1 GNAl 870 had a 4- to 10-fold lower anti-GNA 1870 titer (1:32,000). Of interest, mice immunized with OMV prepared from the wild-type RMl 090 strain had undetectable or negligible anti-GNAl 870 antibody responses as measured against either the variant 1 or 2 proteins. This result suggests that in the absence of over-expression, GNAl 870 in OMV from the wild-type strain is poorly immunogenic.
[00198] Groups of mice were immunized with H44/76 OMV (1.25 μg of total protein) or 5 μg of rGNAl 870 given with aluminum phosphate. Serum samples were obtained 3 weeks after the third dose and pooled (2 pools per vaccine group, each pool prepared from 4 to 5 mice). As shown in Fig. 5, control mice immunized with the aluminum adjuvant alone had no detectable anti-GNA1870 antibody (GMT <l:10, bar 1), whereas mice immunized with rGNA1870 showed the highest responses (GMT 1 :23,500, bar 2). Mice immunized with OMV prepared from H44/76 that over-expressed GNAl 870 had ~10-fold higher anti- GNAl 870 antibody responses than the respective group immunized with OMV from the wildtype strain (compare bars 5 and 3). Mice immunized with OMV prepared from H44/76 ΔGNA1870 had negligible antibody responses (GMT <1 : 10, bar 4).
Table 2. Anti-GNA1870 antibody responses of mice as measured by ELISA
1 /Antibody Titer b rGNAl 870 rGNAl 870 Variant 2
Vaccinea Variant 1
A12(PO4)3 alone <50 <50 rGNAl 870 (v. 1) 120,000 3200 rGNAl 870 (v. 2) ND 1,600,000
RMl 090 OMV
Wild-type 55 <50
ΔGNA1870 <50 <50
Over-express 32,000 1200
GNAl 870
ΔGNA1870 + rGNAl 870 v.l 300,000 4000 aThe vaccines consisted of 5 μg of total protein absorbed with A12(PO4)3. The OMV + rGNAl 870 vaccine consisted of a mixture of 2.5 μg of OMV and 2.5 μg of rGNAl 870 (v.l). bSerum dilution in an ELISA giving an OD of 0.5 after 30 mins incubation with substrate. Data shown are the respective geometric means of titers measured in 2 serum pools from each vaccine group. Each pool contained equal volumes of sera from 4 to 5 immunized mice.
[00199] Figure 3A summarizes the serum bactericidal antibody responses of the different groups of mice as measured against four of the test strains. Mice immunized with the recombinant GNAl 870 protein vaccine alone, or with the recombinant GNAl 870 vaccine in combination with an OMV vaccine, or with the OMV over-expressing GNAl 870, developed high bactericidal titers against strain Cu385 that were not significantly different from each other (compare bars 4, 5 and 6 of upper panel). In contrast, there was no' detectable bactericidal activity against strain Cu385 in sera from control mice immunized with OMV vaccines prepared from the wild-type RM1090 or the GNAl 870 knockout strains (bars 2 and 3, respectively; titers <1 :10). Note that strain Cu385 expresses the canonical GNAl 870 v. 1 protein (identical amino acid sequence as that of strain MC58, the gene used to express the recombinant GNAl 870 protein), and was known from our previous study to be highly susceptible to bactericidal activity of antibody elicited in mice by the recombinant GNAl 870 vaccine (Table 1). Also, Cu385 has a heterologous PorA serosubtype (Pl.19,15) to that of the vaccine strain RM1090 (Pl.5,2), and, therefore, strain Cu385 was expected to be resistant to bactericidal activity of antibodies raised against the control OMV vaccine that did not over-express GNAl 870 variant 1 (Tappero et al. JAMA 1999;281 : 1520-7; Moe et al. 2002, supra). .
[00200] Figure 3 A, also shows the corresponding serum bactericidal titers measured against strain M6190 (second panel from the top) that expresses a sub-variant of v. 1 GNAl 870 protein as compared with that of the engineered vaccine strain. There was no detectable bactericidal activity in sera from mice immunized with the recombinant GNAl 870 variant 1 protein (bar 6, geometric mean titer <1 : 10), a result identical to that of our previous study (Table 1). However, because the PorA serosubtype (Pl.5,2) of strain M6190 is homologous with that of the RMl 090 vaccine strain, sera from mice immunized with any of the OMV-containing vaccines were highly bactericidal (bars 2, 3, 4 or 5). [00201] Figure 3 A5 (third and fourth panels from top), show the corresponding bactericidal responses against strains Zl 092 and NZ98/254, respectively. Both strains express PorA molecules that are heterologous with that of the RMl 090 vaccine strain (Table I)5 and were not killed by sera from mice immunized with OMV vaccines prepared from the RM1090 wild-type or GNAl 870 knockout strains (bars 2 and 3, geometric mean titers <l:10). However, mice immunized with OMV vaccine prepared from strain RMl 090 that over-expressed GNAl 870 (bar 5) had a significantly higher geometric mean serum bactericidal antibody titer against strain Z 1092 than that of mice immunized with recombinant GNAl 870 (bar 6, PO.02), or with a mixture of the recombinant GNAl 870 protein and OMV vaccine (bar 4, PO.04). Similar trends were observed for the respective serum bactericidal responses measured against strain NZ98/254 (bottom panel), or against strains BZ198 and M1390 (data not shown). However, for these latter three strains, the magnitude of serum bactericidal responses of mice immunized with the OMV vaccine with over-expressed GNAl 870 were lower than those measured against strain Zl 092. Also, the geometric mean serum bactericidal titers against strains NZ98/294, BZl 98 and Ml 390 of mice immunized with OMV that over-expressed GNAl 870 were not statistically significant different as compared with the respective geometric mean titers of the mice in the other vaccine groups (P>0.10). [00202] Figure 3B summarizes the serum bactericidal antibody responses against six strains, including H44/76, which were used to prepare the OMV vaccine. Five of the six strains have PorA serosubtypes heterologous to that of H44/76. Strain H44/76 also expresses a GNAl 870 variant 1 protein sequence identical to that of strain MC58, which contains the gene used to clone and express the recombinant GNAl 870 protein vaccine. All of the vaccine preparations except the negative control aluminum adjuvant elicited high serum bactericidal antibody responses when measured against the H44/76 vaccine strain (Fig. 3B5 Panel A). In contrast, when measured against heterologous strains 4243 (Panel B), Z1092, NZ98/254, and BZ198 (Panel C), or M6190 (Panel D), sera from mice immunized with the rGNA1870 vaccine, or the OMV vaccines prepared from the H44/76 wildtype or H4476ΔGNA1870 strains, had low or undetectable bactericidal titers (bars 2, 3, and 4, respectively). Mice immunized with the OMV vaccine with over-expressed GNAl 870 (bar 5) had high bactericidal antibody responses against strain 4243, low but detectable bactericidal responses against strains NZ98/254, BZl 98, and Zl 092, and no detectable bactericidal activity against M6190 (titer <1 :10). Although not shown on Figure 3B, all strains were readily killed by complement together with positive control antibodies to the respective PorA and/or polysaccharide capsules.
EXAMPLE 4: ACTIVATION OF C3B COMPLEMENT DEPOSITION ON THE SURFACE OF LIVE ENCAPSULATED N. MENINGITIDIS CELLS.
[00203] In previous studies we found that certain mouse anti-meningococcal antibodies that lacked bactericidal activity conferred passive protection against meningococcal bacteremia in the absence of bactericidal activity (Welsch et al. J Immunol 2004; 172:5606-15; Welsch et al. 2003 supra). Protection correlated with the ability of the antibodies to activate deposition of C3 complement components on the surface of live encapsulated meninogococci as measured by flow cytometry. The presence of C3b provides a ligand for opsonization, which is the most likely mechanism conferring protection in the absence of bactericidal activity. Therefore, the ability of the antisera from mice immunized with different OMV vaccines to activate human C3b deposition was investigated (Fig. 4). Two test JV. meningitidis strains, NZ98/254 (Figure 4A, row A) and Ml 390 (Figure 4A, row B) and four test N. meningitidis strains, NZ98/254, BZl 98, Zl 092, and M6190 (Figure 4B) were used for these experiments. These were strains for which the antisera from mice immunized with the OMV vaccine that over-expressed GNAl 870 did not show statistically significantly higher bactericidal titers than the other vaccine groups. [00204] There was no evidence of complement deposition when the bacterial cells of either test strain were incubated with the human complement source together with a 1 :40 dilution of a negative control serum pool from mice immunized with aluminum phosphate alone (filled areas of panels in Fig. 4A, column 1). Similarly, there was no detectable C3b deposition with heat-inactivated complement plus 5 μg/ml of a mouse monoclonal antibody to GNAl 870 (JAR 3) (filled areas of panels in Fig. 4A, column 2). In contrast, the addition of active complement to 25 μg/ml of a positive control group B monoclonal anticapsular antibody (open areas of panels in Fig. 4A, column 1), or 1 μg/ml of an anti-GNA1870 monoclonal antibody (open areas of panels in Fig. 4A, column 2), elicited strong deposition of C3b on the bacterial surface of both test strains, as evidenced by an increase in the percentages of bacteria showing strong immunofluorescence with the anti-C3c antibody, which recognizes both C3b and iC3bi.
[00205] The panels in columns 3 to 6 of Fig. 4A show the effect of adding complement to dilutions of serum pools obtained from groups of immunized mice immunized with the different vaccines. The addition of complement to a 1:100 dilution of serum from mice immunized with recombinant GNAl 870 (column 3), or OMV prepared from the wild-type strain of RMl 090 (column 4), or OMV mixed with recombinant GNAl 870 (column 5), did not activate C3b deposition on either test strain. In contrast, dilutions of 1 : 100 or 1 :400 of a serum pool from mice immunized with OMV prepared from strain RMl 090 that over-expressed GNAl 870 activated strong C3b deposition against both test strains (column 6).
[00206] As shown in Fig. 4B, the positive control anticapsular mAbs elicited complement deposition on each of the strains (open areas in column A), whereas a l;100 dilution if the negative control antiserum from mice immunized with the aluminum adjuvant alone was negative (filled areas in column A). A 1 : 100 dilution of sera from mice immunized with the rGNA1870 vaccine (filled areas in column B), or H44/76 OMV vaccine prepared from the wildtype strain (filled areas in column C), also did not elicit significant complement deposition on any of the strains. In contrast, an anti-rGNA1870 mAb elicited complement deposition on strains NZ98/254, BZ198, and Z1092, but not on strain M6190 (open areas in column B). Similarly a 1:100 dilution of antiserum from mice immunized with the H44/76 vaccine with over-expressed GNAl 870 activated C3 deposition for strains Z 1092, NZ98/254, and BZ198 (open areas in column D), but not for strain M6190. EXAMPLE 5. DEFINING THE ANTIGENIC TARGET OF ANTIBODIES THAT ARE
BACTERICIDAL OR ACTIVATE C3B DEPOSITION ON HETEROLOGOUS STRAINS
[00207] A Ni-NTA affinity column loaded with His-tagged recombinant GNAl 870 was used to absorb anti-GNA1870 antibodies from a serum pool prepared from mice immunized with H44/76 OMV with over-expressed GNAl 870. As shown in Table 3, by ELISA, 98% of the anti-GNA1870 antibodies were removed by this column as compared with that of serum absorbed with a negative control column containing the Ni-NTA matrix only. After absorption on the negative control column, bactericidal activity against strain 4243 was similar to that of the original non-absorbed serum pool, while adsorption of the anti-GNA1870 antibodies resulted in complete loss of bactericidal activity. [00208] The effect of absorption of anti-GNAl 870 antibodies on C3 deposition was analyzed against strains Z1092, NZ98/254, BZ198, and M6190 (Table 3 and Figure 4B3 Row 4). As shown in Fig. 4B, column D, removal of the anti-GNAl 870 antibodies from sera of mice immunized with H44/76 OMV with over-expressed GNAl 870 resulted in complete loss of the ability of the antisera to activate complement deposition in the three strains susceptible to activation and deposition of iC3b/C3b (filled areas of Figure 4B). These results as well as the bactericidal data on absorbed sera summarized above indicate that for strains with PorA proteins heterologous to that of the H44/76 vaccine strain, activation of C3 deposition and bactericidal activity of antisera prepared against H44/76 OMV containing over-expressed GNAl 870 are mediated by anti-GNAl 870 antibodies.
Table 3: Activity of sera from mice immunized with OMV with over-expressed GNAl 870 after absorption of anti-GNA1870 antibodies
Figure imgf000065_0001
[00209] A pool prepared from sera from mice immunized with H44/76 OMV with overexpressed GNAl 870 was adsorbed on a column containing a Ni-NTA matrix (Qiagen) that had been incubated over night with 50 μg/ml recombinant His-tagged GNAl 870. The flow through was collected and concentrated to the original volume. The control column contained Ni-NTA matrix without the His-tagged protein.
EXAMPLE 6. ROLE OF ANTI-GNA1870 ANTIBODY IN FUNCTIONAL ACTIVITY.
[00210] The OMV vaccine prepared from the RM1090 N. meningitis strain that is engineered to over-expresses GNAl 870 showed decreased expression of several other cell envelope proteins as compared with the respective proteins in OMV prepared from the wild- type vaccine RM1090 strain, or the RM1090 ΔGNA1870 knockout strain (Fig. 2A, Panel A). Therefore, it was possible that the higher functional activity of the antisera from mice immunized with OMV that over-expressed GNAl 870 resulted from antibodies elicited by antigens other than GNAl 870. To investigate this possibility, a serum pool from mice immunized with RMl 090 OMV over-expressing GNAl 870 was absorbed using an anti- GNAl 870 affinity column. By ELISA, 99% of the anti-GNA1870 antibodies was removed. The resulting absorbed antiserum also lost all the ability to activate human C3b deposition on N. meningitidis strain NZ98/294 (Table 4). In contrast, there was no effect on C3b deposition by absorbing the serum pool on an anti-NadA affinity column, which served as a negative control (Table 4). Table 4. Functional activity of antiserum from mice immunized with OMV that over-expresses GNAl 870 after depletion of anti-GNA1870 antibodies'1
1 /Antibody Titer Assay Serum Not Serum Serum
Absorbed Absorbed Absorbed with with NadA
GNAl 870
Anti-GNAl 87 ELISA 40,000 400 30,000
C3b complement >400 <25 >400 deposition (flow cytometry)b
Bactericidal activity
Strain Cu385 2500 <10 3000
Strain M6190 1000 600 600 aA serum pool was prepared from five mice immunized with the OMV vaccine from strain RMl 090 engineered to over-express GNAl 870. The antiserum was absorbed on a recombinant GNAl 870 affinity column or, as a negative control, an affinity column containing recombinant NadA (See methods). The pass- through fractions were combined and concentrated to their original serum volume by membrane filtration (see methods). bSerum dilution in the flow cytometric complement activation assay that elicited a 10-fold increase in immunofluorescence as compared with negative control serum (See Figure 4).
[00211] Table 4 also summarizes the bactericidal titers of the absorbed serum pools as measured against strains Cu385 and M6190. Absorption of the anti-GNA1870 antibodies completely removed the bactericidal activity against strain Cu385 but had no significant effect on the titer against strain M6190. This latter result was expected since strain M6190 expresses a PorA with has a homologous serosubtype to PorA expressed by the RM 1090 vaccine strain and the bactericidal anti-PorA antibodies would not be removed by the GNAl 870 or NadA affinity columns.
EXAMPLE 8; PASSIVE PROTECTION IN THE INFANT RAT MENINGOCOCCAL BACTEREMIA MODEL.
[00212] Infant rats were pretreated with serum pools from the different groups of mice, and challenged 2 hours later with N. meningitidis strain NZ98/254. Fig. 6 shows the geometric means of the CFU/ml in blood obtained 4- to 6-hours after the challenge. All 10 rats treated with a 1 : 15 dilution of the serum pool from negative control mice immunized with aluminum phosphate alone had bacteremia with a geometric mean CFU/ml of ~105 (Panel A, bar 1). In contrast, pretreatment with 10 μg/rat of a positive control group B anticapsular antibody (bar 2) or an anti~GNA1870 monoclonal antibody (bar 3) resulted in a 3- to 4-log lower geometric mean CFU/ml (PO.0001). Compared with animals treated with the negative control serum, there was no significant passive protective activity by serum pools from mice immunized with the OMV vaccine prepared from the RM1090ΔGNA1870 knockout strain (bar 4), or the OMV vaccine mixed with recombinant GNAl 870 (bar 5). In contrast, the serum pool from mice immunized with the OMV vaccine that over-expressed GNAl 870 (bar 6) conferred protection (4 log decrease in geometric mean CFU/ml, PO.0001). The serum pool from mice immunized with the recombinant GNA1870 vaccine alone (bar 7) conferred modest protection (~2 log decrease, P<0.0001) but the protective activity was less than that of the serum pool from the mice immunized with OMV that over- expressed GNAl 870 (PO.0001, comparing the respective geometric means of the CFU/ml). [00213] Figure 6, Panel B shows the corresponding geometric means of the CFU/ml of rats pre-treated with 1 :60 dilutions of the serum pools. At this higher dilution, the serum pool from the mice immunized with the OMV vaccine that over-expressed GNAl 870 (bar 6) conferred protection (PO.0002 compared with the geometric mean of rats treated with a 1:15 dilution of the negative control serum) but there was no significant protective activity by the higher dilution of the serum pools from the mice immunized with any of the other 3 vaccine groups tested, including the serum from mice given the recombinant GNAl 870 vaccine (bar 7, P>0.10).
EXAMPLE 9. IMMUNIZATION OF MICE WITH A VESICLE VACCINE PREPARED FROM STRAIN RM1090 THAT OVER-EXPRESSES NEISSERIAL SURFACE PROTEIN A (NSPA) IS NOT ASSOCIATED WITH ENHANCED SERUM BACTERICIDAL ANTIBODY RESPONSES.
[00214] It was of interest to determine whether the enhanced protection induced by the vesicle vaccine prepared from the RMl 090 strain engineered to over-express GNAl 870 was specific for GNAl 870, or also would occur with a vesicle vaccines prepared from a strains engineered to over-express another vaccine target. Therefore, a microvesicle vaccine was prepared from strain RMl 090 in which the gene for NspA in the wildtype strain had been inactivated. A second vesicle vaccine was prepared from the RMl 090 NspA-knockout strain transformed with the shuttle vector pFP12 containing the NspA gene from strain 8047. By SDS PAGE, the resulting vesicles from the strain transformed with the shuttle vector contained 10- fold increased expression of the NspA protein as compared with the RMl 090 wildtype strain (data not shown).
[00215] Groups of mice were immunized with 3 doses of the vesicle vaccines given with aluminum phosphate, and serum was collected 3 weeks after the last immunization. The vaccine over-expressing NspA elicited high anti-NspA antibody titers as measured by ELISA (1 : 19,000 as compared with a titer of 1 :700 in mice immunized with the vesicle vaccine prepared from the NspA knockout strain, and a titer of <1 :50 from mice immunized with aluminum phosphate alone). Table 5 summarizes the serum bactericidal antibody responses as measured against four test strains, BZl 98, NZ98/254, Cu385 and Z1090.
Figure imgf000068_0001
a Microvesicles were prepared as described by Moe et al (Infection Immunity 2002:70:6021-6031) from a NspA-knockout the knockout strain transformed with shuttle vector pFP12 containing the
NspA gene from strain 8047. Mice were immunized with three injections and bled ~3 weeks after the last injection. The titers shown are from pooled serum from 9 to 10 mice in each vaccine group.
The respective anti-NspA antibody titers as measured by ELISA were <l:50 (aluminum phosphate group), 1:700 (vesicles from RM1090 NspA knockout strain) and 1:19,000 (vesicles from RM1090 strain over-expressing NspA). b Lowest concentration giving 50% killing of bacteria after 1 hr. incubation with human complement c Highest dilution of serum giving 50% killing of bacteria after 1 hr. incubation with human complement d Expressed in the NspA knockout background
[00216] All four strains expressed a heterologous PorA as compared with that of the vaccine strain RMl 090. With strain BZl 98, which was selected for testing bactericidal activity in this experiment based on previous data showing high susceptibility to bactericidal activity of anti-NspA antisera prepared against recombinant NspA expressed in E. coli vesicles (Moe et al., Infection and Irnmunity 1999;67:5664-5675), there was evidence of increased bactericidal activity in the antiserum from mice immunized with the vesicle vaccine derived from the strain over-expressing NspA. However, against strain NZ98/254 there was no increase in bactericidal activity, and for strains Cu385 and Zl 090 there was evidence that immunizing with a vesicle vaccine that over-expressed NspA induced 3- to 10- fold lower serum bactericidal antibody responses than those induced by a control vesicle vaccine prepared from the corresponding NspA-knockout strain. Thus, in contrast with vesicle vaccines that over-express GNAl 870, a vesicle vaccine that over-expresses NspA did not consistently provide for enhanced bactericidal antibody responses, and appears to have suppressed bactericidal antibody responses to some strains.

Claims

CLAIMS WHAT IS CLAIMED IS:
1. A composition comprising: isolated antigenic vesicles prepared from a first Neisseria species bacterium, wherein the Neisseria species bacterium produces a level of a GNAl 870 polypeptide sufficient to provide for production of a vesicle that, when administered to a subject, elicits anti- GNAl 870 antibodies; and a pharmaceutically acceptable carrier.
2. The composition of claim 1, wherein the vesicles are outer membrane vesicles (OMVs), microvesicles (MV), or a mixture of OMVs and MVs.
3. The composition of claim 1, wherein the Neisseria species bacterium is naturally occurring.
4. The composition of claim 1, wherein the GNAl 870 polypeptide is endogenous to the Neisseria species bacterium.
5. The composition of claim 1, wherein the Neisseria species bacterium is genetically modified in GNAl 870 polypeptide production.
6. The composition of claim 5, wherein the Neisseria species bacterium is genetically modified to provide for expression of a GNAl 870 polypeptide from a heterologous promoter.
7. The composition of claim 1, wherein the Neisseria species bacterium is genetically modified to contain a nucleic acid encoding an exogenous GNAl 870 polypeptide.
8. The composition of claim 1, wherein the Neisseria species bacterium is genetically modified to disrupt production of an endogenous GNAl 870 polypeptide.
9. The composition of claim 1, wherein the Neisseria species bacterium is deficient in capsular polysaccharide.
10. The composition of claim 1, wherein the composition further comprises: an isolated antigenic vesicle prepared from a second Neisseria species bacterium, wherein the second Neisseria species bacterium produces a level of a GNAl 870 polypeptide sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNA1870 antibodies, and wherein the second Neisseria species bacterium is genetically diverse to the first Neisseria species bacterium.
11. The composition of claim 10, wherein the first and second Neisseria species bacteria are genetically diverse in that they differ in at least one of serogroup, serotype, or serosubtype.
12. The composition of claim 10, wherein the GNAl 870 polypeptide of the second Neisseria species bacterium is different from the GNAl 870 polypeptide of the first Neisseria species bacterium.
13. The composition of claim 10, wherein the composition further comprises: an isolated antigenic vesicle prepared from a third Neisseria species bacterium, wherein the second Neisseria species bacterium produces a level of a GNAl 870 polypeptide sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNAl 870 antibodies, and wherein the third Neisseria species bacterium is genetically diverse to the first Neisseria species bacterium.
14. The composition of claim 13, wherein the first, second and third Neisseria species bacteria are genetically diverse in that they differ in at least one of serogroup, serotype, or serosubtype.
15. The composition of claim 12, wherein the GNA1870 polypeptides of the first, second and third Neisseria species bacterium are different.
16. The composition of claim 1, wherein the first Neisseria species bacterium is genetically modified to produce at least two different GNAl 870 polypeptides.
17. The composition of claim 16, wherein the GNA1870 polypeptides are of different GNAl 870 polypeptide variant groups, wherein the variant groups are v.l, v.2 and v.3.
18. A method of producing an antigenic composition, the method comprising: culturing a Neisseria species bacterium producing a GNAl 870 polypeptide, wherein the GNAl 870 polypeptide is produced at a level sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNA1870 antibodies; preparing vesicles from the cultured bacterium; and combining the vesicles with a pharmaceutically acceptable carrier to produce an antigenic composition suitable for administration to a subject.
19. The method of claim 18, wherein the vesicle is an outer membrane vesicle (OMV) or a microvesicle (MV).
20. The method of claim 18, wherein the Neisseria species bacterium is naturally occurring.
21. The method of claim 18, wherein the GNAl 870 polypeptide is endogenous to the Neisseria species bacterium.
22. The method of claim 18, wherein the Neisseria species bacterium is genetically modified in GNAl 870 polypeptide production.
23. The method of claim 22, wherein the Neisseria species bacterium is genetically modified to provide for expression of a GNAl 870 polypeptide from a heterologous promoter.
24. The method of claim 21, wherein the Neisseria species bacterium is genetically modified to contain a nucleic acid encoding an exogenous GNAl 870 polypeptide.
25. The method of claim 22, wherein the Neisseria species bacterium is genetically modified to disrupt production of an endogenous full-length GNAl 870 polypeptide.
26. The method of claim 18, wherein the Neisseria species bacterium is genetically modified to produce at least two different GNAl 870 polypeptides.
27. The method of claim 26, wherein the GNAl 870 polypeptides are of different GNAl 870 polypeptide variant groups, wherein the variant groups are v.l, v.2 and v.3.
28. The method of claim 18, wherein the Neisseria species bacterium is deficient in capsular polysaccharide.
29. A method of eliciting an immune response against Neisseria, said method comprising the steps of: administering to a mammal an immunologically effective amount of a composition comprising a first antigenic preparation comprising vesicles prepared from a first Neisseria species bacterium, wherein the Neisseria species bacterium produces a level of a GNAl 870 polypeptide sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNA1870 antibodies; wherein said administering is sufficient to elicit an immune response to a GNAl 870 polypeptide present in the vesicles.
30. The method of claim 29, wherein the vesicles are outer membrane vesicles (OMVs), microvesicles (MVs), or a mixture of OMVs and MVs.
31. The method of claim 29, wherein the Neisseria species bacterium is naturally occurring or is genetically modified in GNAl 870 polypeptide production.
32. The method of claim 29, wherein the GNA1870 polypeptide is endogenous to the Neisseria species bacterium.
33. The method of claim 29, wherein the Neisseria species bacterium is genetically modified to provide for expression of a GNAl 870 polypeptide from a heterologous promoter.
34. The method of claim 29, wherein the Neisseria species bacterium is genetically modified to contain a nucleic acid encoding an exogenous GNAl 870 polypeptide.
35. The method of claim 29, wherein the Neisseria species bacterium is genetically modified to disrupt production of an endogenous GNAl 870 polypeptide.
36. The method of claim 29, wherein the composition further comprises an immunologically effective amount of a second antigenic preparation comprising vesicles prepared from a second Neisseria species bacterium, wherein the second Neisseria species bacterium produces a level of a GNAl 870 polypeptide sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNA1870 antibodies, and wherein the second Nesseria species bacterium is genetically diverse to the first Neisseria species bacterium.
37. The method of claim 36, wherein the GNAl 870 polypeptide of the second Neisseria species bacterium is different from the GNAl 870 polypeptide of the first Neisseria species bacterium.
38. The method of claim 36, wherein the composition further comprises a third isolated antigenic preparation comprising vesicles prepared from a third Neisseria species bacterium, wherein the second Neisseria species bacterium produces a level of a GNAl 870 polypeptide sufficient to provide for production of vesicles that, when administered to a subject, elicit anti-GNA1870 antibodies, and wherein the third Neisseria species bacterium is genetically diverse to the first or second Neisseria species bacterium.
39. The method of claim 38, the first, second and third Neisseria species bacteria are genetically diverse in that they differ in at least one of serogroup, serotype, or serosubtype.
40. The method of claim 38, wherein the GNAl 870 polypeptides of the first, second and third Neisseria species bacteria are different.
41. The method of claim 29, wherein the first Neisseria species bacterium is genetically modified to produce at least two different GNAl 870 polypeptides.
42. The method of claim 41, wherein the GNAl 870 polypeptides are of different GNA1870 polypeptide variant groups, wherein the variant groups are v.l, v.2 and v.3.
43. The method of claim 29, wherein said administering elicits a protective immune response in the subject against more than one strain of Neisseria meningitidis.
44. The method of claim 29, wherein the Neisseria species bacterium is a Neisseria meningitidis of serogroup B.
45. A method of eliciting an immune response against Neisseria, said method comprising administering to a mammal an immunologically effective amount of a composition comprising a preparation comprising vesicles prepared from a strain of Neisseria species bacterium that naturally expresses high amounts of GNAl 870 or that has been engineered to over-express GNAl 870; wherein said administering is sufficient to elicit an immune response to a GNAl 870 polypeptide present in the vesicles.
46. The method of claim 45, wherein the vesicles are outer membrane vesicles (OMVs), microvesicles (MVs), or a mixture of OMVs and MVs.
47. The method of claim 45, wherein the strain of Neisseria species bacterium is H44/76.
48. A composition comprising an antigenic vesicle prepared from a strain of Neisseria species bacterium that naturally expresses high amounts of GNAl 870 or that has been engineered to over-express GNAl 870; and a pharmaceutically acceptable carrier.
49. The composition of claim 48, wherein the strain of Neisseria species bacterium is H44/76.
50. A composition comprising: a first antigenic vesicle prepared from a first Neisseria meningitidis bacterium genetically modified to overexpress a GNAl 870 polypeptide; a second antigenic vesicle prepared from a second Neisseria meningitidis bacterium genetically modified to overexpress a GNAl 870 polypeptide; and a pharmaceutically acceptable carrier; wherein the GNAl 870 polypeptide of the first and second bacterium are different GNAl 870 polypeptide variant groups, and the first and second bacteria produce different PorA polypeptides.
51. The composition of claim 50, wherein the composition further comprises a third antigenic vesicle prepared from a third Neisseria meningitidis bacterium genetically modified to overexpress a GNAl 870 polypeptide, wherein the GNAl 870 polypeptide of the third bacterium is of a different GNAl 870 polypeptide variant group than that of the first and second bacteria, and wherein the third bacterium produces a PorA polypeptide different from the PorA polypeptide of the first and second bacteria.
52. The composition of claim 50, wherein the vesicles of the first and second antigenic vesicle are prepared without use of a detergent.
PCT/US2006/002523 2005-01-27 2006-01-23 Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis WO2006081259A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EP06733859A EP1855715B1 (en) 2005-01-27 2006-01-23 Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
JP2007553181A JP4993750B2 (en) 2005-01-27 2006-01-23 Vesicular vaccine based on GNA1870 for broad protection against diseases caused by Neisseria meningitidis
BRPI0607374A BRPI0607374B8 (en) 2005-01-27 2006-01-23 gna1870-based vesicle vaccines for broad-spectrum protection against diseases caused by neisseria meningitidis
AU2006208208A AU2006208208B2 (en) 2005-01-27 2006-01-23 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
CN2006800029319A CN101107007B (en) 2005-01-27 2006-01-23 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
CA2590974A CA2590974C (en) 2005-01-27 2006-01-23 Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
US11/795,739 US9034345B2 (en) 2005-01-27 2006-01-23 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
NZ555937A NZ555937A (en) 2005-01-27 2006-01-23 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
MX2007008785A MX2007008785A (en) 2005-01-27 2006-01-23 Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis.
HK08100214.2A HK1107526A1 (en) 2005-01-27 2008-01-08 Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
US13/279,006 US8968748B2 (en) 2005-01-27 2011-10-21 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US14/688,594 US9452208B2 (en) 2005-01-27 2015-04-16 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US15/237,495 US10046043B2 (en) 2005-01-27 2016-08-15 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US16/024,145 US10478484B2 (en) 2005-01-27 2018-06-29 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US16/596,556 US10857221B2 (en) 2005-01-27 2019-10-08 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US17/085,924 US11801293B2 (en) 2005-01-27 2020-10-30 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64791105P 2005-01-27 2005-01-27
US60/647,911 2005-01-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US64791105P Continuation 2005-01-27 2005-01-27

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US11795739 A-371-Of-International 2005-01-23
US11/795,739 A-371-Of-International US9034345B2 (en) 2005-01-27 2006-01-23 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US13/279,006 Continuation US8968748B2 (en) 2005-01-27 2011-10-21 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US14/688,594 Continuation US9452208B2 (en) 2005-01-27 2015-04-16 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis

Publications (2)

Publication Number Publication Date
WO2006081259A2 true WO2006081259A2 (en) 2006-08-03
WO2006081259A3 WO2006081259A3 (en) 2007-03-01

Family

ID=36741009

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/002523 WO2006081259A2 (en) 2005-01-27 2006-01-23 Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

Country Status (20)

Country Link
US (7) US9034345B2 (en)
EP (3) EP2682126B1 (en)
JP (1) JP4993750B2 (en)
CN (1) CN101107007B (en)
AU (1) AU2006208208B2 (en)
BR (1) BRPI0607374B8 (en)
CA (1) CA2590974C (en)
CY (1) CY1118732T1 (en)
DK (1) DK2682126T3 (en)
ES (1) ES2616294T3 (en)
HK (1) HK1107526A1 (en)
HU (1) HUE033196T2 (en)
LT (1) LT2682126T (en)
MX (1) MX2007008785A (en)
NZ (1) NZ555937A (en)
PL (1) PL2682126T3 (en)
PT (1) PT2682126T (en)
RU (1) RU2432962C2 (en)
SI (1) SI2682126T1 (en)
WO (1) WO2006081259A2 (en)

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111337A1 (en) 2008-03-03 2009-09-11 Irm Llc Compounds and compositions as tlr activity modulators
WO2010046715A1 (en) * 2008-10-25 2010-04-29 Imperial Innovations Limited Vaccine compositions comprising a mutated factor h binding protein
JP2010512792A (en) * 2006-12-22 2010-04-30 ワイス エルエルシー Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2010067202A2 (en) 2008-12-11 2010-06-17 Novartis Ag Mixing lyophilised meningococcal vaccines with non-hib vaccines
WO2010070453A2 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
WO2010144734A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
WO2011024071A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
WO2011024072A2 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
WO2011049677A1 (en) 2009-09-02 2011-04-28 Irm Llc Compounds and compositions as tlr activity modulators
WO2011051893A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
EP2331562A2 (en) * 2008-09-03 2011-06-15 Children's Hospital & Research Center at Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
WO2011084549A1 (en) 2009-12-15 2011-07-14 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
JP2011521976A (en) * 2008-05-30 2011-07-28 ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー オブ ジ アーミー， オン ビハーフ オブ ウォルター リード アーミー Meningococcal multivalent native outer membrane vesicle vaccine, its preparation method and use thereof
WO2011119759A1 (en) 2010-03-23 2011-09-29 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
WO2012032498A2 (en) 2010-09-10 2012-03-15 Novartis Ag Developments in meningococcal outer membrane vesicles
EP2462949A2 (en) 2007-10-19 2012-06-13 Novartis AG Meningococcal vaccine formulations
US8273360B2 (en) 2000-01-17 2012-09-25 Novartis Ag Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
CN102834410A (en) * 2010-03-30 2012-12-19 奥克兰儿童医院及研究中心 Factor h binding proteins (fhbp) with altered properties and methods of use thereof
US20130004530A1 (en) * 2010-03-10 2013-01-03 Jan Poolman Vaccine composition
US8394390B2 (en) 1999-10-29 2013-03-12 Novartis Ag Neisserial antigenic peptides
US8398988B2 (en) 2009-03-24 2013-03-19 Novartis Ag Adjuvanting meningococcal factor H binding protein
WO2013113917A1 (en) 2012-02-02 2013-08-08 Novartis Ag Promoters for increased protein expression in meningococcus
US8524251B2 (en) 1998-05-01 2013-09-03 J. Craig Venter Institute, Inc. Neisseria meningitidis antigens and compositions
US8563006B2 (en) 2001-10-11 2013-10-22 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP2424563A4 (en) * 2009-04-30 2013-10-30 Childrens Hosp & Res Ct Oak Chimeric factor h binding proteins (fhbp) and methods of use
US8642733B2 (en) 2009-11-06 2014-02-04 Children's Hospital & Research Center Oakland T-cell stimulating protein B and methods of use
WO2014030003A1 (en) * 2012-08-23 2014-02-27 Isis Innovation Limited Neisseria meningitidis fhbp variant and its use for vaccination
WO2014037472A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
WO2014122232A1 (en) 2013-02-07 2014-08-14 Novartis Ag Pharmaceutical compositions comprising vesicles
US8840907B2 (en) 2001-09-06 2014-09-23 Novartis Vaccines And Diagnostics S.R.L. Isolated protein and compositions comprising the protein
US8980286B2 (en) 2002-11-22 2015-03-17 Novartis Ag Multiple variants of meningococcal protein NBM1870
EP2886551A2 (en) 2008-02-21 2015-06-24 Novartis AG Meningococcal fhbp polypeptides
USRE45587E1 (en) 2001-07-26 2015-06-30 Glaxosmithkline Biologicals Sa Vaccines comprising aluminum adjuvants and histidine
US9150898B2 (en) 2000-02-28 2015-10-06 Glaxosmithkline Biologicals Sa Heterologous expression of Neisserial proteins
US9156894B2 (en) 2005-11-25 2015-10-13 Glaxosmithkline Biologicals Sa Chimeric, hybrid and tandem polypeptides of meningococcal NMB1870
US9364528B1 (en) 1999-05-19 2016-06-14 Glaxosmithkline Biologicals Sa Combination neisserial compositions
RU2607021C2 (en) * 2011-07-07 2017-01-10 Де Стат Дер Недерланден, Верт. Дор Де Министер Ван Ввс Process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
US9556240B2 (en) 2010-08-23 2017-01-31 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
US9561269B2 (en) 2012-03-09 2017-02-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3027206A4 (en) * 2013-08-02 2017-03-08 Children's Hospital & Research Center Oakland Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
AU2015275311B2 (en) * 2008-10-25 2017-07-13 Imperial Innovations Limited Vaccine compositions comprising a mutated factor h binding protein
US9757443B2 (en) 2010-09-10 2017-09-12 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
US9822150B2 (en) 2013-09-08 2017-11-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10196429B2 (en) 2012-03-09 2019-02-05 Pfizer Inc. Neisseria meningitidis composition and methods thereof
US10195264B2 (en) 2004-04-22 2019-02-05 Glaxosmithkline Biologicals S.A. Immunising against meningococcal serogroup Y using proteins
US10266572B2 (en) 2014-07-23 2019-04-23 Children's Hospital & Research Center At Oakland Factor H binding protein variants and methods of use thereof
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
AU2018204779B2 (en) * 2006-04-26 2019-10-31 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3782643A1 (en) 2014-02-28 2021-02-24 GlaxoSmithKline Biologicals SA Modified meningococcal fhbp polypeptides

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
MXPA03000822A (en) * 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
HUE033196T2 (en) * 2005-01-27 2017-11-28 Children's Hospital & Res Center At Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
CA2695467A1 (en) * 2007-08-02 2009-03-26 Children's Hospital & Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
EP2039764A1 (en) * 2007-09-19 2009-03-25 Pevion Biotech AG Truncated secretory aspartyl proteinase 2
EP2265640B1 (en) 2008-03-10 2015-11-04 Children's Hospital & Research Center at Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
WO2010109324A1 (en) * 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
US9201072B2 (en) * 2009-09-01 2015-12-01 Aeon Medix Inc. Gut flora-derived extracellular vesicles, and method for searching for a disease model, vaccine, and candidate drug and for diagnosis using the same
US9149542B2 (en) * 2010-07-01 2015-10-06 Aeon Medix Inc. Microvesicles derived from cell protoplast and use thereof
CN104736563A (en) 2012-07-27 2015-06-24 国家健康与医学研究院 Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
AU2013320313B2 (en) * 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
EP3655031A1 (en) 2017-07-21 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Neisseria meningitidis immunogenic compositions

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (en) 1982-01-22 1985-10-31 Sandoz Ag METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
IL84285A (en) 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5001065A (en) 1987-05-27 1991-03-19 Cetus Corporation Human cell line and triomas, antibodies, and transformants derived therefrom
RU2023448C1 (en) 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Method for manufacturing vaccine against various pathogenic serotypes of group b neisser's meningitis
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5231026A (en) 1987-12-31 1993-07-27 Tanox Biosystems, Inc. DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
US5292867A (en) 1988-11-16 1994-03-08 Tanox Biosystems, Inc. Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin
ES2070312T5 (en) 1988-12-19 2003-05-16 American Cyanamid Co CLASS 1 MENINGOCOCIC EXTERNAL MEMBRANE PROTEIN VACCINE.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
IL94872A (en) 1989-06-30 1995-03-30 Oncogen Monoclonal or chimeric antibodies reactive with human carcinomas, recombinant proteins comprising their antigen binding region, pharmaceutical compositions and kits comprising said antibodies and methods for imaging human carcinoma using same
US5081235A (en) 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
US5075431A (en) 1989-07-26 1991-12-24 City Of Hope Chimeric anti-CEA antibody
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
ES2143716T3 (en) 1992-06-25 2000-05-16 Smithkline Beecham Biolog VACCINE COMPOSITION CONTAINING ADJUVANTS.
NL9201716A (en) 1992-10-02 1994-05-02 Nederlanden Staat Outer membrane vesicle comprising a group of polypeptides which have at least the immune function of membrane bound outer membrane proteins (OMPs), method of preparation thereof and a vaccine comprising such an outer membrane vesicle.
US5472693A (en) 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167377B2 (en) 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur Proteinase k resistant surface protein of neisseria meningitidis
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
FR2751000B1 (en) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med SPECIFIC DNA FROM NEISSERIA MENINGITIDIS BACTERIA, PROCESSES FOR OBTAINING THEM AND BIOLOGICAL APPLICATIONS
ES2241042T3 (en) 1996-10-11 2005-10-16 The Regents Of The University Of California IMMUNO STIMULATOR POLINUCLEOTIDE CONJUGATES / IMMUNOMODULATOR MOLECULA.
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69838294T2 (en) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Process for the preparation of nucleic acid constructs
PT1003850E (en) 1997-06-06 2009-08-13 Dynavax Tech Corp Inhibitors of dna immunostimulatory sequence activity
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
DE69815692T2 (en) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. OIL IN WATER EMULSIONS WITH SAPONINES
BR9813930A (en) 1997-11-06 2006-12-19 Chiron Spa neisserial antigen
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
JP2002511423A (en) 1998-04-09 2002-04-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム vaccine
JP5102414B2 (en) 1998-05-01 2012-12-19 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Meningococcal antigens and compositions
US8007815B1 (en) 1998-05-29 2011-08-30 Novartis Ag Combination meningitidis B/C vaccines
EP1144998A3 (en) 1998-10-09 2002-08-07 Chiron Corporation Neisseria genomic sequences and methods of their use
CA2773698C (en) 1998-10-16 2015-05-19 Glaxosmithkline Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
US20030215469A1 (en) 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
CA2348928C (en) 1998-11-03 2010-01-26 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn,Volksgezondheid En Cultuur Lps with reduced toxicity from genetically modified gram negative bacteria
US7081244B2 (en) 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
HU228499B1 (en) 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
PT1187629E (en) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa ADJUVANT COMPOSITION THAT UNDERSTANDS SAPONIN AND AN IMMUNOSTIMULATOR OLIGONUCLEOTIDE
BR0010361A (en) 1999-04-30 2003-06-10 Chiron Corp Genetic sequences of neisseria and use of these
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
CO5200837A1 (en) 1999-09-24 2002-09-27 Smithkline Beecham Corp VACCINES
PL355232A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CN1416352B (en) * 2000-01-17 2011-05-25 启龙股份公司 Outer membrane vesicle (OMV) vaccine comprising N. Meningitidis serogroup B outer membrane
NO20002828D0 (en) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinaceous vaccine against Neisseria meningtidis serogroup and method of preparation thereof
MXPA03000822A (en) * 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis.
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0024200D0 (en) 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103169D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US6839862B2 (en) 2001-05-31 2005-01-04 Koninklijke Philips Electronics N.V. Parallel data communication having skew intolerant data groups
MXPA04000653A (en) 2001-07-27 2004-11-22 Chiron Srl Meningococcus adhesins nada, app and orf 40.
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
EP1374892A1 (en) 2002-06-28 2004-01-02 Braun, Jan Matthias, Dr. Medicament for the treatment of diseases due to infection by Neisseria Meningitidis
WO2004015099A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine composition comprising lipooligosaccharide with reduced phase variability
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CA2501812C (en) 2002-10-11 2012-07-10 Mariagrazia Pizza Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
HUE033196T2 (en) * 2005-01-27 2017-11-28 Children's Hospital & Res Center At Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
CA2695467A1 (en) 2007-08-02 2009-03-26 Children's Hospital & Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
US8476032B2 (en) * 2008-08-27 2013-07-02 Children's Hospital & Research Center Oakland Complement factor H-based assays for serum bactericidal activity against Neisseria meningitidis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1855715A4 *

Cited By (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524251B2 (en) 1998-05-01 2013-09-03 J. Craig Venter Institute, Inc. Neisseria meningitidis antigens and compositions
US9266929B2 (en) 1998-05-01 2016-02-23 Glaxosmithkline Biologicals Sa Neisseria meningitidis antigens and compositions
US9249198B2 (en) 1998-05-01 2016-02-02 Glaxosmithkline Biologicals Sa Neisseria meningitidis antigens and compositions
US9249196B2 (en) 1998-05-01 2016-02-02 Glaxosmithkline Biologicals Sa Neisseria meningitidis antigens and compositions
US9364528B1 (en) 1999-05-19 2016-06-14 Glaxosmithkline Biologicals Sa Combination neisserial compositions
US9610342B2 (en) 1999-05-19 2017-04-04 Glaxosmithkline Biologicals Sa Combination neisserial compositions
US9067987B2 (en) 1999-10-29 2015-06-30 Glaxosmithkline Biologicals Sa Neisserial antigenic peptides
US8734812B1 (en) 1999-10-29 2014-05-27 Novartis Ag Neisserial antigenic peptides
US8394390B2 (en) 1999-10-29 2013-03-12 Novartis Ag Neisserial antigenic peptides
US8273360B2 (en) 2000-01-17 2012-09-25 Novartis Ag Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
US9150898B2 (en) 2000-02-28 2015-10-06 Glaxosmithkline Biologicals Sa Heterologous expression of Neisserial proteins
USRE45587E1 (en) 2001-07-26 2015-06-30 Glaxosmithkline Biologicals Sa Vaccines comprising aluminum adjuvants and histidine
US8840907B2 (en) 2001-09-06 2014-09-23 Novartis Vaccines And Diagnostics S.R.L. Isolated protein and compositions comprising the protein
US8980277B2 (en) 2001-09-06 2015-03-17 Novartis Ag Hybrid and tandem expression of neisserial proteins
US9011869B2 (en) 2001-09-06 2015-04-21 Glaxosmithkline Biologicals Sa Hybrid and tandem expression of Neisserial proteins
US9056075B2 (en) 2001-09-06 2015-06-16 Glaxosmithkline Biologicals Sa Methods of inducing an immune response with compositions comprising a Neisseria meningitidis 741 protein
US8563006B2 (en) 2001-10-11 2013-10-22 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US9132182B2 (en) 2001-10-11 2015-09-15 Wyeth Holdings Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
US9623101B2 (en) 2001-10-11 2017-04-18 Wyeth Holdings Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
US9107873B2 (en) 2001-10-11 2015-08-18 Wyeth Holdings Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
US9757444B2 (en) 2001-10-11 2017-09-12 Wyeth Holdings Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
US10300122B2 (en) 2001-10-11 2019-05-28 Wyeth Holdings Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
US9168293B2 (en) 2001-10-11 2015-10-27 Wyeth Holdings Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
US11116829B2 (en) 2001-10-11 2021-09-14 Wyeth Holdings Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
US8563007B1 (en) 2001-10-11 2013-10-22 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US10328142B2 (en) 2002-11-22 2019-06-25 Glaxosmithkline Biologicals Sa Multiple variants of meningococcal protein NMB1870
US9550814B2 (en) 2002-11-22 2017-01-24 Glaxosmithkline Biologicals Sa Multiple variants of meningococcal protein NMB1870
US8980286B2 (en) 2002-11-22 2015-03-17 Novartis Ag Multiple variants of meningococcal protein NBM1870
US10195264B2 (en) 2004-04-22 2019-02-05 Glaxosmithkline Biologicals S.A. Immunising against meningococcal serogroup Y using proteins
US9156894B2 (en) 2005-11-25 2015-10-13 Glaxosmithkline Biologicals Sa Chimeric, hybrid and tandem polypeptides of meningococcal NMB1870
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2018204779B2 (en) * 2006-04-26 2019-10-31 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8574597B2 (en) 2006-12-22 2013-11-05 Wyeth Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
JP2010512792A (en) * 2006-12-22 2010-04-30 ワイス エルエルシー Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2462949A2 (en) 2007-10-19 2012-06-13 Novartis AG Meningococcal vaccine formulations
EP3263591A1 (en) 2008-02-21 2018-01-03 GlaxoSmithKline Biologicals S.A. Meningococcal fhbp polypeptides
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
EP2886551A2 (en) 2008-02-21 2015-06-24 Novartis AG Meningococcal fhbp polypeptides
US9468673B2 (en) 2008-02-21 2016-10-18 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
WO2009111337A1 (en) 2008-03-03 2009-09-11 Irm Llc Compounds and compositions as tlr activity modulators
JP2011521976A (en) * 2008-05-30 2011-07-28 ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー オブ ジ アーミー， オン ビハーフ オブ ウォルター リード アーミー Meningococcal multivalent native outer membrane vesicle vaccine, its preparation method and use thereof
US9387239B2 (en) 2008-05-30 2016-07-12 U.S. Army Medical Research And Materiel Command Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
EP2296699A4 (en) * 2008-05-30 2013-11-13 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
EP2331562A4 (en) * 2008-09-03 2012-07-04 Childrens Hosp & Res Ct Oak Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
US8470340B2 (en) 2008-09-03 2013-06-25 Children's Hospital & Research Center Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
EP2331562A2 (en) * 2008-09-03 2011-06-15 Children's Hospital & Research Center at Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
AU2009306114B2 (en) * 2008-10-25 2015-10-01 Imperial Innovations Limited Vaccine compositions comprising a mutated factor H binding protein
AU2015275311B2 (en) * 2008-10-25 2017-07-13 Imperial Innovations Limited Vaccine compositions comprising a mutated factor h binding protein
EP3501534A1 (en) * 2008-10-25 2019-06-26 Imperial Innovations Limited Vaccine compositions comprising a mutated factor h binding protein
WO2010046715A1 (en) * 2008-10-25 2010-04-29 Imperial Innovations Limited Vaccine compositions comprising a mutated factor h binding protein
WO2010067202A2 (en) 2008-12-11 2010-06-17 Novartis Ag Mixing lyophilised meningococcal vaccines with non-hib vaccines
WO2010070453A2 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
US10245311B2 (en) 2009-03-24 2019-04-02 Glaxosmithkline Biologicals Sa Adjuvanting meningococcal factor H binding protein
US8834888B2 (en) 2009-03-24 2014-09-16 Novartis Ag Adjuvanting meningococcal factor H binding protein
US9572884B2 (en) 2009-03-24 2017-02-21 Glaxosmithkline Biologicals Sa Adjuvanting meningococcal factor H binding protein
US10568953B2 (en) 2009-03-24 2020-02-25 Glaxosmithkline Biologicals Sa Adjuvanting meningococcal factor H binding protein
US8398988B2 (en) 2009-03-24 2013-03-19 Novartis Ag Adjuvanting meningococcal factor H binding protein
EP2424563A4 (en) * 2009-04-30 2013-10-30 Childrens Hosp & Res Ct Oak Chimeric factor h binding proteins (fhbp) and methods of use
WO2010144734A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
WO2011024072A2 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
WO2011024071A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
EP3017828A1 (en) 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
WO2011049677A1 (en) 2009-09-02 2011-04-28 Irm Llc Compounds and compositions as tlr activity modulators
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
WO2011039631A3 (en) * 2009-09-30 2011-06-16 Novartis Ag Expression of meningococcal fhbp polypeptides
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
CN102724988A (en) * 2009-09-30 2012-10-10 诺华有限公司 Expression of meningococcal fHBP polypeptides
CN102724988B (en) * 2009-09-30 2014-09-10 诺华股份有限公司 Expression of meningococcal fHBP polypeptides
WO2011051893A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
US8642733B2 (en) 2009-11-06 2014-02-04 Children's Hospital & Research Center Oakland T-cell stimulating protein B and methods of use
US9408907B2 (en) 2009-12-15 2016-08-09 Glaxosmithkline Biologicals Sa Homogenous suspension of immunopotentiating compounds and uses thereof
WO2011084549A1 (en) 2009-12-15 2011-07-14 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
US10046048B2 (en) 2009-12-15 2018-08-14 Glaxosmithkline Biologicals S.A. Homogenous suspension of immunopotentiating compounds and uses thereof
US20130004530A1 (en) * 2010-03-10 2013-01-03 Jan Poolman Vaccine composition
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
WO2011119759A1 (en) 2010-03-23 2011-09-29 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
CN102834410A (en) * 2010-03-30 2012-12-19 奥克兰儿童医院及研究中心 Factor h binding proteins (fhbp) with altered properties and methods of use thereof
US9827300B2 (en) 2010-03-30 2017-11-28 Children's Hospital & Research Center Oakland Factor H binding proteins (FHBP) with altered properties and methods of use thereof
US10342860B2 (en) 2010-03-30 2019-07-09 Children's Hospital & Research Center At Oakland Factor H binding proteins (FHBP) with altered properties and methods of use thereof
EP4036104A1 (en) * 2010-03-30 2022-08-03 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
US10905754B2 (en) 2010-03-30 2021-02-02 Children's Hospital & Research Center At Oakland Factor H binding proteins (fHbp) with altered properties and methods of use thereof
EP3327028A1 (en) * 2010-03-30 2018-05-30 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
EP2552942A1 (en) * 2010-03-30 2013-02-06 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
US9439957B2 (en) 2010-03-30 2016-09-13 Children's Hospital & Research Center Oakland Factor H binding proteins (FHBP) with altered properties and methods of use thereof
EP2552942A4 (en) * 2010-03-30 2014-01-22 Childrens Hosp & Res Ct Oak Factor h binding proteins (fhbp) with altered properties and methods of use thereof
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
US9556240B2 (en) 2010-08-23 2017-01-31 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
US9757443B2 (en) 2010-09-10 2017-09-12 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
US11077180B2 (en) 2010-09-10 2021-08-03 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
WO2012032498A2 (en) 2010-09-10 2012-03-15 Novartis Ag Developments in meningococcal outer membrane vesicles
US10512681B2 (en) 2010-09-10 2019-12-24 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
RU2607021C2 (en) * 2011-07-07 2017-01-10 Де Стат Дер Недерланден, Верт. Дор Де Министер Ван Ввс Process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
US9707286B2 (en) 2011-07-07 2017-07-18 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Ministerie Van Volksgezondheid, Welzun En Sport Process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
EP3299467A3 (en) * 2012-02-02 2018-05-30 GlaxoSmithKline Biologicals SA Promoters for increased protein expression in meningococcus
WO2013113917A1 (en) 2012-02-02 2013-08-08 Novartis Ag Promoters for increased protein expression in meningococcus
US9657297B2 (en) 2012-02-02 2017-05-23 Glaxosmithkline Biologicals Sa Promoters for increased protein expression in meningococcus
US9561269B2 (en) 2012-03-09 2017-02-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10196429B2 (en) 2012-03-09 2019-02-05 Pfizer Inc. Neisseria meningitidis composition and methods thereof
AU2021201721B2 (en) * 2012-03-09 2023-03-30 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11472850B2 (en) 2012-03-09 2022-10-18 Pfizer Inc. Neisseria meningitidis composition and methods thereof
US10829521B2 (en) 2012-03-09 2020-11-10 Pfizer Inc. Neisseria meningitidis composition and methods thereof
US9724402B2 (en) 2012-03-09 2017-08-08 Pfizer Inc. Neisseria meningitidis composition and methods thereof
US10550159B2 (en) 2012-03-09 2020-02-04 Pfizer Inc. Neisseria meningitidis composition and methods thereof
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
WO2014030003A1 (en) * 2012-08-23 2014-02-27 Isis Innovation Limited Neisseria meningitidis fhbp variant and its use for vaccination
US9629905B2 (en) 2012-08-23 2017-04-25 Oxford University Innovation Limited Neisseria meningitidis fHbp variant and its use for vaccination
AU2013304832B2 (en) * 2012-08-23 2017-07-20 Oxford University Innovation Limited Neisseria meningitidis fHbp variant and its use for vaccination
WO2014037472A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
WO2014122232A1 (en) 2013-02-07 2014-08-14 Novartis Ag Pharmaceutical compositions comprising vesicles
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
US9914756B2 (en) 2013-08-02 2018-03-13 Children's Hospital & Research Center At Oakland Non-naturally occurring factor H binding proteins (fHbp) and methods of use thereof
EP3027206A4 (en) * 2013-08-02 2017-03-08 Children's Hospital & Research Center Oakland Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
US10899802B2 (en) 2013-09-08 2021-01-26 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11680087B2 (en) 2013-09-08 2023-06-20 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US9822150B2 (en) 2013-09-08 2017-11-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3782643A1 (en) 2014-02-28 2021-02-24 GlaxoSmithKline Biologicals SA Modified meningococcal fhbp polypeptides
US11673920B2 (en) 2014-07-23 2023-06-13 Children's Hospital & Research Center At Oakland Factor H binding protein variants and methods of use thereof
US10266572B2 (en) 2014-07-23 2019-04-23 Children's Hospital & Research Center At Oakland Factor H binding protein variants and methods of use thereof
US11834476B2 (en) 2014-07-23 2023-12-05 Children's Hospital & Research Center At Oakland Factor H binding protein variants and methods of use thereof
US10995122B2 (en) 2014-07-23 2021-05-04 Children's Hospital & Research Center At Oakland Factor H binding protein variants and methods of use thereof
US10836799B2 (en) 2014-07-23 2020-11-17 Children's Hospital & Research Center At Oakland Factor H binding protein variants and methods of use thereof
US10487122B2 (en) 2014-07-23 2019-11-26 Children's Hospital & Research Center At Oakland Factor H binding protein variants and methods of use thereof
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10543267B2 (en) 2017-01-31 2020-01-28 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10813989B2 (en) 2017-01-31 2020-10-27 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11730800B2 (en) 2017-01-31 2023-08-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US11708394B2 (en) 2018-08-09 2023-07-25 Glaxosmithkline Biologicals Sa Modified meningococcal FHBP polypeptides
WO2020030782A1 (en) 2018-08-09 2020-02-13 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides

Also Published As

Publication number Publication date
EP1855715B1 (en) 2013-03-13
US20210308247A1 (en) 2021-10-07
CA2590974A1 (en) 2006-08-03
AU2006208208A1 (en) 2006-08-03
BRPI0607374B1 (en) 2020-04-22
EP2682126B1 (en) 2016-11-23
JP4993750B2 (en) 2012-08-08
US20170065699A1 (en) 2017-03-09
CA2590974C (en) 2017-10-03
US9452208B2 (en) 2016-09-27
MX2007008785A (en) 2008-02-15
JP2008528597A (en) 2008-07-31
US20120093867A1 (en) 2012-04-19
US9034345B2 (en) 2015-05-19
NZ555937A (en) 2009-05-31
BRPI0607374B8 (en) 2021-05-25
BRPI0607374A2 (en) 2009-09-01
AU2006208208B2 (en) 2011-05-19
US20180369356A1 (en) 2018-12-27
SI2682126T1 (en) 2017-03-31
CY1118732T1 (en) 2017-07-12
EP1855715A4 (en) 2009-06-17
RU2432962C2 (en) 2011-11-10
WO2006081259A3 (en) 2007-03-01
EP2682126A1 (en) 2014-01-08
US20080248065A1 (en) 2008-10-09
HK1107526A1 (en) 2008-04-11
RU2007128332A (en) 2009-01-27
CN101107007B (en) 2011-08-17
US10478484B2 (en) 2019-11-19
US8968748B2 (en) 2015-03-03
US10046043B2 (en) 2018-08-14
PT2682126T (en) 2017-02-28
US11801293B2 (en) 2023-10-31
EP2433647A2 (en) 2012-03-28
EP1855715A2 (en) 2007-11-21
PL2682126T3 (en) 2017-07-31
US20200138931A1 (en) 2020-05-07
CN101107007A (en) 2008-01-16
US20150290312A1 (en) 2015-10-15
HUE033196T2 (en) 2017-11-28
DK2682126T3 (en) 2017-02-27
US10857221B2 (en) 2020-12-08
ES2616294T3 (en) 2017-06-12
EP2433647A3 (en) 2012-06-06
LT2682126T (en) 2017-02-27

Similar Documents

Publication Publication Date Title
US11801293B2 (en) GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US20090035328A1 (en) fHbp- AND LPXL1-BASED VESICLE VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS
EP1322328B1 (en) Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
EP2265640A2 (en) Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
JP2012525151A (en) Chimeric factor H binding protein (FHBP) and method of use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680002931.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2590974

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006208208

Country of ref document: AU

Ref document number: 555937

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006733859

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006208208

Country of ref document: AU

Date of ref document: 20060123

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/008785

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007553181

Country of ref document: JP

Ref document number: 2007128332

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 11795739

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0607374

Country of ref document: BR

Kind code of ref document: A2